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 Human brain aging is associated with robust “normal” functional, structural, and 
molecular changes that underlie changes in cognition, memory, mood and motor 
function, amongst other processes. Normal aging is also a requirement for onset of 
many neurological diseases, ranging from later onset neurodegenerative diseases such 
as Alzheimer’s(AD) and Parkinson’s diseases(PD), to earlier onset psychiatric disorders 
such as bipolar disorder(BPD) and schizophrenia(SCHZ). Understanding the molecular 
mechanisms and genetic underpinnings of normal age-related brain changes would 
have profound consequences for prevention and treatment of age-related impairments 
and disease. Here I introduce current knowledge of these functional changes, their 
structural and molecular underpinnings, their genetic modulators, and the contribution of 
normal aging to age-related neurological disease. I then present my contribution to this 
field in the form of three papers on genetic modulation of mammalian brain molecular 
aging. These studies demonstrate and investigate mechanisms underlying the causal 
modulation of molecular brain aging rates by Brain Derived Neurotrophic Factor (BDNF) 
and Serotonin (5-HT) in knock-out (KO) mice, and associative modulation by the 
putative longevity gene, Sirtuin 5, in humans (novel low-expressing promoter 
polymorphism (Sirt5prom2)). In humans we additionally investigate the potential 
mechanism(s) underlying neurological disease gating by normal aging, providing 
supporting evidence for molecular aging being a genetically controlled “transcriptional 
program” that progressively promotes age-regulated neurological diseases. In the 
discussion, I place these studies in a broader context within the field, detailing their 
implications and future directions. 
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INTRODUCTION 
 
 
 “Normal” brain aging is understudied compared with peripheral aging and has 
many fundamentally different mechanisms and modulators, which are intrinsic to the 
onset and progression of age-related declines and neurological diseases. Some 
mechanisms, such as those related to insulin signaling and cellular insult are shared 
between the periphery and brain; however, mechanisms related to cellular turnover 
and depletion, such as telomere shortening and senescence, are not as pertinent in 
the largely non-dividing brain. Instead, progressive morphological and molecular 
changes within life-long existing neurons and glia likely underlie age-related 
cognitive, motor, and mood changes and disease susceptibility (see Figure 1). Brain 
aging also has many unique genetic modulators such as neurotransmitters, 
neurotrophins, and neurological disease-related genes (see Figure 1). Here I 
introduce current knowledge of functional correlates of brain aging and then 
progressively discuss their putative underpinnings, starting with gross structural and 
functional, then cellular, then molecular and finally genetic modulators. Lastly, I 
introduce the overlap between and contribution of normal brain aging to age-gated 
neurological disease. 
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Figure 1. Overarching schema. “Normal” age-related molecular changes in 
neurons and glia: putative modulators, mediators and consequences. 
 
 
 
 
 
 
Figure 1. Known age-related cellular phenotypes are in bold in neurons (left) and 
glia (right).  Many neuronal phenotypes (such as DNA damage) also occur in glia but 
are not depicted here for clarity. In parentheses are single representative examples 
(amongst many) of age-regulated gene expression changes seen by human brain 
microarray that may contribute to/underlie a particular cellular phenotype. 
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I.A.i  Normal age-related changes in cognition, motor function, and affect. 
 
 Normal age-related declines in neurological functioning have been extensively 
studied and are robust and consistent. Meta-analysis of cross-sectional and 
longitudinal datasets have demonstrated a 40-60% decline in cognitive speed at age 
80 from age 20 in non-demented adults (1, 2). Aging differentially affects aspects of 
neurological functioning (1, 3-5). “Fluid abilities” or those reliant on processing speed, 
problem solving, inhibitory function, working memory, long-term memory and spatial 
ability, decline with age (see Figure 2 (1, 2, 6)).  In fact, performance IQ (reliant 
primarily on fluid abilities) measured by the Welchsler test drops on average 30 
points from age 20 to age 70 (2, 7). In contrast, so-called “crystallized abilities” 
related to knowledge or expertise such as vocabulary, world knowledge, general 
knowledge, implicit memory, understanding proverbs, and occupational expertise do 
not decline or even show improvement over the lifespan (see Figure 2, reviewed in 
(1, 4, 6)).  Consistent with this, verbal IQ measured in WAIS-R standardization 
sample only drops on average only 5 points from age 20 to age 70 (2, 8). Importantly, 
selectively affected cognitive changes follow the same continuous and progressive 
pattern starting in the 20s and continuing through old age as grey matter volume loss 
and molecular changes, which may underlie these functional changes (9).  
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Figure 2. Differential effects of aging on cognitive processes. 
(adapted from Park DC, Reuter Lorenz P. 2009 (6)) 
 
 
 
Figure 2.  Z-score (y-axis) is a measure of distance from the mean in standard 
deviations ((value- mean)/stdev). 
  
 A variety of motor functions, including reaction time, speed of movement, and 
hand and foot coordination have also been shown to consistently slow with age (10-
12). This is likely mediated by aging of the central nervous system as cortical 
Dopamine D2 receptor level, which declines with age (13, 14), correlates with motor 
speed as well as cognitive function (14). Like cognitive aging, these changes follow a 
continuous and progressive pattern, as exemplified in the Baltimore longitudinal 
study, which demonstrated that simple and disjunctive (i.e. go no go task) reaction 
times increased by 0.5 (~4.0%/decade) and 1.6 msec/year (3.9%/decade), 
respectively, starting at age 20 and continuing through the oldest ages (90+ years) 
(10). 
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 Meta-analyses have shown that changes in mood and affective perception 
also exist with age. Older adults are worse at recognizing sad or angry emotions than 
younger adults, which can not be accounted for by general cognitive decline as they 
perform equally as well in recognition of happiness and better in recognition of 
disgust (5).  Generally, older adults show a positivity-bias in attention and memory, 
recover from negative events faster, and are less likely to engage in destructive 
interpersonal interactions such as shouting during conflict (reviewed in (15)). 
Consistent with this and contrary to popular belief, older adults have less risk of major 
depression, with average onset of major depression at age 30.5 with declining risk 
beginning in the early 40s (16). This seems counterintuitive given that suicide rates 
are greatly increased in people over 65 versus the general population (14.2 and 10.2 
per 100,000 respectively), with even greater rates in non-hispanic white males over 
85 (48 per 100,000) (http://www.nimh.nih.gov/health/publications/suicide-in-the-us-
statistics-and-prevention/index.shtml#CDC-Web-Tool). However, this is not due to 
increasing rates of major depression but higher ratios of completion to attempts 
largely in men, especially those living alone, widowed, and/or terminally ill (17, 18). 
Additionally, the lower rates of depression seen in older adults seems counterintuitive 
because the same frontal brain areas required for cognition, which decline 
functionally with age, are required for emotional control, which does not decline with 
age. However, it has been shown that adults with poorer performance on cognitive 
tests also show less positivity-bias, suggesting they have less emotional control (15). 
There is also very high co-morbidity of depression with neurodegenerative and 
dementia-related diseases such as Alzheimer’s and Parkinson’s disease, in people 
with poorer cardiovascular health, and especially in stroke patients (19). Combined, 
this suggests that people adaptively learn and become more proficient at maintaining 
a positive affect with age, but that control of this declines with declining cognition and 
in degenerative states. Thus, age-related loss of emotional regulation in people with 
more rapidly declining cognition may be an important factor for risk of depression in 
old age and disease. 
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 It is important to note that there is large individual variability in the rates of age-
related cognitive decline, ranging from little or no decline in cognition to more rapid 
decline (see Figure 3 (20)). A potential caveat to many cross-sectional studies on this 
topic is that the largest predictor of cognitive capacity in old age is cognitive capacity 
in youth, accounting for ~50% of the variance (21). With this in mind, there is good 
longitudinal evidence for both genetic and environmental contributors to rates of 
cognitive decline. The APOE-ε4 allele, for example, which increases risk for and 
lowers onset age of Alzheimer’s disease, has been extensively studied and has 
substantial evidence for association with accelerated cognitive decline (21-24). There 
is also some evidence for genetic contribution of COMT, BDNF, Klotho, PRNP, and 
DISC-1 although neither non-candidate high-throughput approaches or meta-
analyses of candidate genes have been performed (see also genetics section (21, 
22, 25)). Environmental factors that have been associated with slower cognitive 
decline include exercise, healthy body mass index, higher education level, good 
cardiovascular health, being a non-smoker, caloric restriction, and there is some 
evidence for nutritional factors such as antioxidant, omega-3 fatty acids, and red wine 
consumption (21, 24, 26-29).  
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Figure 3.  Individual differences in rates of cognitive decline.   
(From Wilson et. al. 2002 (20)). 
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I.A.ii  Normal age-related changes in brain structure/function. 
 
 What structural and functional changes potentially underlie these changes in 
cognition, motor function, and affect? Longitudinal and cross-sectional MRI studies 
have demonstrated significant grey matter loss with age at rates of (3.2-5.3 ml/year) 
or approximately 0.5%/year (See Figure 3)(30-33).   
 
Figure 4. Grey-matter volume decreases linearly with age throughout  
  adulthood.  (Adapted from Good et. al 2001 (33)) 
 
 
 
Figure 4. Total grey matter volumes are corrected for total intracranial volume (TIV) 
to correct for differences in head size. 
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 A striking example of this was conducted by Resnick et. al in 2003 , which 
followed longitudinally 92 non-demented adults (ages 59-85) at baseline, 2, and 4 
years out and found significant (p<.001) decreases in total grey matter at each time 
point within individuals (34). These changes are area-specific as frontal areas such 
as anterior cingulate cortex, prefrontal cortex, left and right insula, and left inferior 
frontal cortex have the most consistent decreases in volume with age in the literature 
whereas hippocampus and amygdala were unchanged or variable between studies 
(30, 31, 33-36).  The area-specificity of these changes is consistent with age-related 
cognitive changes, i.e. the most robust changes are seen in frontal areas required for 
cognitive processing and working memory. Additionally, losses of white matter 
integrity and changes in brain activity in response to tasks on fMRI, such as 
hippocampal hypo-responsiveness and greater frontal bi-laterality in memory tasks, 
are seen with age (reviewed in (6)). There is also a fair amount of evidence that these 
gross structural and functional changes correlate with changes in cognition (reviewed 
in (6)). 
 
I.A.iii Normal age-related changes in cellular morphology.  
 
 What underlies changes in grey-matter/white matter volumes? It was 
previously thought that neuronal death occurs in the brain with age. However, better 
stereotactic techniques and careful exclusion of subjects with neurodegenerative 
disease has shown that little or no neuronal death occurs during normal aging (37-
39). Instead grey-matter volume losses are the result of dendritic arbor shrinkage and 
synaptic losses in individual neurons (37-39).  Duan et. al demonstrated a ~43% and 
27% loss of apical and basal cortical neuron dendritic spines in aged versus young 
macaque monkeys (see Figure 5 (40)). These reductions in synapse density may 
underlie cognitive deficits, as they correlate with prefrontal cortex activity reduction in 
executive processing tasks (37).  
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Figure 5. Age-related loss of dendritic spine density  
(from Dickstein et. al, 2007 (39)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Spine densities on neocortical pyramidal neurons from young and aged 
rhesus monkeys. Panels A and B show confocal laser scanning images of apical 
dendritic segments in a young (10-12 yrs) (A) and aged (24-25 yrs) (B) rhesus 
monkey (scale bar = 8 µm). Note the increased spine density in the young monkey 
compared to the old monkey. Panels C and D show examples of a retrogradely 
traced neuron, filled with Lucifer Yellow, and reconstructed in 3-dimensions using 
NeuroZoom and NeuroGL software applications. The neuron in (C) is from a young 
animal and the neuron in (D) is from an aged animal. The arrow points to the 
dendritic segments analyzed in A and B. (Adapted from Duan et al., 2003). 
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 Similarly, for glia, older studies concluded that astrocytic gliosis and 
microgliosis, as visualized by MHC-II or GFAP (glial markers) staining in brain slices, 
was caused by increasing glial numbers with age, which has also been shown to be 
false with more careful stereological techniques (41-43). Instead, glial processes 
thicken with age (and thus show greater glial marker staining), termed “glial 
dystrophy”, perhaps to preserve correct distances from shrinking neuronal processes 
for glial-neuronal exchange (41-43).  
 
I.B.  Molecular pathways of brain aging. 
 
 In addition to cellular morphological changes, within neurons there is 
increasing DNA damage, reactive oxygen species, calcium dysregulation, 
mitochondrial dysfunction and inflammatory processes (reviewed in (37)). Underlying 
these cellular phenotypes, central nervous system (CNS) molecular aging both 
shares and has unique molecular pathways from the periphery. Shared pathways 
include those related to metabolism and caloric restriction, as well as those related to 
cellular insult, including DNA damage, inflammation, and reactive oxygen species 
(ROS) (see below; reviewed in (37)). In peripheral tissues, aging is additionally driven 
by senescence-related mechanisms such as telomere shortening and depletion of 
precursor cells, which are not as pertinent in CNS because cellular turnover is limited. 
There are also nervous system-predominant molecular mechanisms, including those 
driven by neurotrophins (BDNF) and neurotransmitters (serotonin, dopamine, 
glutamate)(see below (44-47)).   
 
I.B.i. Molecular pathways of brain aging: metabolic. 
 
 Caloric restriction (CR) is one of the most studied mechanisms of increasing 
longevity across species from yeast to primates (48). Relevant to brain aging 
specifically, a primate CR model demonstrated delayed brain atrophy (49) and in 
older humans short-term CR is associated with improved memory prospectively (50). 
This may be an evolutionarily conserved means of sensing poor nutritional 
  12 
environments and thus increasing reproductive lifespan to wait for richer 
environments. It is tied into and shares signaling with ROS-related mechanisms, as 
CR-driven metabolic slowing results in fewer mitochondrial produced ROS and thus 
less DNA damage (reviewed in (51)). Mediators of CR, Growth Hormone, Insulin, 
IGF-1, and the circulating longevity hormone, Klotho, which binds to the IGF-1 
receptor, as well as the Sirtuin family of longevity genes, have been shown to 
modulate both organismal lifespan and healthspan across species (48, 52, 53). There 
is emerging evidence that these are key players in brain aging, including causal 
studies in model organisms and some genetic association of human polymorphisms 
in these genes with brain aging (see genetics section). The Sirtuin family of longevity 
genes, encompassing seven homologous NAD-dependent histone and protein 
deacetylases, is the target of resveratrol, the putative lifespan extending compound in 
red wine and grapes. These genes are particularly promising targets for key brain 
aging modulators. Related to their varied subcellular localizations, they have 
pleitropic anti-aging effects in neurons and glia, including abrogation of protein 
aggregates and accumulating misfolded proteins, enhancing stress response and 
improving DNA repair, prevention of cell death pathways and mitochondrial 
dysfunction, and preventing inflammatory processes in glia (reviewed in (54)). 
Additionally Sirt1 has been shown to prevent Wallerian-type axonal degeneration 
after injury (55) and to be a key player in neurogenesis (56). Other players in this 
pathway, elucidated predominantly from studies of peripheral tissues in the model 
organism literature, include FOXO, Daf16, p66, PTEN, m-TOR, and CLOCK-1 
amongst many others (48).  Mechanisms of metabolic pathway control of brain aging 
have only begun to be understood.  
 
I.B.ii. Molecular pathways of brain aging: cellular insult. 
 
 Nuclear and mitochondrial DNA damage, predominantly single base 
mutations, such as 8-oxoguanine, steadily accumulate in the aging brain across 
species (reviewed in (37, 57)). There is considerable support for pathways 
downstream of increasing DNA damage and ROS directing brain aging, including 
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accelerated brain aging and neurodegeneration, in many people with progeria 
syndromes caused by DNA repair gene mutations (37). Additionally, severity of age-
related memory impairment is correlated with brain and plasma levels of antioxidants 
(reviewed in (57)). Besides genes mutated in progeria syndromes there is also a role 
specifically for P53 in brain aging and centrally driven lifespan regulation, as selective 
brain knock-down of P53 in drosophila results in increased longevity and resistance 
to oxidative stress (37, 58). However, the specific pathways linking DNA damage to 
age-related neuronal/glial morphological changes remain poorly understood. 
 
I.B.iii. Molecular pathways of brain aging: neurotrophins. 
 
 While there is a large literature relating neurotrophins such as GDNF, NGF 
and bFGF to treatment and prevention of neurodegenerative disease such as AD and 
PD, Brain Derived Neurotrophic Factor (BDNF) is the most well studied modulator of 
normal brain aging (reviewed in (59)). Particularly, there is a large literature 
connecting the human BDNF val66met (secretion deficient) polymorphism to brain 
aging in mice and humans (see genetics section below). Additionally, it is a logical 
modulator of molecular aging, as it is an activity-dependent secreted growth factor, 
which declines steadily with age in the brain (60), is neuroprotective against a variety 
of insults, and is required for changes in spine density underlying learning and 
memory systems that decline with age (reviewed in (59)). Indeed, infusion of BDNF 
can restore age-related impairment in Long Term Potentiation (LTP) in middle-aged 
rats (61). BDNF is also required for neurogenesis in mice and it’s expression is 
induced by exercise and caloric restriction, which are known to be modulators of 
normal brain aging (reviewed in (59)). How pathways downstream of BDNF 
specifically modulate cellular age-related molecular changes remains unclear. We 
begin to explore this here by investigating the effects of BDNF ablation both 
embryonically and conditionally in adulthood by microarray in frontal cortex (paper 1 
(62)). 
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I.B.iv.  Molecular pathways of brain aging: neurotransmitters. 
 
 There is increasing evidence for a role for neurotransmitters, particularly 
serotonin, glutamate and dopamine, in modulating normal brain aging. This has 
important implications for public health and also new treatment strategies for aging 
and age-related disease because so many current psychiatric and neurological drugs 
target neurotransmitter receptors. Serotonin has been hypothesized to play a role in 
normal brain aging by us and others because it and its receptors have age-regulated 
levels and share many signaling pathways with other age-regulatory molecules such 
as BDNF and IGF-1, and because SSRIs can modulate neurogenesis (reviewed in 
(44, 45), see also paper 2 (63)). Additionally, serotonin blocking drugs and serotonin 
synthesis (tph-1) and receptor mutants (ser-1, ser-4) delay age-related phenotypes 
and/or extend longevity in c. elegans (64-67). However, causal studies specific to the 
brain and in higher order model organisms, as well as prospective studies of human 
age-related phenotypes in relation to serotonergic drugs, are still lacking. In paper 2 
(63), we demonstrate the first causal evidence linking genetic disruption of 
serotonergic signaling with anticipated molecular brain aging in mice. 
 Glutamate, the brain’s predominant excitatory neurotransmitter, is also a 
probable candidate for modulating brain aging because it facilitates release of BDNF 
and is essential for LTP and synaptic plasticity, as well as neurogenesis, activity-
dependent neuronal survival, and neural outgrowth during development (reviewed in 
(46)). Through elevation of intracellular Ca2+ and effects on CREB and NFκB 
mediated signaling, glutamate effects both rapid changes in dendritic architecture and 
long term transcriptional effects on a variety of genes, including neurotrophins, 
through which it likely exerts it’s effects on age-related morphological changes 
(reviewed in (46)). Glutamate is also an important player because of its role in both 
protection in the context of ischemic preconditioning, and facilitation of excitotoxic 
neuronal injury and death (46). 
 Dopamine has strong correlative and causative evidence for modulation of 
brain aging (47) as well as being implicated in several age-gated diseases, including 
PD, HD, SCHZ, and BPD. Components of the dopamine system also decline with 
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age, including the dopamine transporter (DAT), and the D1 and D2 receptors 
(reviewed in (47)). Mice fed the dopamine precursor, Levodopa, have extended 
longevity by 50% and improved fertility, perhaps through the caloric restriction 
pathway, as they showed reduced growth despite the same amount of food intake as 
controls (68, 69). This cross-talk with caloric restriction pathways is corroborated by 
D2 receptor knock-out (ko) mice, which have decreased levels of GH and IGF-1 (70). 
In humans, pharmacological studies in healthy volunteers have shown that D-
amphetamine enhances performance on a variety of tasks and that found that the D2 
receptor agonist, Bromocriptine, facilitates spatial working memory, suggesting that 
D2 receptor down-regulation with age may play a role in age-related memory and 
cognitive decline (47). Additionally, PET studies have demonstrated that in healthy 
adults striatal D2 receptor binding correlates with executive and motor functioning as 
well as perceptual speed (both of which correlated with subject age) even when 
controlling for chronological age (14, 47, 71), suggesting that D2 levels may be 
partially responsible for the effects of molecular aging on cognitive function. In 
addition to declining dopamine signaling having cross-talk with caloric restriction 
pathways and directly mediating age-related cognitive decline, dopamine pathways 
also have cross-talk with ROS age-related pathways. For example, Monoamine 
oxidase B, which acts to inactivate robustly increases with age (60), generates large 
numbers of free radicals and thus may contribute to increasing ROS with age 
(reviewed in (72)). Dopamine also regulates glial dystrophy-related pathways by 
regulating NFκB and GFAP levels (reviewed in (72)) and interacts with calcium-
related pathways and circadian-rhythm pathways through interaction with Clock 
amongst other genes (reviewed in (73)). 
 
I.C. Molecular underpinnings (gene expression correlates) of normal human 
brain aging. 
 
 Several groups, including our own, have characterized the gene expression 
underpinnings of these age-related changes using human post-mortem brain 
microarray (60, 74, 75). Consistently a selective portion of the genome (~5-10%) has 
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been shown to have age-regulated changes in expression levels in the brain (60, 74). 
The most affected genes are consistent with the age-related cellular phenotypes they 
likely underlie, i.e. decreasing neurotrophic factors (BDNF, IGF-1), calcium-related 
proteins (Calbindin), markers of synaptic density (SYN2), and neurotransmitter 
receptors (HTR2A, DRD2), and increasing markers of DNA damage (BCL-2), and 
glial dystrophy (GFAP, NFk-B). The mechanism(s) driving these selective age-
regulated expression changes is largely unknown. Lu et. al in their seminal 2004 
paper, postulated a clock mechanism whereby accumulating DNA damage with age 
could selectively alter promoter regions of age-regulated genes(74). In support of this 
theory, they demonstrated that genes with age-regulated expression levels in human 
Prefrontal cortex had promoter regions that were more vulnerable to DNA damage 
than genes that were not age-regulated(74).  
 At the same time, our group demonstrated that age-regulated gene expression 
changes were highly conserved across two areas of prefrontal cortex. Fitting with 
these expression changes underlying shrinking neuronal processes and glial 
dystrophy, we demonstrated that age down-regulated transcripts were predominantly 
of neuronal origin, whereas age up-regulated transcripts were predominantly of glial 
origin ((60) see Figure 4).  These changes were so robust and consistent that 
molecular age (calculated from a composite score of age-regulated gene transcript 
levels) could be used to predict subject chronological age (See Figure 6 (60)). 
Consistent with the large individual variability seen in rates of age-related cognitive 
decline, we saw individual variability in rates of molecular brain aging, which could 
not be attributed to cohort characteristics such as body mass index (see Figure 7 
(60)).  
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Figure 6. Molecular aging is conserved in the prefrontal cortex. 
(From L. Erraji-Benchekroun et. al 2005 (60)). 
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Figure 6. Expression levels for 588 age-affected probesets are presented together 
for BA9 and BA47. Each probeset is represented by a row, each array, or brain area 
per subject by a column. Samples are organized left to right by brain area and 
increasing age. Green and red bars indicate decreased and increased gene 
expression, respectively, versus the averaged signal for these genes across all 
samples. For example, a horizontal row going from red to green indicates a gene 
whose expression decreases with age in that brain area. Along the Y-axis, probesets 
are clustered according to similarities in expression profiles across age. A similar 
number of probesets were downregulated (n=291, upper panel) and upregulated 
(n=297, lower panel) throughout lifetime. Columns to the right indicate the distribution 
of genes with glial-(WM) or neuronal-enriched (GM) signals. Notice the high 
concentration of glial-enriched genes with increased expression with age, while most, 
but not all, neuronal-enriched genes appeared to be downregulated with age. 
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Figure 7. Molecular age predicts chronological age. 
(From L. Erraji-Benchekroun et. al 2005(60)). 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The “Molecular” age, or age as defined by gene expression levels, 
represents a summary number for each sample that depicts the average deviation in 
gene expression within this sample when compared to age-affected transcripts in all 
other subjects (See Methods). Overall, there was a high correlation between 
“molecular” and chronological ages (BA9: r=0.65; BA57, r=0.73). A few samples 
demonstrated larger deviation than average at both young and older ages. These 
subjects did not correspond to any identifiable clinical, demographic or experimental 
parameters.  
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 The consistency of age-related gene expression changes suggested to us that 
they are likely under control of a biological “program”, similar to peripheral aging of 
somatic tissue and perhaps analogous to genetically controlled transcriptional 
programs occurring during development. This led us to hypothesize that individual 
differences in molecular brain aging rates can be partially accounted for by genetic 
variation (see paper 3). These studies have opened up leads to understanding what 
the master molecular driving forces are behind age-regulated molecular changes 
underlying structural and functional brain aging. A better understanding of the 
mechanism behind these changes and their genetic regulation may be key to creating 
new therapies for treatment of age-related declines and disease. In the three papers 
presented here, we begin to address these questions. Next I will discuss what is 
known about genetic regulation of “normal” brain aging. 
 
I.D. Genetics of normal brain aging. 
 
 The genetics of normal brain aging has a vast associated literature. Here I 
present candidate genes with the most evidence for association. They can be 
organized into three broad categories: genes related to molecular pathways of aging, 
longevity genes, and genes associated with age-gated neurological disease, although 
substantial overlap occurs between these categories.  
 
I.D.i.a. Genes related to molecular pathways of aging: BDNF. 
 
 One of the most well studied polymorphisms in relation to brain aging is the 
BDNF val66met single amino acid substitution polymorphism, which results in 
decreased activity-dependent secretion of BDNF in neuronal cultures (76). The Met 
allele is associated with poorer episodic memory, and abnormal fMRI-assessed 
hippocampal function, accelerated age-related loss in verbal reasoning, and 
anticipated age-related grey matter volume losses by structural MRI (76-79). 
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I.D.i.b. Genes related to molecular pathways of aging: serotonergic genes. 
 
 The short allele of the Serotonin transporter promoter polymorphism (SERT 
SLC6A4), most famous for association with depression in the context of stressful life 
events (80), associated with worse delayed recall and smaller hippocampal volumes 
in older adults (81). Consistent with this, the long allele of this polymorphism was 
shown to be overrepresented in Japanese centenarians (82). Another study linked 
the other well-studied SERT polymorphism (VNTR2) with rates of cognitive decline 
but not baseline cognition on a variety of measures, but failed to find association with 
SLC6A4 (83). A Serotonin 2A receptor polymorphism has also been linked with 
longitudinal decrease in delayed recall (84). These results are encouraging for a role 
of Serotonin polymorphisms in brain aging, but most require replication. Additionally, 
causal studies in model organisms linking these genes to brain aging are lacking, and 
the mechanism behind the contribution of these polymorphisms to altered rates of 
brain aging remain unknown. In paper 2, we present the first causal evidence linking 
a serotonergic gene to brain aging, demonstrating that HTR1B receptor KO mice 
display anticipated molecular brain aging. 
 
I.D.i.c Genes related to molecular pathways of aging: dopaminergic genes. 
 
 Among dopaminergic polymorphisms, Catechol-O-methyl transferase (COMT) 
Val158Met Val allele, which is associated with decreased prefrontal cortex dopamine 
levels, has been most studied in relation to brain aging. It is consistently associated 
with accelerated rates age-related cognitive decline (85-87) and differences in 
longitudinal loss of grey matter(88). However, KO or knock-down studies of COMT 
establishing causation in model organisms are still lacking. Other than COMT in the 
dopaminergic system, one study has linked the Tyrosine hydroxylase locus to human 
longevity (89). 
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I.D.ii.a . Longevity genes: Klotho. 
 
 Klotho (KL),named after the Greek goddess who spun the thread of life, was 
first identified as a longevity gene in 1997 by analysis of a strain of short-lived mice 
(lifespan around 2 months) who had early onset of age-related disorders (ectopic 
calcification, osteopenia, arteriosclerosis, emphysema, and insulin resistance) (52, 
90). They were subsequently shown to have accelerated age-related neuronal 
pathology (91) and premature cognitive aging (92). KL is expressed in the distal 
tubule cells of the kidney and the choroid plexus of the brain and codes for a 
circulating hormone that binds to the insulin-like growth factor (IGF-1) receptor and 
represses intracellular insulin signaling (52). KL-hypermorphs, conversely, have an 
approximate 20% increase in longevity and delayed age-related disorders (52). The 
human KL-VS polymorphism results in a two amino acid change in the protein (93) 
and is associated with a heterozygous advantage for increased life span, increased 
risk for cardiovascular disease, osteoporosis, and stroke, as well as decreased IQ at 
age 79, however this was not significant after controlling for baseline IQ at age 11(93-
98).  In paper 3, we investigate the effects of this polymorphism on rates of molecular 
aging in the human brain. 
 
I.D.ii.b. Longevity genes: insulin signaling genes. 
 
 In C. elegans and Drosophila, insulin-signaling genes, which when mutated 
can increase lifespan up to sixfold, are the most extensively studied longevity genes 
(99, 100). Specific to the brain, knock-out of daf-2 (orthologue to the human IGF-I 
receptor (IGF-IR)) in only a small subset of neurons significantly extends lifespan 
(reviewed in (100)). One study examined the effects of human polymorphisms in the 
IGF-I receptor (IGF-IR), PIK3CB (phosphoinositol 3-kinase; C. elegans AGE-1 
orthologue), IRS-1 (D. melanogaster CHICO gene orthologue), FOXO1A (C. elegans 
DAF-16 orthologue) on human lifespan, and found a significant association with IGF-
IR G/A 1013 polymorphism (99). Also, polymorphisms in AKT-1 and FOXO3A (101) 
have subsequently been associated with human longevity, even in meta-analysis 
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(102). The large literature and extensive evidence linking insulin signaling 
polymorphisms and human lifespan is reviewed in (103), however, the relation of 
these polymorphisms specifically to brain aging has not been investigated. 
 
I.D.ii.c.  Longevity genes: P53. 
 
Reduced expression of Cep-1 (P53 orthologue) extends lifespan in C. elegans and 
overexpression of P53 reduces lifespan in mice (reviewed in (103)). An human 
arginine/proline polymorphism in codon 72 of P53 has some (albeit conflicting) 
evidence for association with human lifespan (reviewed in (103)), which has not been 
investigated in relation to brain aging. 
 
I.D.ii.d. Longevity genes: Sirtuins. 
 
 Overexpression of Sirtuins extends longevity in C. Elegans and drosophila 
(104). Additionally, Sirtuin KO mouse models show decreased longevity and 
accelerated age-related phenotypes (reviewed in (105)). In humans, an association 
between two Sirt3 polymorphisms and longevity has been found (106, 107) as well as 
between a Sirt1 polymorphism and cognitive function in old age (108). However, the 
link between sirtuins and brain aging remains largely unexplored. In paper 2 (63), we 
demonstrate altered Sirt5 expression in brains of an HTR1B KO mouse model of 
anticipated brain aging and in paper three, we go on to demonstrate accelerated 
molecular brain aging in association with a novel low-expressing Sirt5 polymorphism. 
 
I.D.iii.a. Age-gated neurological disease-related genes: APOE. 
 
 APOE is a lipoprotein that binds to the LDL receptor family and has three 
human variants, (E2, E3, and E4) that each differ by a single amino acid. The E4 
allele is consistently associated with greater risk and earlier onset of cardiovascular 
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disease, stroke, and Alzheimer’s disease in a dose dependent manner, while the E2 
allele has been shown to be protective (reviewed in (25)). Carriers of the E4 allele 
also show greater age-related decline in cognition (reviewed in (25)), as 
demonstrated by lower IQ at age 70 but  not at age 11(23).  The molecular 
mechanism behind the E4 allele’s association with more rapid cognitive aging and 
greater risk of age-related disease appears to be threefold: an association with 
increased subject cholesterol levels, greater Aβ accumulation, and less ability for 
dendritic sprouting in E4 carriers, which has been causally related to E4 in models 
(reviewed in (109)). 
 
I.D.iii.b. Age-gated neurological disease-related genes: PRNP 
 
 A prion protein gene (PRNP) variant met129val, is associated with risk of 
Creutzfeldt-Jakob disease, Alzheimer’s disease, cognitive impairment, dementia, and 
brain morphology, and normal cognitive aging which interacts with the Klotho KL-VS 
polymorphism ((110-112) see also genetics: Klotho).  The mechanism behind this 
likely relates to ROS pathways as PRNP functions neuroprotectively, likely as a super 
oxide dismutase (112). 
 
I.D.iii.c. Age-gated neurological disease-related genes: DISC-1 
 
 Disrupted in schizophrenia 1 (DISC-1), most famous for its association with 
schizophrenia and bipolar disorder, likely functions by influencing neurite extension, 
signal transduction, neurotransmission, and the cytoskeleton, although these 
mechanisms have not been fully elucidated (92).  A snp in this gene that results in a 
single amino acid substitution results in reduced hippocampal volume and 
accelerated age-related cognitive decline (92). 
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I.E. How normal brain aging may contribute to age-gated neurological 
disease 
 Aging is a requirement for onset of many neurological diseases ranging from 
late onset neurodegenerative diseases such as Alzheimer’s and Parkinson’s 
diseases (average onset 60 and 75 years respectively) (113) to earlier onset 
psychiatric disorders such as schizophrenia and bipolar disorder (average onset 25 
years) (114). While many studies have focused on contrasting disease brains with 
chronologically age-matched controls, this strategy may be problematic as it is 
becoming increasingly evident that normal aging is an integral aspect and modulator 
of disease onset and progression. Evidence for this comes from the sheer prevalence 
of diseases with increasing age, such as Alzheimer’s disease, for which prevalence 
increases exponentially from age 65 upward, reaching nearly 45% by age 95 (Figure 
7 (113)).  
 
Figure 8. Prevalence of AD by age (From Nussbaum et. al 2005 (113)) 
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Also, genetic modulators and molecular pathways of normal brain aging share 
substantial overlap with those associated with age-gated neurological disease. For 
example, BDNF val66met, COMT val158met, APOE4 and PRNP met129val have all 
been associated with risk for AD and PD (22, 115, 116) and the BDNF val66met has 
additionally been associated with age of onset schizophrenia (117). Epidemiological 
studies have shown that low calorie diets are associated with decreased risk of AD 
and PD (reviewed in (27)) and CR delays Aβ deposition in squirrel monkeys (118) 
and improves functional outcome in a monkey model of PD (119). Additionally, BDNF 
administration can delay neurodegeneration in animal models of Huntington’s 
disease (HD) (reviewed in (46)) and AD (reviewed in (120)). Sirt1 is also implicated in 
disease, as overexpression has been shown to be protective against 
neurodegeneration in both AD and ALS model organisms (reviewed in (121)). 
 Additional evidence for normal aging modulating onset of age-gated disease 
comes from genetic models of increased longevity, which have been associated with 
delay in age-related disorders. For example, mice hypermorphic for the longevity 
gene, Klotho, not only live ~20% longer but also have a corresponding delay in onset 
of ectopic calcification, osteopenia, arteriosclerosis, emphysema, and insulin 
resistance (52, 122). This also has increasing evidence for age-gated neurological 
diseases specifically, as lifespan extension via reduction of insulin/insulin growth 
factor signaling (IIS pathway) resulted in delayed proteotoxicity in both C. elegans 
and mouse Alzheimer’s disease models (123, 124). 
 While normal aging appears to modulate disease, it is important to point out 
that the converse does not hold, ie. not all disease susceptibility genes modulate 
aging. For example, the familial AD genes, PSEN1, PSEN2, and APP appear to have 
no association with cognitive aging (22, 25). Also, neuronal loss is a key feature of 
neurodegenerative disease, which as previously discussed, does not occur during 
normal aging. 
 The modulation of a variety of neurological diseases by normal aging is 
promising for the creation of novel magic-bullet type anti-aging therapeutics for 
treatment of disease and age-related decline. However, how aging gates neurological 
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diseases and what contributes to individual variability in age of onset is essential to 
this and still remains largely unknown. In paper 3, we postulate and demonstrate 
evidence for a gene-expression level gating mechanism behind this. We show that 
neurological disease-related genes are overrepresented amongst those with age-
regulated expression levels and change almost unanimously in pro-disease directions 
and that rates of these changes are associated with a novel longevity gene 
polymorphism (Sirt5prom2). The studies presented here contribute to knowledge of 
genetic and molecular pathways of normal brain aging and how they gate age-related 
neurological disease.            
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ABSTRACT 
 
 Brain-derived neurotrophic factor (BDNF) has been reported to be critical for 
the development of cortical inhibitory neurons. However, the effect of BDNF on the 
expression of transcripts whose protein products are involved in GABA 
neurotransmission has not been assessed. In this study, gene expression profiling 
using oligonucleotide microarrays was performed in prefrontal cortical tissue from 
mice with inducible deletions of BDNF. Both embryonic and adulthood ablation of 
BDNF gave rise to many shared transcriptome changes. BDNF appeared to be 
required to maintain gene expression in the SST-NPY-TAC1 subclass of GABA 
neurons, although the absence of BDNF did not alter their general phenotype as 
inhibitory neurons. Furthermore, we observed expression alterations in genes 
encoding early-immediate genes (ARC, EGR1, EGR2, FOS, DUSP1, DUSP6) and 
critical cellular signaling systems (CDKN1c, CCND2, CAMK1g, RGS4). These BDNF-
dependent gene expression changes may illuminate the biological basis for 
transcriptome changes observed in certain human brain disorders. 
 
INTRODUCTION 
 
 Brain-derived neurotrophic factor (BDNF) is a critical regulator of neural 
development, promoting the survival of a variety of neurons in the CNS (for a review, 
see (125)). For example, the development of certain phenotypic features of cortical 
GABA neurons requires BDNF (126-130). In addition, BDNF is produced and 
released in an activity-dependent fashion by pyramidal neurons, a major target of 
GABA neurons. Together, these data suggest that BDNF is a target-derived trophic 
factor for GABA interneurons. In turn, GABA neurons might regulate BDNF synthesis 
and release from pyramidal cells in an activity-dependent manner (131, 132). 
 Cortical GABA neurons are heterogeneous and can be subdivided into a 
variety of subclasses based on their expression of different calcium binding proteins 
and neuropeptides (for a review, see (133, 134). These subclasses also differ in their 
laminar distribution, connectivity and physiological properties. However, the 
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dependence of different subclasses of GABA neurons on BDNF signaling remains to 
be determined. For example, the inducible deletion of BDNF (135) does not result in 
altered mRNA levels of the 67 kDa isoform of glutamic acid decarboxylase (GAD1) or 
parvalbumin (PARV) in adult mice (136).  
 Furthermore, the dependence of any given neuronal type on BDNF may differ 
as a function of developmental stage (137).  For example, BDNF is a critical mediator 
of the maturation of glutamatergic synapses in developing mouse somatosensory 
cortex (138). Similarly, developing dorsal thalamus neurons need BDNF for survival 
from the cerebral cortex, and dorsal thalamic cell death can be regulated by 
increasing or blocking cortical levels of BDNF (139). In addition, behavioral deficits 
are more pronounced in mice with embryonic than adult ablation of BDNF (135). 
These data suggest that BDNF requirement of neurons may change from 
development to adulthood, and mice with embryonic and adult deletion of BDNF may 
exhibit markedly different neocortical transcriptome profiles.  
 To obtain comprehensive insight into the BDNF-dependent transcriptome 
changes and determine what aspects of interneuronal phenotypes are affected by 
reduced BDNF levels, we performed high-density oligonucleotide microarray profiling 
of the prefrontal cortex of mice with inducible deletion of BDNF. The goals of the 
current study were to: 1) establish transcriptome changes which are a result of 
embryonic deletion of BDNF, 2) identify transcriptome changes that are a result of 
adult deletion of BDNF, 3) describe the genes that are most influenced by the 
absence of BDNF across both conditions, 4) define the transcriptome differences 
between the embryonic and adult BDNF-deficient mice, and 5) identify neuronal 
cortical phenotypes that may be preferentially affected by the absence of BDNF. 
 
MATERIALS AND METHODS 
 
A. BDNF-deficient mice 
 All mice used in this experimental series were described previously (135, 136). 
To generate the animals for the current experimental series, two genetically-altered, 
independently-derived mouse strains were used. Reduction of BDNF expression was 
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achieved using an inducible knockout (KO) of the BDNF gene where two transgenes, 
the tetracycline transactivator (tTA) gene driven by neuron-specific enolase (NSE) 
promoter (nse-tTA) (140) and the Cre recombinase gene under the control of tTA-
responsive tetO promoter (tetO-cre) (141, 142) regulate the deletion of floxed exon V 
of BNDF (143) in a tetracycline-dependent manner.  The two mouse lines with NSE-
tTA and tetO-cre transgenes were both maintained as homozygotes.  Crossing of 
these lines resulted in bigenic mice (143). For the embryonic deletion of BDNF, mice 
were bred in the absence of the tetracycline analogue doxycycline; this resulted in 
late embryonic ablation of BDNF (140). For the adulthood deletion of BDNF, mice 
were bred in the presence of doxycycline (1 mg/ml) in drinking water and maintained 
on this until 3 months of age.  At that time doxycycline was removed from the drinking 
water, thus inducing recombination.  Maximum recombination was achieved 4 weeks 
after doxycycline removal (135) resulting in a >70% reduction in BDNF transcript and 
protein levels (135, 136). Littermates with NSE-tTA and tetO-cre transgenes were 
used as controls. These mice expressed similar levels of BDNF as wild type mice 
(135). 
Mice with BDNF deletion induced from embryogenesis or in adulthood, together with 
the corresponding control animals, were sacrificed between 5 and 6 months of age. 
The experimental series consisted of frontal cortices from a total of 38 animals with 
different animals used for each method of gene expression analysis. For the 
microarray experiments, the adulthood and embryonic BDNF ablation groups 
consisted of 4 animals each, and these animals were compared to 3 control animals 
for each of the experimental groups (14 animals in total). For qPCR experiments, we 
used 3 animals for each experimental and control group (12 animals in total). For the 
in situ hybridization experiments, an additional 3 animals per group were assessed 
(12 animals in total). 
 
B. Microarray experiments 
 Frontal cortices were rapidly dissected, frozen on dry ice, and stored at –80°C 
until RNA extraction. Total RNA was isolated using the Trizol reagent. RNA quality 
was assessed using the Agilent Bioanalyzer. Reverse transcription, in vitro 
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transcription and fragmentation were performed according to manufacturer’s 
recommendation (Affymetrix, Sunnyvale, CA). Samples were hybridized onto 
MOE430A mouse Affymetrix GeneChips which contained >22,000 probesets using 
the Affymetrix hybridization station. To avoid microarray batch variation only 
microarrays from a single lot were used. Microarrays were considered for use only if 
the average 3’:5’ ratio for GAPDH and actin did not exceed 1:1.2. Segmentation of 
scanned microarray images was performed by Microarray Analysis Suite 5.0 (MAS5). 
Determination of expression levels and scaling were performed using Robust Multi-
array Average (RMA) (144, 145). The resulting dataset was filtered for genes that 
reported <30% present calls based on MAS5 analysis. For scale linearity, the data 
were log2 transformed, and differential expression was established using average 
log2 ratio (ALR) between the studied cohorts (|ALR|=1 corresponds to a 2-fold 
increase or decrease, |ALR|= 0.585 represents a 50% change, while |ALR|= 0.263 
depicts a 20% expression alteration). 
 
C. Data analysis 
 Identification of differentially expressed genes across mice with adult and 
embryonic BDNF-deletion. We identified genes as differentially expressed between 
all wild type and all BDNF KO samples if they fulfilled the following 4 criteria: 1) 
reported > 0.263 |average log2 ratio| (|ALR|) in embryonic BDNF-deleted mice versus 
their matched wild-type controls, 2) a groupwise Student t-test reported p< 0.05 in the 
embryonic BDNF-deleted mice versus their matched wild-type controls, 3)  reported > 
0.263 |ALR| in adult BDNF-deleted mice versus their matched wild-type controls and 
4) a groupwise Student t-test reported p< 0.05 in the adult BDNF-deleted mice versus 
their matched wild-type controls. These combined criteria were implemented to 
reduce false positive findings and eliminate significant, but very small, expression 
changes that may have a marginal biological effect (146). A gene was “definitively 
changed” if it met all 4 aforementioned criteria, while a gene was considered 
“putatively changed” if it met 3 of these 4 criteria. 
 Identification of differentially expressed genes showing a more robust 
expression change in mice with embryonic BDNF-deletion. A gene was considered to 
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show a more robust expression change in the comparison of mice with embryonic 
BDNF deletion and matching wild-type controls if it reported: 1) an |ALR| difference > 
0.263 between the two BDNF-deleted mouse groups versus their own controls 
(ALRDIF = ALRADULT KO-WT - ALREMBRYONIC KO-WT) and 2) Student t-test significance for 
the embryonic BDNF-ablated mice at p< 0.05 level in comparison to the control 
littermates. 
 Estimation of false discovery ratio (FDR). Estimation of FDR was performed 
for the genes that were commonly altered between the mice with embryonic and adult 
deletion of BDNF using a custom-designed permutation-based method (147-149). 
Briefly, microarrays were randomly mixed into two groups containing near equal 
numbers of experimental and control arrays (see Supplemental Figure 1). Six random 
permutations were performed with a blocking factor of mouse type (e.g., embryonic or 
adult deletion). For each permutation the two array groups were subjected to the 
same analysis that was used to determine the expression differences (see above). 
The discovered genes (false positive discovery) were averaged across the 6 
comparisons and this value was expressed as a % of genes uncovered in the true 
experimental comparison, thus representing FDR in our experimental design.  
 Calculation of pooled significance. As we used independent samples with 
independent controls across the two groups of BDNF-ablated mice, expression levels 
were compared independently. Combined significance in all Tables was achieved by 
calculating the -2*(ln(pvalue embryonic BDNF KO comparison) + ln(pvalue for adult 
BDNF KO comparison)). The calculation was performed with four degrees of 
freedom. 
 Correlations: Correlations were calculated using Pearson r value for the log2 
ratios between the two compared conditions. Clustering: Two-way clustering (sample 
and gene vectors) was performed on RMA generated log2-transformed expression 
levels using Euclidian distance measurement in Genes @ Work developed by IBM 
(150). Custom database: RMA normalized data and statistical measurements were 
imported into MS-Access. This database is searchable by significance, accession 
number, log ratio and gene name. The database displays individual RMA normalized 
data points across all experimental conditions. Data sharing: The MS-Access 
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database with all data points (~130 MB) is available upon request. All the raw 
microarray data has been deposited into GEO in a MIAME-MGED compliant format 
and is publicly available without any restrictions. 
 
D. Transcript quantification by real-time quantitative polymerase chain reaction 
(qPCR) 
 For selected genes qPCR was performed on a new set of animals from each 
group (3 each for both experimental and control groups, 12 in total). Validation was 
performed on all samples, each originating from a single animal. After primer 
validation (primer efficiency 95-100%) the experiments were performed using 
standard delta Ct-Sybr Green measurement protocols with two independent reverse 
transcriptions and 4 replicates for each of the reverse transcriptions (151). Beta-actin 
was used as a standard normalizer. Statistical significance was calculated using a 
Student t-test using ΔCt measurements for each well. ΔΔCt was calculated as 
(average ΔCt experimental) – (average ΔCt control) between the tested groups. All 
primer sequences are available upon request. 
 
E. In situ hybridization 
 Coronal sections of 20-µm thickness were cut from tissues containing the 
frontal cortex using a cryostat at -20°C, mounted on to gelatin-coated glass slides 
and stored at -80°C until use.  cRNA [35S]-labeled riboprobes were generated by 
PCR amplification of cDNA obtained from normal mouse brain. Approximately 3 ng 
(~2 X 106 DPM) of labeled probe was hybridized per each section. Methods used for 
hybridization were described previously (152, 153). 
  Slides were exposed to BioMax MR film (Kodak) for 8-22 h and then dipped 
and exposed to autoradiographic emulsion (NTB-2, Kodak) for 3-5 days at 4°C.   
Scion Image (version 4.0b) was used to obtain high-resolution scans of each film 
image for quantification.  Darkfield images were captured from the developed slides.  
Slides were coded as to render the investigator performing the analysis blind to the 
condition of each specimen.  KO and control sections were processed in parallel. 
Control hybridization with sense probe did not result in detecTable signal. 
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 Quantification was performed by subtracting the average white matter optical 
density (OD) from the average signal measured across the neocortex (Scion Image). 
Relative expression differences were determined as a mean background-corrected 
OD differences of three animals per group, and significance was determined by 
Student t-test. 
 
RESULTS 
 
Transcriptome changes of mice with conditional ablation of BDNF during adult 
and embryonic life: similarities in expression patterns 
 
 Transcriptome analysis of BDNF-ablated mice at embryonic and adult age 
revealed a number of similarities. When compared to their respective control animals, 
31 gene probesets reported significantly changed expression in both groups of 
BDNF-deficient mice (RMA measured |ALR| >0.263 and p<0.05 in both groups of 
mice; Table 1). None of these probesets reported expression changes that were 
opposite in direction across the two BDNF KO groups. These expression data were 
part of a dataset with a low false discovery ratio (FDR<2%, Supplemental Figure 1). 
Of the genes with changed expression across both groups of mice, reductions in 
gene expression were more commonly observed than transcript inductions (24 
probesets with a mean ALR= -0.59 and 7 probesets with a mean ALR= 0.39, 
respectively). In a two-way hierarchical clustering (Figure 1), both BDNF-deficient 
groups showed a clear separation of experimental and control animals, suggesting 
that this robust pattern is a clear consequence of BDNF deficiency. The expression 
ratios of the adult and embryonic BDNF-ablated mice versus their own controls 
showed a remarkable correlation for this set of genes (r=0.96, p<0.001; see Figure 
2A for details). 
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Figure 9. Two-way clustering of the normalized expression levels of 31 
genes showing common expression changes in adult and embryonic BDNF-
ablated mice. 
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Figure 10.  Correlation of expression changes between the adult and 
Embryonic BDNF-deficient animals. 
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 We also identified a set of genes that showed a putative expression change 
across the two BDNF-ablated mouse groups (Table 2). When compared to their own 
controls, these genes showed a significant expression change for at least 3 of the 4 
statistical criteria used in this study (ALR>0.263 and p<0.05 in both groups). Based 
on the following arguments, the majority of these 46 transcripts are very likely to 
represent true biological expression differences: 1) The FDR for this group was ~16 
% (Supplemental Figure 1); 2) This group contained several duplicate microarray 
probe sets against genes that already reported a definitive expression change in 
Table 1; 3) Clustering with these genes perfectly separated out the KO and the WT 
animals in both the adult and embryonic BDNF ablation (Supplemental Figure 2); 4) 
For these genes, the expression levels between the two groups of BDNF-ablated 
mice were highly correlated (r=0.92; Figure 2B). 5) Selected transcript changes from 
this group were successfully verified by qPCR (see below).  
 Not surprisingly, the gene with the most reduced expression level was BDNF 
in both the adult and embryonic BDNF-ablated mice (ALR=-1.18 with p=0.0042 and 
ALR=-1.20 with p<0.0006, respectively), which further validates our findings and is 
consistent with previously published finding that these mice have a >70% expression 
deficit in BDNF expression (135, 136). The observed expression changes also 
involved 3 independent probesets of cyclin D2 (CCND2), as well as genes that 
interact with CCND2 (cyclin-dependent kinase inhibitor 1C - CDKn1c and Ca/CaM-
dependent protein kinase I gamma - CAMK1g). Furthermore, the levels of the early 
immediate genes (IEG) activity reg cytoskeletal-associated protein (ARC), early 
growth response 1 (EGR1), early growth response 2 (EGR2), FBJ osteosarcoma 
oncogene (FOS), dual specificity phosphatase 1 (DUSP1) and dual specificity 
phosphatase 6 (DUSP6) were also robustly altered, suggesting that BDNF levels are 
critical for regulation of a complex IEG-dependent transcription network.  
 Furthermore, regulator of G-protein signaling 4 (RGS4) transcript was 
significantly decreased in the cortex of mice with the adulthood deletion of BDNF 
(ALR=-0.35; p=0.0046). A similar trend was observed in the mice with embryonic 
BDNF deletion (ALR=-0.35; p=0.0638), suggesting a causal relationship between 
BDNF expression and RGS4 transcript levels. 
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 Somatostatin (SST), neuropeptide Y (NPY) and tachykinin 1 (TAC1) are all 
interneuronal peptide transcripts which are co-expressed to a large degree and 
define a subset of GABA-containing neocortical interneurons (154-156). All three 
transcripts were downregulated in both mice with embryonic (SST: ALR=-0.41; 
p=0.0279; NPY: ALR=-0.38; p=0.0348; TAC1: ALR=-0.31; p=0.0525) and adulthood 
(SST: ALR=-0.49; p=0.0054; NPY: ALR=-0.39; p=0.0254; TAC1: ALR=-0.86; 
p=0.0392) deletion of BDNF.  
  
Transcriptome changes of mice with conditional ablation of BDNF during adult 
and embryonic life: differences in expression patterns 
 
 In addition to gene expression changes that were shared between the 
embryonic and adult KO animals, we also observed a number of gene expression 
changes that were specific to one of the BDNF-ablated groups. For the listing of all 
differentially expressed genes, see Supplemental Table 1 and Supplemental Table 2. 
From all these changes, one group of genes attracted our attention in particular. 
Namely, as the embryonic BDNF deletion creates a behavioral phenotype not 
observed in the adult BDNF-deficient animals (135), we hypothesized that the 
embryonic BDNF-deficient mice would show an expression phenotype not present in 
the adult KO animals. To identify this putative gene expression phenotype, we 
defined a set of genes that showed significant expression differences in the 
comparison of embryonic BDNF KO and control animals, but which were not 
observed (or not observed to the same degree) in the comparison of the adult BDNF 
KO mice and their matching wild-type controls (Table 3). Only 31 gene probesets 
matched these criteria. Of these expression changes, 11 were more upregulated in 
the embryonic comparison vis-à-vis the adult comparison, while 20 genes were more 
downregulated. Gene expression differences included alterations in critical 
developmental genes (HOMER1, neurogenic differentiation 6-NEUROD6/MATH2 
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neuronal pentraxin 2-NPTX2 and growth arrest specific 5-GAS5), RAN-RAP system 
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genes (RAN GTPase activating protein 1-RANGAP1, RAN binding protein 2, 
RANBP2,  RAP1 GTP-GDP dissociation stimulator 1-RAPGDS1) and a variety of 
other functional classes.   
 Interestingly, the two most upregulated gene probes encoded the same gene, 
D7RP2e (DNA segment, Chr 7, Roswell Park 2 complex), a gene with 
uncharacterized function. These 31 genes, using a two-way hierarchical clustering, 
separated correctly the animals with the embryonic deletion of BDNF from their 
matched controls (Figure 3, left panel). However, the same genes could not 
distinguish between the adult BDNF-ablated animals and their control littermates 
(Figure 3, right panel).  
 
Validation of microarray findings 
 All of the 10 expression changes (SST, NPY, ARC, CCND2, EGR1, RGS4, 
CAMK1g, DUSP6, amyloid beta precursor protein-binding A1 - APBA2bp, Kv 
channel-interacting protein 2 - KCNIP2 and BDNF) tested were successfully verified 
by RT-qPCR on a new set of control and BDNF-ablated animals (Figure 4). When the 
microarray-reported groupwise ALR values were compared to the groupwise qPCR -
ΔΔCt values for the 10 genes, the microarray and qPCR datasets showed a high 
concordance in both the embryonic and adult BDNF-ablated animals (r=0.88, 
p<0.001 and r=0.83, p<0.001, respectively). The magnitudes of observed expression 
changes were more prominent in the qPCR experiment than those reported by the 
GeneChips, confirming previous reports that RMA analysis may underestimate the 
expression differences in microarray experiments (144, 148). 
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Figure 11. Figure 3. Expression changes specific for mice with the embryonic 
deletion of BDNF. 
 
 
 
Figure 3. Expression changes specific for mice with the embryonic deletion of 
BDNF. A clustering of the 31 identified gene probes was performed and is presented 
similar to that seen in Figure 1. For source data and abbreviations see Table 3. Note 
that the wild-type and BDNF-ablated mice separate according to genotype (vertical 
dendrogram) in the mice with the embryonic deletion of BDNF (left panel), but not in 
mice with adult deletion of BDNF (right panel). Some of these expression changes 
may be responsible for behavioral differences between the two BDNF-deleted groups 
of mice. 
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Figure 12. Figure 4 Real-time qPCR and GeneChip microarray data are highly 
correlated. 
 
  
Figure 4. Real-time qPCR and GeneChip microarray data are highly correlated 
10 genes were chosen for further verification based on their biological significance on 
new cohorts of BDNF-deficient and control mice. The statistical data obtained with 
the two methods showed a high degree of similarity (A). The qPCR – microarray 
correlation was very high in both the animals with adult (B) and embryonic (C) BDNF 
deletion (r=0.88, p<0.001 and r=0.83, p<0.001, respectively). 
 
 
  48 
BDNF is required for maintenance of SST-NPY interneuronal phenotype in the 
frontal cortex 
 
 BDNF is believed to be critical for the development of cortical interneurons 
(128, 130, 157-159), but the specificity of BDNF action for specific subclasses of 
interneurons is not known. Our previously published study suggested that the PARV 
containing interneuronal class is not affected in either one of these BDNF-ablated 
mice and that the overall GABA-ergic phenotype of the interneurons, judged by 
presence of GAD1 transcript levels, is preserved (136). However, both the microarray  
and qPCR datasets strongly suggested that BDNF expression has a critical effect on 
SST, NPY and TAC1-containing interneuronal populations. In addition, in situ 
hybridization (Figure 5) revealed a robust and significant downregulation of SST in 
the neocortex of both the adult and embryonic BDNF-ablated mice (1.7 and 1.9-fold, 
respectively) in another cohort of mice. Because SST, NPY and TAC1 are co-
expressed to a large extent in a subset of GABA-ergic cortical cells (154-156, 160-
163), we suggest that these transcripts are downregulated in the same interneuronal 
sub-population and most likely represent an interlinked, BDNF-dependent pathology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  49 
Figure 13. Figure 5. Somatostatin (SST) and neuropeptide Y (NPY) mRNA 
expression is reduced I with embryonic and adulthood BDNF-deletion. 
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Figure 14. Figure 6. BDNF regulation of interneuronal transcripts. 
 
 
 
 
 
DISCUSSION 
 
 In this study we analyzed neocortical transcriptome changes in response to 
embryonic and adult conditional ablation of BDNF. This study revealed that: 1) the 
transcriptomes of the adult and embryonic BDNF-deficient mice show highly 
correlated similarities, including altered expression of the transcripts encoding 
neuropeptides (SST, NPY, TAC1), early-immediate genes (ARC, EGR1, EGR2, FOS, 
DUSP1, DUSP6) and critical cellular signaling systems (CDKN1c, CCND2, CAMK1g, 
RGS4); 2) the embryonic BDNF KO animals, when compared to the adult BDNF KO 
mice, reported significant expression changes in several genes related to neuronal 
differentiation (GAS5, NPTX2, NEUROD6, HOMER1), GTPase activating systems 
(RAP1GDS1, RAN2BP2, RANGAP1) and multiple other genes;  and 3) BDNF 
appears to be critical for maintaining SST-NPY-TAC1 expression in interneurons in 
both embryonic and adult KO mice, but without altered expression of GAD1, GAD2, 
calretinin-CALR or PARV. 
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Transcriptome similarities between the embryonic and adult BDNF-deficient 
mice 
 
Deletion of the BDNF gene in embryonic and adult BDNF-deficient mice is primarily 
characterized by transcript decreases. In the context of the physiological role of 
BDNF, this apparent “loss of function” is expected; increased BDNF is associated 
with activity (164, 165), cell survival (166-168), learning and memory (169), synaptic 
plasticity (170, 171), increased synthesis of mRNA and other processes that can be 
looked upon as “positive” cellular events. Loss of BDNF would therefore be expected 
to decrease the expression of genes that mediate these effects. The genes with 
altered transcription implicate the following processes that are likely to be altered in 
these mice. 
 First, a number of the IEGs (ARC, EGR1, EGR2, FOS, DUSP1, DUSP6) 
showed robust decreases in both adult and embryonic KO animals.  In contrast, 
upregulation of BDNF by exercise (149, 164, 165) or by other in vitro manipulations 
leads to induction of these genes (172). IEG induction is known to be strongly 
regulated via the MEK-ERK pathway (173, 174), which is also one of the main 
effectors of BDNF signaling (175, 176). Hence, we propose that the IEG transcript 
downregulations we see in the BDNF-deficient animals are due to the lack of release 
of BDNF and impaired trophic support (177, 178). 
 Second, the cyclin-dependent kinase inhibitor 1C (CDKN1c) and cyclin D2 
(CCND2) also showed expression changes in both groups of KO animals.  CDKN1c 
has been shown to be an inhibitor of the CCND2/CDK complexes (179), and 
consistent with this functional interaction, CDKN1c is the most upregulated gene 
product in the BDNF-deficient mice, while CCND2 is one of the genes showing the 
most robust transcript decreases. In addition, a strong functional relationship exists 
between cyclins and Ca/CAM kinase activity (180), suggesting that the observed 
CDKN1c, CCND2 and CAMK2g transcript alterations are causally related. Recent 
evidence suggests that CCND2 is important in development for neurogenesis, 
proliferation, and differentiation (181, 182), and may be involved in promotion of 
GABA-ergic phenotype (183, 184). As CCND2 is under the control of the previously 
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discussed IEGs, we believe that the CDKN1c, CCND2 and CAMK2g transcript 
changes are mediated via the BDNF-MEK/ERK-IEG pathway.   
 
Expression differences between the embryonic and adult BDNF deficient mice 
 
 Beyond common transcriptome alterations, mice with embryonic and adult 
deletion of BDNF also showed several significant gene expression differences. Most 
notably, the embryonic BDNF KO animals, when compared to the adult BDNF KO 
mice, reported significant expression changes in several genes related to neuronal 
differentiation (GAS5, NPTX2, NEUROD6, HOMER1) and GTPase activating 
systems (RAP1GDS1, RAN2BP2, RANGAP1). As alterations in either of these 
systems may lead to altered behavior (185-187), we propose that some of the 
observed transcriptome changes, in the frontal cortex or other brain regions, are the 
underlying cause of the behavioral changes in the mice with conditional ablation of 
BDNF. 
 
Effect of BDNF on interneuronal gene expression phenotype 
 
 As our microarray experiments were performed on bulk cortical tissue, the 
expression changes we observed in the absence of BDNF reflect a sum of 
transcriptome changes that may occur in a number of different cell types. In the 
context of the phenotypic diversity of the neocortex, the transcriptome of projection 
neurons, glial cells and interneurons could be differentially affected by BDNF 
ablation. To overcome this limitation of the microarray technology, we decided to 
focus our primary attention to expression changes related to specific markers of 
neuronal subpopulations that show a well-defined neocortical distribution.  
 PV, CCK and SST are expressed in separate classes of cortical interneurons 
(188-192). In interneurons SST, NPY and TAC1 are co-expressed to a great extent 
and SST/NPY expression can be induced by a BDNF/TrkB-dependent mechanism 
(193-195). While we observed a strong downregulation in the SST-NPY-TAC1 
transcripts in both adult and embryonic BDNF-ablated mice, we found the expression 
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of other GABA co-localizing neuropeptides and GABA-production enzymes 
unchanged. These data are in agreement with our recent findings that PV and GAD1 
expression are not directly BDNF-dependent (136). Rather, GAD1 and PV expression 
depend on the expression of a functional TrkB receptor: TrkB-deficient mice show a 
remarkable downregulation in GAD1 and PV transcripts, which is not observed in the 
BDNF-deficient animals. These data, combined with the SST-NPY-TAC1 expression 
reduction in the BDNF-deleted mice, argue that interneuronal gene expression is 
regulated in a complex manner (Figure 6). While PV expression may be co-regulated 
with GAD1, the SST-NPY-TAC1 phenotype appears to be GAD1-independent. This 
suggests that BDNF may influence different subclasses of interneurons through 
different molecular mechanisms: the PV-GAD1 regulation is achieved through the 
TrkB receptor, while the maintenance of SST-NPY-TAC1 interneuronal phenotype 
may depend on both BDNF and TrkB expression.  
  
BDNF regulation of the transcriptome: relevance to human brain disorders 
 
 Multiple lines of evidence imply that the BDNF gene is involved in the 
pathophysiology of schizophrenia. Although population studies have yielded 
divergent data about the association of variants in the BDNF gene with increased risk 
and developmental features of schizophrenia (196-202), human postmortem studies 
suggest that individuals with schizophrenia have reduced expression of TrkB and 
BDNF in the cerebral cortex (136, 203-206), as well as decreased BDNF protein 
levels in the serum (207). In addition, various animal models of schizophrenia 
consistently show a down-regulation of BDNF transcript or protein (128, 199-202, 
208-212). Importantly, just as in our current study of BDNF-ablated animals, SST, 
NPY and RGS4 transcripts are downregulated in the prefrontal cortex (PFC) of 
subjects with schizophrenia (153, 213, 214). However, we acknowledge that other, 
BDNF-independent mechanisms may also account for the altered expression of 
these genes in schizophrenia (215, 216). The extent to which a BDNF-dependent 
transcriptome profile is present in schizophrenia remains to be established in 
hypothesis-driven assessment of gene expression changes in the human PFC. 
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 Our findings are also important in the context of recent research on 
Alzheimer’s disease (AD) related pathology. Existing evidence suggests that BDNF-
TrkB controlled SST-NPY levels may play a critical role in the progression of AD. 
First, SST-NPY containing interneurons have been implicated in learning and 
memory (217-220) and postmortem brain studies of AD repeatedly observed a 
severe loss of SST immunoreactive neurons and axons (155, 219, 221-224). In 
addition, APPswe/PS1dE9 amyloid plaque producing mice show reduced SST levels 
in the cortex (225), and this is likely mediated through the interference of amyloid-
beta (Aβ) with the BDNF-induced activation of the Ras-mitogen-activated protein 
kinase/extracellular signal-regulated protein kinase (ERK) and phosphatidylinositol 3-
kinase (PI3-K)/Akt pathways (226).  In contrast, it appears that inducing increased 
expression of SST may be beneficial for patients suffering from AD: compounds 
increasing SST expression are in phase II clinical trials as cognition enhancing 
agents (FK962, Fujisawa Pharmaceutical) (227), and transgenic models of amyloid 
deposition are reversed by environmental enrichment (228), which is known to induce 
SST-NPY expression via a BDNF-dependent pathway. Thus, while altered BDNF 
expression may not represent the primary disturbance in AD, changed expression of, 
or altered responsiveness to BDNF (and subsequently decreased SST levels) may 
represent a critical feature of Alzheimer’s disease progression. 
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ABSTRACT 
 
Normal aging of the brain differs from pathological conditions and is associated with 
increased risk for psychiatric and neurological disorders. In addition to its role in the 
etiology and treatment of mood disorders, altered serotonin (5-HT) signaling is 
considered a contributing factor to aging, however no causative role has been 
identified in aging. We hypothesized that a deregulation of the 5-HT system would 
reveal its contribution to age-related processes and investigated behavioral and 
molecular changes throughout adult life in mice lacking the regulatory presynaptic 5-
HT1B-receptor (5HT1BR), a candidate gene for 5-HT-mediated age-related functions. 
We show that the lack of 5-HT1BR (Htr1bKO-mice) induced an early age-related motor 
decline and resulted in decreased longevity. Analysis of life-long transcriptome 
changes revealed an early and global shift of the gene expression signature of aging 
in the brain of Htr1bKO mice. Moreover, molecular changes reached an apparent 
maximum effect at 18-months in Htr1bKO mice, corresponding to the onset of early 
death in that group. A comparative analysis with our previous characterization of 
aging in the human brain revealed a phylogenetic conservation of age-effect from 
mice to humans, and confirmed the early onset of molecular aging in Htr1bKO mice. 
Potential mechanisms appear independent of known central mechanisms (Bdnf, 
inflammation), but may include interactions with previously identified age-related 
systems (IGF-1, sirtuins). In summary, our findings suggest that the onset of age-
related events can be influenced by altered 5-HT function, thus identifying 5-HT as a 
modulator of brain aging, and suggesting age-related consequences to chronic 
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manipulation of 5-HT. 
 
Introduction.  
Aging leads to morphological(34, 229-232)  and functional(9, 233-235) changes in 
the brain and is associated with increased risk for psychiatric and neurological 
disorders(236-239). However, the mechanisms underlying normal aging of the brain 
likely differ from those associated with neurodegenerative and pathological conditions 
and are still poorly understood(38). Several lines of evidence suggest a role for 5-HT 
during aging, including structural and functional age-related changes in the 5-HT 
system in rodents(240-242), and in humans, as documented by postmortem receptor 
binding studies(243-245), RNA level studies(246), in vivo imaging studies(247) and 
neuroendocrine challenges(236). Depending on the brain region investigated, the 5-
HT modulation of cerebral glucose metabolism increases or decreases during normal 
aging, suggesting a deregulated control of 5-HT(248) (see also (249)). The 
mechanisms for age-related changes in 5-HT function are not known and may 
include gene variants, pharmacological manipulation in adult/old population or late-
onset functional declines. Based on converging roles in energy metabolism, cellular 
signaling pathways and synaptic plasticity, interactions between 5-HT, neurotrophic 
function (Brain-derived neurotrophic factor, BDNF) and insulin-like growth factor (IGF) 
have been proposed as potential determinants of homeostasis and health during 
aging(44). Therefore, due to the critical role of 5-HT in mood regulation, age-related 
changes in 5-HT function are considered a risk factor for developing mood disorders 
in older subjects(238).  
A candidate gene for deregulated 5-HT control in aging is the 5HT1BR(250). 
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5HT1BR is the predominant pre-synaptic autoreceptor modulating 5-HT release in the 
brain(251). Decrease in 5HT1BR function, and not in its somatodendritic counterpart 
(5HT1AR), has been reported in aged rodents(250), consistently with the role of this 
receptor subtype in motor function(252) and with the well-characterized decline in 
motor function during aging. As aging can be viewed as the accumulation of a variety 
of events that together create a chronic challenge to the brain, and since 5-HT is a 
key factor for adaptation to stress(253), we hypothesized that a central deregulation 
of the 5-HT system in Htr1bKO mice would affect the brain response to this challenge 
and reveal the contribution of 5-HT to age-related processes. Accordingly, 
inactivation of 5HT1BR in Htr1bKO mice(254) results in mostly normal baseline, but 
altered 5-HT kinetics upon recruitment of the 5-HT system (i.e. increased release and 
higher synaptic levels), as revealed by pharmacological challenges and microdialysis 
studies(251, 255, 256). Here we addressed the issue of causality versus correlation 
between 5-HT and aging, by investigating age-related behavioral and molecular 
changes as a result of the disruption of serotonin signaling through the 5HT1BR in 
Htr1bKO mice. We now show that the lack of 5HT1BR-mediated signaling induced both 
an early age-related motor decline and a global early shift of the characteristic gene 
expression signature of aging in the brain, ultimately resulting in decreased longevity, 
thus identifying 5-HT as a modulator of brain aging. 
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Material and Methods: 
Animals. All animals were raised under standard conditions: temperature 21±2oC, 
controlled humidity 20-25%, 12:12 photoperiod with lights on at 8:00 pm in order to 
test animals during their scotophase. Food and water were available ad libitum. 
Weaning took place at 21±1 days. At this age, animals were ear-punched and 
genotyped. Littermate wild-type (WT) and Htr1bKO mice were used for all behavior 
and microarray experiments, with the exception of animals used for the 3-month time-
point microarray analysis and for the serum level measurements. These latter groups 
were no more than two generations away from heterozygous breeding. To avoid 
putative confounding effects of the previously reported increased aggressiveness of 
Htr1bKO mice(254), WT and KO mice were housed under reduced cage density, 
resulting in normal or low intra-cage aggression in both experimental groups, as 
revealed by the absence of bite marks or wounds. All experiments were conducted in 
accordance with the European Communities Council Directive of 24 November 1986 
(86/609/EEC) and with the University of Pittsburgh Animal Care and Use Committee. 
Behavior. Separate groups of mice were tested at the age of 2, 6, 12 and 18 months, 
although all animals were generated and born approximately at the same time. This 
means that all animals were submitted to a battery of tests only once, according to 
the following schedule: open-field, elevated-plus maze, rotarod and coat hanger 
tests. At least 1 week separated two different tests. 
Open Field. The apparatus consisted of a grey polyvinyl chloride circular open field, 
40 cm in diameter and 30 cm high. The floor was divided in 6 peripheral and 1 
circular central sectors, all of the same area (180 cm2) and covered by a white sheet 
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of paper which was changed after each mouse. A black-white stripped pattern, 30 x 
20 cm, was present on the wall and provided a local cue. The device was lit by a red 
bulb placed 80 cm above the floor of the open field. Each mouse was introduced in 
the center of the open field and recorded for a period of 5 min. Numbers of peripheral 
and central sector crossings (total locomotion) and of rearing were recorded.  
Elevated Plus maze. The apparatus consists on 2 open and 2 closed 40x10 cm arms, 
located 40 cm above the floor. Mice were placed in the center and the time and 
number of entries in the closed and open arms were recorded for 5 minutes.  
Rotarod. The apparatus consisted of a rotating horizontal rod located 25 cm above 
the floor. A fixed and relatively slow rotating speed was chosen (10 revolution per 
min) in order to increase the sensitivity of this assay at older ages. One block of 10 
trials was applied with an inter-trial interval of 10 min. The latency before falling was 
recorded with a cut-off point of 60 seconds.  
Coat hanger. The triangular-shaped apparatus consisted of a horizontal steel wire 
(diameter: 2 mm, length: 41 cm) flanked at each end by two side-bars (length: 19 cm; 
inclination: 35 ° from the horizontal axis)(257). The horizontal bar was placed at a 
45 cm height from the floor. The mice were placed upside-down in the middle of the 
horizontal wire and released only after gripping with all four paws. Latency before 
falling was recorded. A trial ended when the mice fell or reached the top of the 
apparatus, from which it was retrieved and the maximal score of 1 minute given for 
latencies before falling. A block of 5 consecutive trials was applied with a 15-minute 
inter-trial interval and a 1-minute cut-off period per trial.  
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All behavioural assays were analyzed by ANOVA with age and genotype as fixed 
factors. 
ELISA assays. Blood samples were collected, clotted, and centrifuged at room 
temperature to obtain serum samples, which were aliquoted into microcentrifuge 
tubes and stored at -20°C. Serum samples were thawed and diluted in duplicate, and 
quantitative determination of mouse serum albumin and IgG (Alpha Diagnostic 
International, San Antonio, TX), IGF-1 (Quantikine, R&D Systems, Inc., Minneapolis, 
MN), and insulin (Crystal Chem Inc., Downers Grove, IL) were measured using their 
respective ELISA kits according to specific manufacturer instructions. Within 30 
minutes of terminating each reaction assay, optical densities were measured on an 
ELISA plate reader (SpectraMax Gemini XS, Molecular Devices Corp, Sunnyvale, 
CA) at a wavelength of 450 nm. Mean absorbance for each duplicate sample was 
compared with standard curves to obtain concentration values. 
Intestinal histology. Small and large intestine were harvested, rinsed gently in 
saline to remove food and fecal material, and fixed in 4% buffered formaldehyde for 4 
hours. After washing twice in PBS for 10 minutes, tissue samples were then 
cryoprotected in 30% sucrose in PBS overnight at 4°C. After paraffin embedding, 
tissues were sectioned at 10µm using a sliding microtome, mounted on poly-lysine-
coated slides, dried, and stained with hematoxylin and eosin (Sigma, St. Louis, MO).  
Immunocytochemistry. Small and large intestine were processed for 5-HT1BR 
immunocytochemistry. After cryoprotection with sucrose, intestinal samples were 
frozen in OCT embedding medium (Miles Laboratories, Elkhart, IN), cut in 8µm 
sections on a cryostat, and thaw mounted on poly-lysine-coated slides. Tissue 
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sections were re-hydrated in potassium-phosphate buffer solution (KPBS) at room 
temperature, blocked with 10% normal goat serum, and incubated overnight at 4°C 
with a rabbit polyclonal IgG antibody to the rat 5-HT1B receptor (Acris Antibodies, 
Hiddenhausen, Germany), diluted 1:100 in KPBS, 0.05% goat serum and 0.1% Triton 
X-100. This primary antibody recognizes rat, mouse, and human epitopes 
corresponding to amino acids 8-26 and 263-278 of the rat 5-HT1BR. The following 
day, slides were rinsed with KPBS three times and then incubated with a Cy3-
conjugated goat anti-rabbit IgG secondary antibody (Jackson ImmunoResearch, 
West Grove, PA) at room temperature for two hours at a dilution of 1:800 in KPBS, 
0.05% goat serum, and 0.1% Triton X-100. Slides were washed three times with 
KPBS, coverslipped and imaged using an Olympus Fluoview 500 scanning confocal 
microscope in the Center for Biological Imaging (CBI) at the University of Pittsburgh. 
Optimal antibody concentrations were determined by serial dilutions. Controls for the 
specificity of the antisera consisted of incubation of the tissue with normal rabbit 
serum substituted for the primary antiserum. Using this substitution, no non-specific 
staining was seen. Positive control consisted of substituting mouse cortex for 
intestinal tissue. 
For the dopamine transporter (DAT), a similar protocol was applied on 20µm post-
fixed coronal brain sections incubated with a rat monoclonal anti-DAT antibody 
(Chemicon International Inc., Temecula, CA) in the presence of avidin and biotin 
blocking solutions (Vector Laboratories, Burlingame, CA). Slides were developed with 
the ABC kit (Vector Laboratories, Burlingame, CA). Optimal development time was 
determined on parallel sections. All experimental samples were processed 
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simultaneously with pairs of aged-matched WT and KO sections on the same slides. 
Optical densities were quantified with the ImageJ software (http://rsb.info.nih.gov/ij/). 
 
Microarray samples and processing. Mice were sacrificed by cervical dislocation. 
Brains were split along the sagittal line, frozen in isopentane and stored at –80°C. To 
collect samples, frozen brains were cut on a cryostat to the appropriate anatomical 
level where series of 1 or 2mm diameter micropunches (Sample corer, Fine Science 
Tools, Foser City, CA) were collected from frontal cortex (CTX) and striatum (STR) 
and immediately stored in Trizol reagent (Invitrogen, Carlsbad, CA). CTX samples 
were collected from prelimbic and cingulate cortices corresponding mostly to non-
motor areas between Figure18 and 23 (Bregma ~+2 to +1mm) in the Paxinos-
Franklin Mouse Brain Atlas(258). Dorsal striatum samples were collected starting at 
Figure23 in the same atlas (Bregma ~+1 to 0mm). Total RNA was extracted using the 
Trizol protocol, cleaned with Rneasy microcolumns (QIAGEN, Germany), quantified 
and verified by chromatography using the Agilent Bioanalyzer system. Microarray 
samples (n=3-4 per age-, genotype- and brain regions; total, n~60 arrays) were 
prepared according to the manufacturer’s protocol. In brief, 2µg of total RNA were 
reverse-transcribed and converted into double-stranded cDNA. A biotinylated 
complementary RNA (cRNA) was then transcribed in vitro, using an RNA polymerase 
T7 promoter site which was introduced during the reverse-transcription of RNA into 
cDNA. 20µg of fragmented labeled cRNA sample was hybridized onto MOE 430-2.0 
Affymetrix oligonucleotide microarrays (Affymetrix, Santa Clara, CA). A high-
resolution image of the hybridization pattern on the probe array was obtained by laser 
  66 
scanning, and fluorescence intensity data were automatically stored in a raw file. To 
reduce the influence of technical variability, samples were randomly distributed at all 
experimental steps to avoid any simultaneous processing of related samples. For 
data extraction, single arrays were analyzed with the Affymetrix Microarray GCOS 
software. Microarray quality control parameters were as follows: noise (RawQ) less 
than 5 (CTX: 1.53+0.03; STR: 1.65+0.05), background signal less than 100 (250 
targeted intensity for array scaling; CTX: 46.2+0.9; STR: 45.3+0.8), consistent 
number of genes detected as present across arrays (CTX: 49.7+0.4; STR: 52.6+0.4), 
consistent scaling factors (CTX: 1.80+0.05; STR: 1.52+0.06), Actin and GAPDH 3’/5’ 
signal ratios less than 3 (CTX: ACT, 2.15+0.19, GAPDH, 1.18+0.09; STR: ACT, 
1.43+0.04, GAPDH, 0.90+0.03) and consistent detection of BioB and BioC 
hybridization spiked controls.  
Array statistical analysis. For statistical analysis, probeset signal intensities were 
extracted with the Robust Multi-array Average (GC-RMA) algorithm(145) 
(http://www.bioconductor.org). The 45,101 probesets were reduced to ~20,000 
probesets after preprocessing and filtering (Present calls ≥ 10%, coefficient of 
variation superior than 0.1 and averaged expression ≥ 20). The 3-month WT and KO 
groups were bred at a different experimental time and were not combined in a single 
large-scale analysis.  
Denote by the expression intensities from microarray, where labels indexes for 
genes,  for genotype (k=0: wild-type; k=1: knockout),  for age and 
for biological replicates. Genes with age-related expression changes were selected 
by the following three analytical procedures.  
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- First, expression intensities of each gene g were fitted to a two-way ANOVA model 
in 10-, 18- and 24-month groups and WT and KO groups:. 
In the model,  represents the genotype effect,  the age effect and  the 
interaction term.  
- Second, genotype differences were tested (2-group t-tests) at 3-month of age for all 
genes identified in (1) and, 
- Third, one-way ANOVA models within genotype groups (WT and KO) were fitted to 
genes identified in steps 1 and 2 to characterize the age-related effects in the 
respective WT or KO experimental groups:. 
The goal of the overall analysis was to use the profiles of expression of large 
groups of genes as an “experimental assay” to identify and measure age-related 
molecular effects, and to assess the cumulative effects of changes over groups of 
genes (i.e. correlation, functional analysis…). Therefore thresholds for gene selection 
were kept at medium stringencies (p<0.01, changes greater than 20%). This 
approach has the advantage of allowing the investigation of such patterns, although 
the extent and levels of correlations may have been slightly underestimated. 
 
Mouse-Human age-effect correlation. We have previously reported changes in 
gene expression with age in the human prefrontal CTX using U133Plus-2.0 
arrays(60). Human orthologs of genes with age-effect in the mouse were identified 
between the MOE-430-2.0 and U133Plus-2.0 arrays using the NetAFFX webtools 
(Affymetrix, Santa Clara, CA). In the case of multiple human probesets for a single 
mouse probeset, the human probeset with the lowest age-related p-value was 
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retained. Correlations of age-effects were calculated using log2Ratio values. In 
rodents, the ratios were as described in the text and Figures. For humans, the effect 
of age was calculated as the signal ratio between subjects over 65 years of age 
versus subjects under 30 years(60). Similar results were obtained using different 
threshold criteria for gene selection in the mouse datasets (In Figure2: p<0.001, 
changes greater than 20%). A similar approach was applied to assess correlations in 
transcriptome changes in CTX between BdnfKO mice(62) and age-related profiles in 
Htr1bKO mice, as mouse probesets were directly comparable between the two 
studies.  
Age-pattern correlation. To identify patterns of changes in gene expression in 
relationship to the occurrence of WT/KO behavioral differences (i.e. 10 and 18 
months of age), correlation levels were systematically calculated between WT and 
Htr1bKO mice gene expression at the 10 and 18-months time-points and all possible 
transcript profiles. Profiles were designed based on 2 groups (WT and Htr1bKO), 2 
time-points (10 and 18-months) and 3 ordinal expression levels (high, medium and 
low) for a total of (32)2= 81 possible patterns. The analysis was limited to the 1097 
genes with identified age-effects in either experimental groups. With the exception of 
a very few probesets (See Table S5), all identified genes were expressed at the 
same level at the 3-month time point. 99% of the genes had correlation levels greater 
or equal to 0.7 with at least one pattern. Patterns were then reduced to 3 major 
profiles: i) initial WT/KO differences at 10-months or “early” pattern, ii) initial WT/KO 
differences at 18-months or “late” pattern, and iii) overlapping profiles (no WT/KO 
differences). This approach was more comprehensive than simple group 
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comparisons (i.e. difference or not at 10 or 18 months), although the vast majority of 
genes displayed correlation levels only with a very few patterns that corresponded 
closely to the profiles displayed for averaged values in Figure5.  
Functional class scoring analysis. See details at 
http://www.bioinformatics.ubc.ca/ermineJ/(259, 260). Rather than analyzing genes 
one at a time, gene functional class scoring gives scores to classes or groups of 
genes, representing the overall effect of age on these groups of genes. Gene groups 
were organized according to the Gene Ontology (GO) classification(261) and GO 
groups with greater than 200 or fewer than 8 genes were screened out. GO groups 
were scored as described(260), using age-related p-values as gene scores. Briefly, a 
raw score for each set of genes with a GO family or custom gene group is calculated 
as the mean of the negative log of the gene scores for all genes in each gene class. 
When a gene is represented more than once, only the best score is counted. The raw 
score is transformed into a p-value for age effect on that group by comparing it to an 
empirically-determined distribution of raw scores. This distribution is obtained by 
randomly generating gene classes of the same size as the class being tested; this is 
repeated 100,000 times to generate the distribution of scores expected if high gene 
scores are not concentrated in the class.  
Real-time quantitative PCR was performed as previously described(262). In brief, 
small PCR products (80-120 base-pairs) were amplified in quadruplets on an Opticon 
real-time PCR machine (MJ Research, Waltham, MA), using universal PCR 
conditions (65C to 59C touch-down, followed by 35 cycles [15”at 95C, 10” at 59C and 
10” at 72C]). 150 pg of cDNA was amplified in 20µl reactions [0.3X Sybr-green, 3mM 
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MgCl2, 200µM dNTPs, 200µM primers, 0.5 unit Platinum Taq DNA polymerase 
(Invitrogen, Carlsbad, CA)]. Primer-dimers were assessed by amplifying primers 
without cDNA. Primers were retained if they produced no primer-dimers or non-
specific signal only after 35 cycles. Results were calculated as relative intensity 
compared to actin.  
In situ hybridization was as previously described(263, 264). Primers were designed 
using the primer 3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) 
to amplify half of the gene coding region and half of the 3’ untranslated region of the 
Sirt5 cDNA (NM 178848; base-pairs 510 through 1144). Primers included SP6 and 
T7 RNA polymerase promoter tails for sense and antisense in vitro transcription from 
the amplified PCR products. PCR products were amplified from mouse brain cDNA 
and verified by sequence analysis. Labeled in vitro transcription was performed using 
the Ambion maxiscript kit (Ambion, Inc., Austin, TX) in the presence of 35S-CTP. 
Probes were purified using the Qiagen Rneasy kit (Qiagen, Inc., Valencia, CA) and 
the amount of incorporated radioactivity was quantified on a liquid scintillation 
counter. In situ hybridization was performed on 5 coronal sections per mouse. 5 mice 
were used per genotype and per age group (3, 6, 18, 24 months) according to a 
standard protocol(264, 265). Briefly, slides were incubated for 10 minutes at room 
temperature in 4% buffered paraformaldehyde, washed in 0.1M PBS, serially 
dehydrated in increasing concentrations of ethanol, and then incubated in 
hybridization buffer overnight at 56°C in the presence of antisense or sense probe 
(2,000,000 counts per slide). The following day, the slides were washed, RNAse 
treated, dried and exposed to film. Kodak BioMAx MR film intensities were 
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determined to be optimal after a 4 day exposure. Images were standardized to C14 
standards (ARC-146A and ARC-146D; American Radioloabeled Chemicals, Inc, St-
Louis, MO) and areas corresponding to cortex and striatum were quantified using the 
Microcomputer Imaging Device analysis software (MCID I; Imaging Research, 
London, Ontario, Canada). 
 
Results. 
 
Early onset of age-related motor deficits and reduced longevity in Htr1bKO 
mice.  
Htr1bKO mice presented no obvious developmental changes(252, 254), exhibited a 
normal behavior in young adulthood (Figure1.A-D, 2-month time-points), but 
displayed an early onset of characteristic age-related motor decline, which became 
significant at 6 months of age in the rotarod test and at 12 months in the coat hanger 
test (Figure1.A-B). Total activity in the open field and the elevated plus maze tests 
were not different from WT controls and declined similarly with age (Figure1.C-D). 
This early decline in motor behavior in Htr1bKO mice was not due to learning 
deficits(266), as procedural learning curves were essentially parallel between 
genotypes (Figure1.E). Consistent with previous reports(252) Htr1bKO mice displayed 
normal anxiety-like behavior in young adulthood (FigureS1). Assessing the 
progression of anxiety-related behaviors over time revealed no age-related genotype 
difference, although the interpretation of these measurements was limited by the very 
low activity of older animals in both experimental groups in the challenging 
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compartments of the behavioral apparatus (center of open field and open arms of the 
elevated-plus maze; FigureS1).     
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Figure 15. Figure 1. Early onset of age-related motor decline and reduced 
longevity in Htr1bKO mice. 
 
 
Figure 1. Early onset of age-related motor decline and reduced longevity in 
Htr1bKO mice. A.-B. Htr1bKO mice displayed early age-related motor impairment in 
the rotarod test (A.; Latency to fall: F3,117=11.37, p<e-6; Genotype effect: F=15.04, 
p<0.0005; Genotype*Age: F=2.05, p=0.11) and the coat hanger test (B.; Latency to 
fall: F3,117=8.67, p<0.0001; Genotype effect: F1,120=16.29, p<0.0001; Genotype*Age: 
F3,117=1.98, p=0.12). Post-hoc tests: *p<0.05, **p<0.005. C.-D. Total activity 
decreased with age in WT and Htr1bKO mice in the open field (OF) (C.) and elevated 
plus maze (EPM) (D.) tests (Age effect. OF: F=4.12, p=0.008; EPM: F=20.78, p< e-5), 
although variability in the 12- and 18-month age-groups suggested a potential 
age*genotype interaction (Genotype*Age effect. OF: F=3.09, p=0.03; EPM: F=3.4, 
p=0.02; All other effects, p>0.05). Different cohort of mice were used for each time-
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point to avoid memory savings between experiments (A-D: n=13-18 per group and 
per age). E. Procedural learning curves in the rotarod test were essentially similar, 
but reached lower maximal values in Htr1bKO mice (See A.). F. Kaplan-Meyer survival 
curves revealed a significant decreased in longevity in Htr1bKO mice (p<0.0001). G. 
Mortality curves. Htr1bKO mice displayed a 3.75 fold increased hazard ratio 
(p<0.0005). Hatched curve represents Htr1bKO mortality curve super-imposed on the 
WT curve.  (F-G, WT, n=21; KO, n=24). 
 
The first death events occurred between 16 and 20 months of age in Htr1bKO mice 
and after 21 months of age in WT mice. Htr1bKO mice displayed significantly 
decreased longevity (p<0.0001; Figure1.F), with reductions in maximum (-14%) and 
average (-19%) lifespans. The largest difference was observed at 30 months of age, 
where ~60% of WT mice but only ~5% of Htr1bKO mice were still alive. Inspection of 
complementary log-mortality plots (Figure1.G) and of a Cox proportional hazard 
model revealed that on average Htr1bKO mice had a 3.75 fold increase of hazard ratio 
(p<0.0005). Our analysis also revealed that changes in hazard were time-dependent, 
which means that the increase of hazard could be larger at some points but smaller 
at other times. However, the averaged slopes of the mortality curves were identical 
[WT: 0.159 (0.159–0.177), KO: 0.160 (0.160-0.177)] and the time-related differences 
in estimates were very small, as the Htr1bKO mortality curve was virtually super-
imposable on the WT curve (Figure1G, hatched curve). Thus, together these results 
demonstrated a shift of longevity and mortality curves towards earlier ages in Htr1bKO 
mice, and suggested a causative and modulatory role for 5-HT in age-related motor 
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behavior and longevity.  
 
The “age-related” phenotype of Htr1bKO mice appears mediated by brain 
mechanisms.  
The 5-HT1BR is the main 5-HT presynaptic auto-receptor in the brain(251) and has 
limited functions in the periphery. Thus we hypothesized that the age-related 
phenotype might be mediated by central mechanisms, but first, we investigated 
selected peripheral systems as potential contributors to the phenotype. WT and 
Htr1bKO mice had indistinguishable morphologic features at all ages, including body 
weights (Figure2.A). Mild alopecia and kyphosis appeared in both genotypes after 2 
years of age (not shown). Necropsy procedures revealed no genotype changes in 
organs appearance or weight (not shown), including in kidney and lung, two organs 
with reported roles for 5-HT1BR signaling(267, 268). 5-HT modulates gastro-intestinal 
and immune functions, but the 5-HT1BR plays little-to-no role in these systems(269, 
270). Correspondingly, 5-HT1BR immunoreactivity was undetected in the intestinal 
tract (not shown) and no changes in colonic morphology were identified (Figure2.B). 
Elisa immunoassays on serum obtained from young and old mice revealed normal 
albumin content (Figure2.C), suggesting normal absorptive capacity in Htr1bKO mice 
as compared to controls.  
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Figure 16. Figure 2. Peripheral markers in Htr1bKO and WT mice.  
 
 
Figure 2. Peripheral markers in Htr1bKO and WT mice. A. Body weight (n=14-16 
per group, p>0.05). B. Colon mucosal and smooth muscle layers and lumen were 
equivalent in WT and KO mice (hematoxylin/eosin staining; representative sections 
from old WT and KO groups). C-E. Serum levels of albumin (C.), insulin (D.), insulin-
like growth factor 1 (igf1; E.) and immunoglobulins (IgG, F.). C-E: Young (3 months; 
WT, n=5; KO, n=5), old (18 months; WT, n=6; KO, n=6). Statistical significance: 
main-age effects for albumin (F1,22= 10.2, p=0.005), insulin (F1,22= 11.8, p<0.005) and 
IgG (F1,22= 21.27, p<0.001). Main genotype effect for albumin (F1,22= 4.4, p=0.08), 
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genotype*age interaction (F1,22= 9.2, p=0.02). Main-genotype effect for insulin (F1,22= 
5.02, p<0.05) and age-genotype interaction for IgG (F3,22= 6.5, p<0.05). All other 
effects, p>0.05. Post-hoc tests; *, p<0.05. Error bars represent s.e.m. 
 
Due to the endocrine regulation of aging(271) and potential interaction with the 5-
HT system(44), we measured circulating levels of insulin and insulin-like growth 
factor 1 (IGF-1). Both hormones displayed lower levels in young and old KO mice 
when compared to age-matched control mice (Figure2.C-D), although these 
differences reached statistical significance only for insulin. Serum levels for insulin 
increased with age in Htr1bKO mice, suggesting that the lower levels in young KO 
mice were not due to primary deficits in hormone production. The direction of 
changes also suggests that hormonal levels are not mediating the age-related 
phenotype of Htr1bKO mice for two reasons. First, increased levels above normal, 
rather than lower insulin levels, are associated with deleterious effects of aging(272). 
Second, prior studies in model organisms(271), including mice(273), predict a 
protective effect of decreased IGF-1 levels against aging.  
Finally, an immunoassay for circulating immunoglobulin (IgG) revealed a smaller 
age-related increase in IgG levels in serum of old KO mice (2.3 fold increase) versus 
age-matched WT controls (9.1 fold increase; Figure2.F), thus suggesting a reduced 
inflammatory load, or reduced recruitment of the immune system in aging Htr1bKO 
mice. Thus, combined with the limited functions of 5-HT1BR in the periphery, these 
results suggested that the age-related behavioral phenotype and reduced longevity of 
Htr1bKO mice may have originated from a central deficiency. 
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Dopaminergic terminal density and area are not affected in old Htr1bKO mice. 
In the brain, 5-HT1BR modulates the synaptic release of 5-HT in serotonergic 
projection fields, but also acts as a heterologous autoreceptor indirectly regulating 
dopamine (DA) functions. Indeed, Htr1bKO mice displayed elevated basal DA levels 
and increased striatal overflow after cocaine challenge(255), suggesting potential 
interactions between DA and the age-related motor phenotype. Using 
immunohistochemistry against the DA transporter, we found no differences in DA 
terminals density in the ventral or dorsal striatum of young and old WT or KO mice 
(p>0.5) (Figure 3.A-B). DA terminal striatal areas were also unchanged between 
genotype groups (Figure3.C). Representative Figures and measurements are 
provided at the 18 month time-point, long after the onset of behavioral differences (6-
10 months of age) and corresponding to the time of early onset of death events in the 
KO group. Thus, together these results suggested that the early adulthood onset of 
the motor phenotype in Htr1bKO mice was not due to a structural downregulation of 
the DA system.  
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Figure 17. Figure 3. Intact dopaminergic terminal density in old Htr1bKO mice.  
 
 
 
Figure 3. Intact dopaminergic terminal density in old Htr1bKO mice.  
A. Representative photographs of DA transporter (DAT) immunohistochemistry in 18-
month old WT and Htr1bKO mice (n=4 per group, p>0.05). B. DAT immunoreactivity 
density. C. DAT striatal area. (Similar results were obtained at 3, 6 and 24 months of 
age). 
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Altered gene expression in the brain of aging Htr1bKO mice corresponds to 
“normal” aging.  
Altered 5-HT signaling in Htr1bKO mice could induce brain deficits that are detrimental 
to long-term brain homeostasis and survival and that are yet unrelated to age-related 
processes. Thus, as aging is accompanied by characteristic changes in gene 
expression in the brain(60, 74, 274), we predicted that the “molecular signature of 
aging” might occur earlier in Htr1bKO mice. To this goal we first investigated the 
nature of life-long gene expression changes in cortex (CTX) and striatum (STR), two 
brain areas with well-characterized roles for the 5-HT1BR, and then assessed putative 
differences in the trajectories of age-related changes in Htr1bKO mice.  
Roughly twice as many genes were affected in correlation with age in CTX of 
Htr1bKO mice, compared to WT mice, with fewer genes affected in STR in both 
experimental groups (Figure 4.A.; Tables S1-2). Despite a considerable overlap 
(especially in CTX), some genes were identified only in the WT or in the KO group, 
reflecting either the presence of different age-related effects, or the limitation of the 
analytical procedures at detecting milder effects in one or the other group. To 
address this question, we hypothesized that if selected genes were age-related, then 
the overall changes in transcript levels should correlate across groups, regardless of 
whether genes passed statistical thresholds or not. Indeed, genes identified only in 
Htr1bKO mice demonstrated high correlation levels with the effect of aging on the 
same genes in WT mice (Figure4.B, middle panel), and conversely age-related 
changes in transcript levels identified only in WT mice correlated highly with changes 
in KO mice (Figure4.B, left panel), thus revealing that a similar pool of genes was 
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affected across genotypes. The higher slope values in the correlation graphs of KO-
only selected genes [CTX, KO=1.5, WT=1.2; STR (not shown), KO=2.3, WT=1.4] 
further suggested a larger and more extensive age-effect in Htr1bKO mice. 
Interestingly, correlations were the highest when comparing 18 months-old KO mice 
to 24 months-old WT mice (Figure4.C), suggesting that Htr1bKO mice reached a 
pronounced age-effect earlier than WT mice. This “maximum” age-effect 
corresponded to the period where death events started to occur in Htr1bKO mice 
(Figure1.F). 
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Figure 18. Figure 4.  Correlation of age-related gene expression “signatures” in 
the brains of WT and Htr1bKO mice, and phylogenetic conservation of age-effect 
between mice and humans. 
 
 
 
 
 
 
Figure 4. A-C. WT/Htr1bKO age-effect comparison. A. Venn diagrams of age-related 
transcript changes in CTX and STR (n=3-4 arrays per age-, genotype- and brain 
regions; total, n~60 arrays). B. Correlation graphs between age-effects 
(LogR=log2Old/Young) in CTX between genes identified only in WT (n=106, left), only 
in KO (n=672, middle) and in both groups (n=319, right).  
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C. Correlation levels (r) of age-effects between indicated WT and Htr1bKO age-
groups. All p<0.0001. D-F. Mouse/Human age-effect comparison. D. Age-effect 
correlation graph between genes identified in the mouse and for which age-related 
expression levels of orthologous genes were available in the human CTX(60). Black 
dots indicate genes with most conserved age-effects that are likely to support a large 
proportion of the overall correlation (See F. and Table S3.).  
E. Correlation levels between age-related transcript changes in WT or Htr1bKO mouse 
CTX and two areas of the human prefrontal CTX. All p<0.005, except WT18 versus 
BA47, p=0.01. Correlations were based on age-effect in rodent (p<0.001) and 
identifiable human orthologs (WT, n=88 genes; KO, n=271 genes). F. Selected genes 
with conserved age-effects in CTX between mouse and human. Values are in 
average log2(Old/Young ratio) (Red: increased; Blue: decreased).  See Table S3 for 
additional genes and details. BA9/47, Brodmann areas 9/47. 
 
Mouse-human phylogenetic conservation of age-effect in brain CTX.  
Comparing results to our previous study of the molecular correlates of aging in the 
human brain(60), we identified highly significant correlations between age-related 
effects in WT or Htr1bKO mice and the two investigated areas of the human prefrontal 
CTX (Figure4.D-F). Mouse-human correlations of age-effects increased from 18 to 24 
months in WT mice, but again were highest for 18 months-old Htr1bKO mice 
(Figure4.E). Selected genes with conserved age effects are displayed in Figure4.F 
and in the supplemental information (Table S3). Together, these results 
demonstrated a phylogenetic conservation of age-effect in mammalian CTX and 
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confirmed the age-related nature and early peak of the brain molecular phenotype of 
Htr1bKO mice.  
 
Early occurrence of the age-related gene expression signature in Htr1bKO mice.  
With very few exceptions (See last paragraph), all identified genes were expressed at 
similar levels in WT and KO mice at 3-months of age (Figure5, 3-month time-point), 
indicating that the molecular correlates of the differential age-related phenotype in 
Htr1bKO mice were initiated later in adulthood, and consistently with the lack of 
behavioral differences in young adulthood. As predicted, investigating the 
appearance and progression of age-related changes revealed that over 98% of 
individual genes affected in CTX displayed early changes in Htr1bKO mice when 
compared to WT controls. 25.6% of changes occurred initially at 10 months 
(Figure5.A-B, “early” pattern) and 72.6% at 18 months of age (Figure5.C-D, “late” 
pattern). Likewise, over 97% of age-related genes identified in STR displayed similar 
anticipated age-related profiles in Htr1bKO mice (not shown). This early onset of age-
related pattern is illustrated for glial fibrillary acidic protein (Gfap; Figure5.E-F), a 
marker of age- and brain-related events(275) (i.e. inflammation), which displayed a 
“late” pattern of changes, with initial WT-KO differences at 18-months of age.  
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Figure 19. Over 98% of age-related genes displayed early onset of age-related 
trajectories in Htr1bKO mice 
 
Figure 5. A-D. Averaged transcripts profiles for genes with onset of age-related 
effects in KO mice occurring initially at 10-months [“Early”: 198 increased (A.) & 81 
decreased (B.) genes; 25.6% of age-related genes] or 18 months [“late”: 670 
increased (C.) & 126 decreased (D.) genes; 72.6% of age-related genes], compared 
to the onset of behavioral differences (Vertical gray arrow). <2% of age-affected 
genes had similar profiles in WT and KO mice (not shown). Values are in percentage 
of WT levels. The 3-month old groups used for array analysis were bred at a different 
time and analyzed separately. E. Gfap age-related transcript profiles as an example 
of “late” pattern (Age-effect, p<0.0005 in WT and KO; *, WT/KO at 18-month, 
p<0.05). F. Confirmation of altered Gfap transcript levels by real-time quantitative 
PCR (qPCR): Array/qPCR correlation (r=0.87, p=0.005). Values are mean+sem. G-H. 
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Functional analysis of molecular aging. G. The 25 most affected color-coded gene 
groups in WT and Htr1bKO mice are regrouped in 5 main functions: translation (blue), 
inflammation (red), metabolism (green), cell growth (yellow), cellular respiration 
(Gray), miscellaneous (White). Details in Table S4. H. Proportional representation of 
genes with “early” (10 months) or “late” (18 months) patterns of initial WT-KO 
differences in age-related trajectories within the main age-related functions. 
*p<0.001, difference from expected proportions (White column and hatched bar).  
 
 
 
The presence of different age-related patterns of changes in transcript levels 
raised the question as to whether specific biological functions were associated with 
these patterns, and could thus have mediated the early onset of behavioral changes 
in Htr1bKO mice. To address this question, we a) systematically identified groups of 
related genes displaying high representation of age-affected genes(259, 260), b) 
compared results between WT and KO mice, and c) further investigated whether any 
of the identified gene groups displayed over- or under-representation of genes with 
changes occurring in parallel to the onset of behavioral differences (i.e. “early “ or 
“late” patterns). The cumulative effect of aging on gene groups was assessed 
according to the Gene Ontology classification(261) and is presented in a color-coded 
fashion for the 25 most affected gene groups in WT or Htr1bKO mice (Figure5.G and 
Table S4). The nature of the identified gene groups revealed that very similar 
biological functions were affected during aging in WT and Htr1bKO mice, albeit with 
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minor differences: Translation-related gene groups (Blue bars in Figure5.G) were 
prominent in both groups, but displayed increased “ranked” representation in Htr1bKO 
mice, while the representation of inflammation-related gene groups (Red bars in 
Figure5.G) was decreased in Htr1bKO mice, in reminiscence of previous evidence 
suggesting reduced inflammation in the periphery (Figure1.E). Results are presented 
for CTX and were highly similar in STR (not shown). Importantly, the proportion of 
genes with “early” or “late” onset of WT/KO changes differed only marginally from 
their expected proportions within the 5 main identified age-related functions 
(Figure5.H), with the exception of translation-related gene groups that displayed 
significantly more genes with late-onset differences. Genes with early WT/KO age-
related differences were slightly, but non-significantly, over-represented in 
inflammation-related functions.  
Taken together, results from our temporal and functional analyses of age-related 
changes in gene expression did not identify any specific biological function as the 
potential source or mediator of the early onset of the age-related phenotype, but 
rather suggested a global and early shift of the molecular signature of aging in the 
brain of Htr1bKO mice. 
 
A role for Bdnf in age-related transcriptome changes and in the Htr1bKO 
molecular phenotype? 
Altered neurotrophic function, including 5-HT/Bdnf interactions, has been 
suggested to mediate some of the age-related changes occurring in the brain(44). 
Here, we confirmed the previously reported downregulation of Bdnf transcripts with 
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age in CTX(60, 264, 276) (WT: -1.63 fold change, p=0.006; KO: -2.24 fold change, 
p=0.002; Tables S1 and S3) and showed that changes followed an “early” pattern in 
Htr1bKO mice (Table S1), thus suggesting a potential causative role for altered Bdnf 
function in the Htr1bKO age-related phenotype. Therefore, to investigate the potential 
contribution of Bdnf to the molecular phenotype of Htr1bKO mice, we took advantage 
of a recent report describing CTX gene expression changes occurring downstream 
from altered Bdnf function in Bdnf knockout mice (embryonic or adult BdnfKO,(62)) 
and investigated similarities between Bdnf- and age-induced transcriptome changes. 
In particular, if changes in Bdnf function participated in the age-related Htr1bKO 
molecular phenotype, then the effect of BdnfKO on altered gene transcripts would 
correlate with the effect of aging, and should mostly follow an early pattern of 
changes in Htr1bKO mice. Here, we identified a moderate, but significant, correlation 
between changes in BdnfKO mice and age-related changes in Htr1bKO or WT mice 
(r~0.20, p<0.05). Correlations with age-related profiles were slightly higher for adult 
(r=0.22, p<0.05, n=98 genes) versus embryonic BdnfKO-induced changes (r=0.17, 
p<0.05, n=173 genes). Correlations with BdnfKO-induced changes were also slightly 
higher when compared to age-related changes in Htr1bKO (r=0.23, p<0.05, n=271 
genes) versus WT mice (r=0.20, p<0.05, n=271 genes). Importantly, genes affected 
by both Bdnf and aging displayed age-related trajectories that were evenly distributed 
between “early” and “late” patterns on WT/Htr1bKO differences (i.e. 50% “early” 
patterns genes), suggesting that Bdnf downregulation did not play a major role in the 
early onset of age-related events in Htr1bKO mice.  
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Together, these comparative studies revealed a potential active role for Bdnf in 
age-related changes, as altered gene expression induced by decreased Bdnf 
correlated with aspects of the molecular correlates of aging in the brain (r~0.20, 
p<0.05). However, our studies also suggested that the early age-related phenotype in 
Htr1bKO mice was independent of the role of Bdnf in aging.  
 
Increased age-related sirtuin 5 gene expression.  
What possible mechanism could induce the early onset of age-related events in 
Htr1bKO mice? Out of ~45,000 transcripts tested, only 8 gene transcripts displayed 
consistent genotype differences in CTX and STR (Table S5), including at the 3-month 
time-point that preceded the behavioral differences. Two of these probes 
corresponded to the sirtuin 5 gene (Sirt5), which belongs to a family of protein 
deacetylases that regulate lifespan in yeast, C.elegans and drosophila(277). 
Increased Sirt5 transcripts were confirmed by qPCR and in situ hybridization and 
displayed a pattern of increased levels in Htr1bKO mice, converging towards WT 
levels at 24 months (Figure6). The role of sirtuin genes in replicative and 
chronological aging in lower eukaryotes and mammalian cells is complex(278, 279) 
and whether the reported increased Sirt5 transcripts, and potentially Sirtuin 5 
function, may mediate the early onset of aging in Htr1bKO mice or represent an early 
adaptive mechanism is currently under investigation. 
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Figure 20. Figure 5. Upregulated Sirt5 gene expression in CTX of Htr1bKO mice. 
 
Figure 6. A. Microarray (top), qPCR (middle) and in situ hybridization (ISH, bottom) 
analyses revealed significant increased Sirt5 transcript levels in Htr1bKO mice, with 
normalized differences at 24 months of age. Smaller differences by ISH were mostly 
due to Sirt5 expression throughout the brain, which precluded background 
subtraction and likely underestimated specific signal differences. All values are in 
percentage of young WT controls. Genotype effect: array, p<0.01; qPCR, p<0.05; 
ISH, p<0.01. Pair-wise correlations (array-qPCR-ISH), all r>0.65, p<0.05. B. 
Representative color-coded photomicrographs of Sirt5 35S-ISH at 3, 6, 18 and 24 
months of age. Color barcode indicates increased signal intensity. 
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Discussion. 
Together our studies have demonstrated that altering 5-HT signaling through the 
disruption of the 5-HT1B presynaptic autoreceptor can modulate the onset of selected 
age-related events in the central nervous system. We have shown that the lack of 
5HT1BR-mediated signaling induced both an early age-related motor decline 
(Figure1) and an early shift of the characteristic gene expression signature of aging in 
the brain (Figure5), ultimately resulting in decreased longevity (Figure1). Our results 
also suggested that the age-related phenotype in Htr1bKO mice may have originated 
in the brain, as peripheral markers revealed no effect (intestinal tract), or changes 
suggesting protection or adaptive mechanisms (insulin and IGF-1 systems, Figure2) 
against deleterious aspects of the early onset of age-related events. As aging can be 
viewed as the accumulation of a variety of events that together create in essence a 
chronic challenge to the brain, and since the 5-HT system is a key system for 
homeostatic control and adaptation to stress(80), we have provided here evidence 
supporting the notion that the interaction of 5-HT with this challenge influences age-
dependent behavior and molecular events.  
Investigating the nature and progression of age-related changes in brain gene 
expression throughout the adult life, we have uncovered profound changes in Htr1bKO 
mice, which were characteristic of an early onset of brain molecular aging (Figure4). 
The age-related nature and early onset of the brain molecular phenotype in Htr1bKO 
mice was further confirmed by cross-species comparisons with the correlates of 
aging in the human brain(60). Indeed age-related changes occurring in the CTX of 
WT or Htr1bKO mice significantly predicted age-related changes in two areas of the 
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human CTX, and identified numerous individual genes with similar age-effects across 
species (Figure4 and Table S3), thus demonstrating a phylogenetic conservation of 
the molecular correlates of aging from mouse to human. These analyses confirmed 
numerous prior findings at the level of individual genes (e.g. GFAP, BDNF, MOBP, 
complement activation, etc.; Table S3), but to our knowledge, this is the first large-
scale demonstration of a rodent-human phylogenetic conservation of age-effect in the 
mammalian CTX, thus validating the use of rodent models to recapitulate aspects of 
aging of the human brain. Importantly, these cross-species comparisons confirmed 
the age-related nature and the early onset of the brain molecular phenotype in 
Htr1bKO mice, as Htr1bKO-human correlations of age-effect reached similar levels 
than in WT-human comparisons, albeit at an earlier age (Figure 4.E). 
Imaging and molecular studies suggest that age-related changes are continuous 
and progressive throughout the human adult lifespan(34, 60, 74, 229). Here we 
provided evidence supporting the notion of a “maximum” age-related molecular 
effect. Indeed, Htr1bKO mice reached an apparent peak in age-related changes in 
gene transcript levels at 18 month of age (Figure5), which had not yet been attained 
at the latest time-point investigated in WT mice (24 month of age). Interestingly, the 
timing of this “maximum” age-effect corresponded to the age where death events 
started to occur in the KO group, suggesting a failure of the system at maintaining 
proper homeostasis past this point. Indeed, the decreased correlations of age-related 
transcriptome profiles that were observed between very old Htr1bKO mice and either 
control mice or human subjects (Figure2) may have reflected the presence of 
secondary and less-specific events occurring beyond a certain maximum age-related 
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effect. Nevertheless, despite the potential occurrence of a late breakdown in 
homeostasis, our results demonstrated mostly a parallel and early age-related 
phenotype in Htr1bKO mice. This trajectory was different from the exponential 
acceleration in age-related phenotypes and mortality that is commonly observed in 
mouse models of peripheral/somatic age-related mechanisms(90, 280-282). In 
particular, the increased in hazard ratio in Htr1bKO mice (Figure1.H) appears to be 
mostly due to a shift of death events towards earlier ages, rather than a progressive 
increase in frailty leading to an exponential homeostatic failure(90, 280-282). This 
parallel, rather than exponential, trajectory is consistent with a progressive and 
cumulative effect over time, rather than an acute and early mechanistic switch 
leading to a catastrophic failure of the system. Here we suggest that this parallel age-
related trajectory in Htr1bKO mice is consistent with an altered capacity of the 5-HT 
system to initially respond to the chronic challenge that is formed over time by various 
events occurring during brain aging. Indeed, as typical longevity and molecular 
curves display early “buffer” periods where the cumulative effects of aging are not yet 
observed (i.e. 3- through 12-month behavioral and gene-expression time-points in 
WT), Htr1bKO mice display a reduced “buffer” period (3-months time-point), resulting 
in an early onset, rather than altered progression, of age-related phenotypes. 
To identify potential mechanisms mediating the early onset of the Htr1bKO age-
related phenotype, we proceeded with both unbiased surveys of cellular and 
biological functions and with directed evaluation of markers for candidate biological 
systems. Systematic analyses of functional relationships and of temporal patterns 
between age-affected genes (Figure5) did not identify any novel biological functions 
  94 
being recruited during aging in Htr1bKO mice, but rather suggested a global and early 
onset of the molecular signature of “normal” aging in the brain of Htr1bKO mice. 
Regarding  candidate systems, a leading hypothesis for age-related mechanisms 
centers on the role of oxidative stress and inflammation, as mediators of neuronal 
damage and subsequent increase in reactive astrocytes(38, 41). Here, our combined 
observations of decreased ranked representation of inflammation-related functions in 
the brain, of late appearance of WT/KO differences of a cellular marker of 
inflammation (Gfap; Figure5.E-F) and of evidence of reduced peripheral inflammation 
(IgG, Figure2.F) did not support the notion that inflammation-related events mediated 
the early onset of aging in Htr1bKO mice. Nevertheless, we can not rule out the 
possibility that additional peripheral mechanisms may have contributed to the 
phenotype, especially in the absence of more direct measurements of reactive 
oxygen species-mediated damage such as lipid peroxidation and protein 
carbonylation, which may have contributed to the shortened life expectancy. 
Bdnf is a neurotrophic factor supporting neuronal functions during development 
and in the mature brain. Correlative evidence of decreased Bdnf transcript levels with 
age in the human frontal CTX(60, 264, 276) has suggested the possibility of a 
causative role in brain aging. Here, we confirmed the downregulation of Bdnf with 
aging in the mouse CTX. We also identified a modest but significant correlation 
between the effects of Bdnf hypofunction in BdnfKO mice(62) and the gene expression 
correlates of aging in mouse CTX (r~0.20, p<0.05), suggesting that aspects of aging 
in the brain may occur as a consequence of downregulated Bdnf function. However, 
although interactions between 5-HT and Bdnf have been documented(283) and 
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hypothesized to both concur with IGF-1 to influence age-related events(44), our 
results suggest an age-related phenotype in Htr1bKO mice that is independent of Bdnf 
function.  
On the other hand, our studies provided supporting evidence for potential 
interacting mechanisms between 5-HT and the previously identified age-related IGF-
1 and sirtuin systems. A non-significant trend towards downregulated levels of 
circulating IGF-1 levels in Htr1bKO supports the notion of 5-HT/IGF-1 interaction 
during aging. In this case, lower IGF-1 levels would be protective against aging(273) 
and thus it is not known whether lower IGF-1 levels represented a direct 
consequence of altered 5-HT function or rather a reactive/protective process against 
the detection of an early onset of age-related symptoms, as recently hypothesized for 
age-related processes in peripheral organs(284). Interestingly, a clear upregulation of 
sirtuin 5 gene expression was identified in the brain of Htr1bKO mice. Sirtuin genes 
are major cellular components of age-related pathways, however their role in 
replicative and chronological aging in lower eukaryotes and mammalian cells is 
complex(278, 279). The role of altered Sirt5 transcripts in the age-related phenotype 
in Htr1bKO mice is currently under investigation, including as a potential mediator of 5-
HT control over homeostasis, or as an early mechanism for altering the onset of age-
related phenotypes, since Sirt5 transcript changes preceded the appearance of age-
related behavioral and molecular changes. Nevertheless, it suggests that the 
differentiated central nervous system may share common molecular and/or cellular 
components with age-related mechanisms in peripheral somatic tissues.  
Although the observed phenotype originated from a deficiency in 5-HT-mediated 
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presynaptic inhibition, a limitation in the analysis of potential mechanisms supporting 
the observed phenotype resides in the fact that the deletion of this receptor altered 
the kinetics of the 5-HT system(251, 255, 256), and thus could have influenced the 
behavior, molecular and longevity phenotypes through altered signaling at other 5-HT 
receptors. Therefore, the observed phenotypes should be considered in the context 
of altered 5-HT mediated functions in Htr1bKO mice. This observation relates to our 
initial choice of the Htr1bKO mice for investigating the role of 5-HT into aging, as we 
hypothesized that a disrupted 5-HT homeostasis may initially more closely model the 
evidence of a deregulated control of 5-HT during aging (See Introduction). Moreover, 
other neurotransmitters systems interacting with 5HT1BR and not investigated here 
may have played a role in the mutant phenotype. In particular, changes in cholinergic 
functions may have occurred, as suggested by Buhot et al(266), in view of complex 
changes in memory functions in aging Htr1bKO mice(266).  
The presence of an early deficit in motor behavior was consistent with the role of 
5-HT1BR in motor function(252). The distribution and functional contribution of 5-
HT1BR in the spinal cord and cerebellum are low(285, 286), while the nature of the 
phenotype indicated a deficit in complex motor behavior (rotarod and coat hanger 
tests), rather than a decrease in locomotor and/or muscle strength (Total activity and 
rearing in open field and elevated plus maze; early occurrence rather than 
accelerated frailty). This suggested a deficit in higher coordination, rather than a 
potential degeneration of spinal motor neurons, although a direct examination of the 
integrity of these neurons will be necessary to rule out this possibility. In the central 
nervous system, 5-HT1BR indirectly regulates DA release in STR(255). No evidence 
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of altered DA terminal density and area was identified in STR of old (and young) WT 
or KO mice (Figure3), thus also excluding a structural downregulation of the DA 
system as the cause of the motor deficits in young Htr1bKO mice, although a role for 
altered DA kinetics in aging KO animals can not be ruled out. Moreover, the behavior 
decline could also be mediated through altered signaling at several other 5-HT 
receptors, due to altered 5-HT kinetics(251, 255). Thus, currently the exact 
mechanism leading to the motor phenotype is unknown, and may involve additional 
brain areas and systems not investigated here. Due to the complex biological nature 
of motor coordination and for the purpose of this study, we have considered the 
Htr1bKO motor phenotype as an indicator of changes in overall age-related functions, 
while we have concentrated our molecular studies on FC and STR, as two brain 
areas with well-described roles for 5-HT1BR. Furthermore, investigating the FC 
allowed for the direct comparison of age-related molecular changes in WT and 
Htr1bKO mice with our prior characterization of aging in the human brain(60).  
Eventually, studies using regional-, cell type- and time-specific targeted 
manipulations of 5-HT1BR in conditional mutant mice will be necessary to investigate 
the more specific roles of critical brain regions, time-periods and interacting 
neurotransmitter systems that may participate in the different aspects of the 
behavioral and molecular phenotypes, and that underscore the increased 
vulnerability to age-related events in Htr1bKO mice. 
 
In conclusion, our studies suggest a brain-driven age-related phenotype in mice 
lacking the presynaptic 5-HT1B receptor. The notion of altered longevity and early 
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onset of age-dependent events due to changes in the brain represents an important 
novel finding, which is however not unprecedented. For instance, in lower 
eukaryotes, the well-characterized changes in longevity due to mutations in the IGF-1 
pathway is rescued only when signal transduction is restored in neurons and not in 
other cell types of nematodes(287) and flies(288), therefore providing supporting 
evidence for a control of age-related processes by the brain. Here, as the “onset” 
rather than the “nature” of aging was affected in Htr1bKO mice, 5-HT can be 
considered a modulator of “normal” aging of the brain, consistently with its role in 
adapting to environmental challenges and maintaining homeostasis. As the 5-HT 
system is the target of chronic pharmacological interventions for psychiatric and other 
diseases, these results raise the possibility of long-term and/or age-related 
consequences to 5-HT manipulation that will need to be addressed in future studies. 
Pursuant is the potential for altered molecular and/or behavioral age-related 
trajectories in correlation with genetic polymorphisms in the Htr1b gene or other key 
regulators(83) of the 5-HT system. 
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Abstract   
Mechanisms determining characteristic age of onset for neurological diseases are 
largely unknown. Normal brain aging associates with robust and progressive 
transcriptome changes (“molecular aging”), but the intersection with disease 
pathways is poorly characterized. Here, using cross-cohort microarray analysis of 
four human brain areas, we show that neurological disease pathways largely overlap 
with molecular aging and that subjects carrying a low-expressing polymorphism in a 
longevity gene (Sirtuin5; SIRT5prom2) have older brain molecular ages. Specifically, 
molecular aging was remarkably conserved across cohorts and brain areas, and 
included numerous developmental and transcription-regulator genes. Neurological 
disease-associated genes were highly overrepresented within age-related genes and 
changed almost unanimously in pro-disease directions, together suggesting an 
underlying genetic “program” of aging that progressively promotes disease. To test 
this putative mechanism, we developed and used an age-biosignature to assess five 
candidate longevity gene polymorphisms’ association with molecular aging rates. 
Most robustly, aging was accelerated in cortex, but not amygdala, of subjects 
carrying a SIRT5 promoter polymorphism (+9yrs, p=0.004), in concordance with 
cortex-specific decreased SIRT5 expression. This effect was driven by a set of core 
transcripts (+24 yrs, p=0.0004), many of which were mitochondrial, including 
Parkinson’s disease genes, PINK1 and DJ1/PARK7, hence promoting SIRT5prom2 as 
a putative risk factor for mitochondrial dysfunction-related diseases, including 
Parkinson’s, through a novel mechanism of accelerated molecular aging. Our results 
suggest a possible “common mechanism” underlying age of onset across several 
neurological diseases. Confirming this pathway and its regulation by common genetic 
variants would provide new strategies for predicting, delaying, and treating 
neurological diseases. 
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Introduction    
Disease-specific ages of onset are core features of many neurological disorders, 
ranging from late-onset neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s diseases (average onset 60 and 75 years, respectively) (113) to earlier 
onset psychiatric disorders such as schizophrenia and bipolar disorder (average 
onset 25 years) (114). The mechanism(s) underlying age thresholds and the factors 
that contribute to individual variability in ages of onset within diseases are largely 
unknown. Studies have predominantly focused on contrasting disease brains with 
age-matched controls, a strategy that may be problematic, as it is becoming 
increasingly evident that normal aging is an integral aspect and modulator of disease 
onset and progression. Evidence for this comes from the sheer prevalence of 
diseases with increasing age, such as Alzheimer’s disease, which increases 
exponentially from age 75 upward reaching nearly 45% by age 95 (113). Additionally, 
genetic/environmental lifespan extension studies in model organisms have shown 
that slowing normal aging results in delayed onset of age-related disorders. For 
example, mice hypermorphic for the longevity gene, Klotho, not only live ~20% longer 
but also have a corresponding delay in onset of ectopic calcification, osteopenia, 
arteriosclerosis, emphysema, and insulin resistance (52, 122). This has also been 
shown in a caloric restriction model of extended longevity in primates, which 
demonstrated delayed incidence of diabetes, cancer, cardiovascular disease, and 
brain atrophy (49). It is also becoming clear that age-gated neurological diseases can 
be delayed by extending normal lifespan, as lifespan extension via reduction of 
insulin/insulin growth factor signaling resulted in delayed proteotoxicity in both C. 
elegans and mouse Alzheimer’s disease models (123, 124). 
 What is occurring during the normal aging of the brain that is required for 
disease onset? Robust morphological and molecular changes progressively occur in 
the normal aging brain throughout adulthood and into old age (37). Morphological 
changes include progressive loss of grey matter density (34), disrupted myelination, 
and increasing reactive gliosis. These changes reflect dendritic shrinkage, synaptic 
loss, (37, 38) and thickening glial processes (glial dystrophy) (42). Within neurons, 
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increased DNA damage and reactive oxygen species, calcium dysregulation, 
mitochondrial dysfunction and inflammatory processes have been reported 
(Reviewed in (37). Several groups, including our own, have characterized the 
molecular underpinnings of these changes using human post-mortem brain 
microarray (60, 74, 75); however, no systematic effort has been undertaken to 
explore the molecular overlap of normal aging and disease pathways. Moreover, as 
molecular age accurately predicts chronological age (60), we hypothesized that 
observed deviations from predicted molecular age trajectory may be under genetic 
control, whereas longevity gene variants may affect rates of molecular brain aging 
and risk for neurological diseases, through overlapping age-related and disease 
pathways.  
Materials and Methods    
Cohorts and Microarrays.  We employed two previously described microarray 
datasets: Cohort 1 (60) [39 subjects; ages 14-79; prefrontal cortex (PFC) Brodmann 
area 9 (BA9) and 47 (BA47) samples] and Cohort 2 (289) [36 subjects, ages 23-71; 
anterior cingulate cortex (ACC) and amygdala samples]. Subject characteristics, 
dissection protocols, and array controls have been previously described (60, 289) 
and are summarized in Supplementary Table 1. All subjects were free of age-related 
neurological diseases at time of death according to medical records and pathologist 
examination of brain tissue. GC-RMA-extracted data from Affymetrix HU133A (cohort 
1) and HU133Plus2.0 (cohort 2) arrays were used. Control variables included 
technical measures (chip quality controls, RNA integrity, post-mortem interval) and 
subject characteristics (race, gender, and mode of death). All array data are available 
at our website (www.sibille.pitt.edu), including a searchable database for age effects 
on gene transcript levels in the human brain. 
Importantly, both cohorts included subjects diagnosed with major depression 
(Supplementary Table 1). We have previously shown (and confirmed here) that the 
gene expression correlates of depression were of greatly reduced scope compared to 
the effects of aging.  
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Specifically, in Table S1, we show for both cohorts that the effect sizes of aging are 
between 184 and 986 times greater than the effect sizes of major depression at the 
same significance cutoff of p<0.001 per brain area, depression: 2-6 transcripts per 
brain area) a nd 40-50 times greater at the p<0.01 cutoff, and that major depression 
effects do not survive Benjamini-Hochberg control for multiple testing. Moreover, as 
previously described (60), major depression was not associated with deviations in 
molecular ages (Supplemental Figure S1). So since human brain samples are a 
limited resource and as the effects of depression are of limited scope and do not 
associate with altered rates of molecular aging, we have included these subjects in 
the current analysis in order to increase analytical power (See discussion). 
 
Defining and Validating Age-regulated Genes.   
For congruence with the progressive pattern of structural (decreasing grey matter) 
and functional (cognitive decline) brain aging changes (34, 290), we used best-fit 
age-regression coefficients to determine significance of age-related gene transcript 
changes across subjects (Figure 1a, Supplementary Tables 1, 2). For each transcript, 
equations were generated for linear, log, exponential, and power fits of expression 
level versus chronological age and the most significant (best-fit) equation was 
selected (p-values derived from correlation R-values). False discovery rates (FDR) 
were estimated using Benjamini-Hochberg methodology (291). QPCR validation for 
42 array-defined age-regulated genes are described in (60, 289) and in online 
supplements (Supplementary Figure 2).  
Cross-sectional brain area comparisons. Transcripts with age-regression p<0.001 
were selected for each brain area, and regression equations were solved for 
percentile expression changes between 20 and 70 years of age. Directed Pearson 
correlations (292) were performed by correlating these expression changes with 
transcript levels for the same genes in the other three brain areas. 
Age-related Biosignatures.  Genes were included in the cross-area biosignature if 
they displayed age-regression p<0.01 with age in 3/4 brain areas and p<0.05 in the 
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fourth, and if directions of age-regulated changes were concordant in all brain areas. 
Notably, all but one gene that met the first criteria did not pass the second (HTR2A- 
both probesets increased with age in amygdala but decreased in cortical areas). If 
more than one probeset per gene met both criteria, the probeset with the lowest p-
value across areas was selected to avoid any gene having a greater weighted 
influence on molecular age. For ACC and amygdala-specific biosignatures, genes 
were selected if they had age-regression p<0.01 in those areas.  Cross-area 
biosignature genes, cross-area equations, regression R-values, p-values, and 
magnitude of expression changes are available on-line 
(www.sibille.pitt.edu/data.html). 
Transcriptome functional analyses were performed using Ingenuity® version 7.0. and 
the connectivity map (C-MAP), as described in the respective websites 
[http://www.ingenuity.com/; http://www.broadinstitute.org /cmap, (293)] and in the 
supplements.  
Molecular ages.  Individual predicted molecular ages were calculated for all age-
regulated genes using a leave one out approach within ACC or AMY (Supplemental 
Fig S7), as previously described (60). In short, to describe each sample individually in 
the general aging trend, we have devised a one-number-summary (“Molecular age”) 
for each sample, describing the “predicted age” of the sample when removed from 
the analysis. For each sample, the remaining database was analyzed for age-related 
genes using the same correlation-based methods described above, controlling the 
FDR at 0.05. For each selected gene, a best-fit regression analysis with age was 
performed, and the age for the held-out sample was predicted using the resulting 
function. Extreme outlier molecular ages (+/-10 standard deviations from average 
chronological age) were removed. The resulting gene-wise predicted values were 
averaged per sample and used to described the predicted molecular age of each 
subject.  
SIRt5prom2 (rs938222) Effects on Molecular Age.  SIRT5prom2 is located in a 
mouse/human conserved region predicted by two separate programs to contain a 
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promoter, TSSG CGG Nucleotide Sequence Analysis 
(http://genomic.sanger.ac.uk/gf/gf.html) and Promoter 2.0 (http://www.cbs.dtu.dk/ 
services/Promoter/) (Supplementary Figure 6). Cohort 2 subjects were genotyped by 
sequencing of polymerase chain reaction (PCR) amplified segments of genomic DNA 
obtained from brain samples. Subjects were 50% C/C and 37% C/T in agreement 
with Hap-map (www.hapmap.org) published frequencies for CEU subjects 
(Supplementary Table. 9). Rare T/T subjects were excluded from analysis because of 
lack of power. Genotypic differences in all gene transcript levels were calculated 
using two-tailed Students t-tests in middle-aged cross-sectional groups rigorously 
matched for chronological age, C/C (n=12, average age= 52.1 years, range= 49-63 
years) C/T (n=11, average age 52.7 years, range 48-64 years). Similarly significant 
(although ~10% fewer affected genes) results were obtained using the alternative 
approach of including all subjects and controlling for age and other parameters by 
ANOVA.  
To assess snp-based group differences, molecular ages were subtracted from 
chronological ages to assess deviations of molecular from chronological age, thus 
removing the effect of chronological age. Two-tailed t-tests were performed to obtain 
p-values associated with difference in total molecular age between genotype-defined 
groups. A parallel analysis using an ANOVA model yielded similar and significant 
results, although slightly less robust. This analysis was also performed using only age 
x snp effect intersection transcripts (Figure4b). We refer to these transcripts here as 
‘intersection transcripts’.  
Real-time quantitative PCR (qPCR). qPCR was performed as previously described 
(294). Results were calculated as the geometric mean of relative intensities 
compared to three internal controls (actin, glyceraldehyde-3-phosphate 
dehydrogenase and cyclophilin).  
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Results     
Molecular aging is conserved across cohorts and brain areas 
At p<0.001, 814-1972 transcripts were age-regulated in each brain area with 1-
4% estimated FDR (Supplementary Table 1). Array data were previously validated by 
high correlation with independent quantitative PCR (qPCR) results (n=42 genes, 
R=0.72, p=10-10, Supplementary Figure 1) and by known age-regulated genes 
changing in predicted directions, including up-regulated reactive gliosis markers 
(GFAP), and down-regulated growth factors (BDNF and IGF-1), synaptic markers 
(SYN2) and calcium homeostasis genes (CALB-1)(74, 75) (Figure 1a). Expression 
changes did not reflect age-related changes in cell number, as many neuronal-
specific transcripts were unchanged with age [NRSN2 (295); Figure 1a], consistent 
with stereological studies demonstrating minimal neuronal loss during normal aging 
(38). 
Molecular aging was remarkably conserved across cohorts and brain areas (p<10-
10, Figure 1b). Gross area-specific differences were only observed in amygdala, with 
fewer age down-regulated transcripts (Figure 1b, n=87) compared to cortical areas 
(n=684-1133). We have previously shown that down and up-regulated changes are 
predominantly of neuronal and glial origin respectively (60, 296) (Supplementary 
Table 3); thus the fewer observed downregulated neuronally-enriched changes still 
correlated with changes in other brain areas, but were “noisier” (higher p-values, 
Supplementary Tables 3-5), consistent with structural MRI studies reporting robust 
cortical and more variable amygdala age-related grey matter losses (33). 
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Figure 21. Figure 1. Conserved molecular aging profiles across human brain 
areas. 
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Figure 1.  Conserved molecular aging profiles across human brain areas. A) 
Representative age-regression gene plots and B) cross-area comparisons of age-
regulated gene expression changes [70-20 yrs change; ordered from most increased 
with age (red) to most decreased with age (black)]; n=number of age-regulated 
genes; R=directed Pearson coefficient.  
 
A novel age-related biosignature predicts chronological age, contains 
development- and neurological disease-related genes, and is potentially 
regulated by cell-cycle and neurotransmitter-modulatory drugs 
To assess cross-sectional rates of molecular aging, we developed a brain- and 
age-related biosignature, based on conserved changes across areas (n=356 genes). 
Transcript levels were converted into “molecular ages” using cross-area age-
regression equations, which were averaged to generate a single molecular age per 
subject per brain area, using a leave-one-out approach to avoid circularity. The 
biosignature was highly predictive of subject age (p<10-16, Figure 2a), confirming its 
utility as a quantitative assay and the cross-area robustness of age-related transcript 
changes.  
Using large-scale hand-annotated literature information, Ingenuity® biological 
pathway analysis identified the expected categories of known age-related changes in 
the biosignature (cell morphology, signaling, immune response, vascular function, cell 
death, DNA repair and protein modification) (Supplementary Tables 6,7). Additionally, 
nervous system development was a top category (70 associated genes, 
Supplementary Table 6), highlighting epigenetic regulators, transcription factors, and 
histones, as suggested regulators of a putative age-related transcriptional program 
(Figure 2b). Importantly, neurological disease was a top category (115 associated 
genes), supporting our hypothesis of disease promotion by normal aging 
(Supplementary Table 6,7). 
We further characterized the age-related biosignature using the microarray drug-
matching program, C-MAP (293), by identifying drugs causing transcriptional 
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changes in cell culture inversely correlating with our biosignature (candidate anti-
aging drugs). As an internal validation, C-MAP identified known anti-aging and 
neuroprotective agents, such as α-estradiol and GW-8510, an inhibitor of neuronal 
apoptosis (Figure 2c). Interestingly, results pointed to regulatory roles for cell cycle 
proteins and neurotransmitters as candidate anti-aging drugs, as two of the top six 
drugs were cyclin-dependent-kinase inhibitors and two were monoaminergic 
modulators (Figure 2c). 
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Figure 22. Figure 2.  Age-related biosignature: predictability of subject ages 
and proposed regulatory genes. 
 
Figure 2.  Age-related biosignature. a) predictability of subject ages and b) proposed 
regulatory genes; red= age-upregulated, blue= age-downregulated. N (neuronally-
enriched), G (glial-enriched), B (similarly expressed in neurons and glia), E 
(expression 70-20 yrs, all brain areas). c) Biosignature-predicted age-modulatory 
drugs. AD, Alzheimer’s disease; PD, Parkinson’s disease; HD Huntington’s disease; 
ALS, amyotrophic lateral sclerosis; SCZ, schizophrenia; BPD, bipolar disorder. 
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 Neurological-disease related genes are overrepresented amongst age-
regulated genes and change in pro-disease directions 
To characterize the extent of overlap between age and disease pathways, we 
selected a wider gene group (n=3,935) not restricted by significance in all brain areas 
(p<0.001 in one area, or p<0.01 in two). Again, neurological disease was a top 
Ingenuity®-identified functional category, comprising 34% of age-regulated genes 
(Figure 3a, Supplementary Figure 3). Consistent with our hypothesis, the top 
indentified diseases, Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral 
sclerosis, schizophrenia and bipolar disorder were all common neurological diseases 
with well-defined ages of onset (Supplementary Figure 4). Conversely, disease-
associated genes represented only 4% of non-age-regulated genes (p>0.05 in all 
areas), and neurological disease fell to the 44th functional category with no specific 
diseases represented (Figure 3a, Supplementary Figure 5). Furthermore, 
investigations into a subset of genes with well-established disease-associations 
revealed that expression changes were almost unanimously (32/33) in disease-
promoting directions (Figure 3b, Table 1, Supplementary Table 8). Examples of age-
regulated plots for specific disease-related gene are shown in Figure 3b. Note the 
discrepancy in rates observed across brain regions for some genes. For instance, 
clusterin (CLU), an Alzheimer-related gene displayed greatest age-related increase in 
ACC (red), where neuregulin (NRG-1), a schizophrenia-related gene, showed lowest 
age-related downregulation in BA9 (Dark blue) (Figure 3b), together providing a 
potential mechanisms for region-specific onset of pathological symptoms. 
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Figure 23. Figure 3.  Molecular aging of neurological disease genes.   
  
 
 
  113 
 
Figure 3.  Molecular aging and neurological diseases. a) Percentage of age and non 
age-regulated genes identified as neurological disease-related by Ingenuity. Left) 
34% (n=1,098) of age-regulated genes were neurological disease-related, including 
AD (n=185), PD (n=170), HD (n=267), ALS (n=164), SCZ (n=161), and BPD 
associated genes (n=285). Right) 4% (n=321) of non-age regulated genes were 
neurological disease-related with no specific diseases identified. b) Example plots of 
age-regulated disease-related genes. Trendlines are best-fit regression lines for ACC 
(red), Amygdala (grey), PFC BA9 (dark blue), and PFC BA47 (light blue) with color-
coded equations and corresponding regression p-values. 
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Table 4. Table 1. Neurological disease age-regulated gene expression changes 
are in disease-promoting directions. 
 
Table 1. Agreement of directions between disease-related and age-regulated (age 
70-age 20) gene expression changes. ↓ = decreased mRNA/protein  levels reportedly 
pro-disease; ↑= increased mRNA /protein levels reportedly pro-disease; u= unknown/ 
unclear reports of directionality in disease (references in supplementary Table 8); 
n.s.=non-significant (p>0.05) change with age. 
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SIRT5prom2 associates with decreased SIRT5 expression and accelerated 
molecular aging, particularly of mitochondrial-localized proteins, in a brain 
area-specific manner 
We next hypothesized that longevity genes may regulate brain aging and that 
polymorphisms in these genes may influence gene sets involved in risk for disease. 
We assessed 5 polymorphisms in three candidate longevity genes (Supplementary 
Figure 6, Supplementary Table 9), but focus the remainder of this study on the 
SIRT5prom2 single nucleotide polymorphism (snp), as it was associated with the 
largest and most statistically robust effects on molecular aging (Supplementary Table 
10). We chose SIRT5 due to the increasing role of the sirtuin gene family in 
neurodegenerative disease (54) and due to our previous observation of altered Sirt5 
expression in htr1bKO mouse cortex, a mouse model with anticipated brain aging (63). 
We also concentrated on cohort 2 subjects, for which genetic material was available.  
We show by quantitative polymerase chain reaction (qPCR) that the SIRT5Prom2 
polymorphism associates with a 45-55% decrease in expression in two SIRT5 
transcript variants in ACC (Figure 4a). SIRT5 itself did not display age-regulated 
expression levels (age-regression p=0.45), thus genotypic differences in expression 
were present at all ages. No SIRT5Prom2 genotype effect on SIRT5 expression was 
observed in amygdala (Supplementary Figure 8), suggesting a brain-region specific 
effect of SIRT5Prom2. SIRT5 C/C (low-expresser) allele carrier subjects had 
significantly older ACC molecular ages (+8.6 years, p=0.003, Figure 4b) compared to 
C/T carriers (Supplementary Figure 7). This resulted from apparent accelerated ACC 
molecular aging rates in C/C carriers (increased molecular vs. chronological age 
slope, Figure 4b). Using an amygdala-specific biosignature (Supplementary Figure 
7), we show that SIRT5prom2 was not associated with altered amygdala molecular 
aging, consistent with its ACC-specific effect on expression (Supplementary Figure 
8). 
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Figure 24. Figure 4.  SIRT5prom2 effects on ACC molecular aging 
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Figure 4.  SIRT5prom2 effects on ACC molecular aging. a) SIRT5 expression in 
ACC by prom2 genotype b) Venn diagram (ACC) of age (p<0.01) and SIRT5prom2 
(p<0.01) associated transcripts; (number yr)= average number of molecular years 
greater in C/C subjects than C/T (left); molecular ages of subjects by SIRT5prom2 
genotype (top-right) based on all age-regulated transcripts and core transcripts 
(bottom-right) c) Schematic of mitochondrial age-regulated genes with accelerated 
age-trajectories in SIRT5-low-expresser subjects; blue are age down-regulated 
transcripts; red are age-upregulated transcripts; grey circles identify HD or PD-
associated genes. d) Representative core transcript age-regressions (PD genes) by 
SIRT5prom2 genotype. E) Multi-hit model of age of onset. Rates of age-regulated 
changes in disease gene expression are accelerated in subjects carrying “risk alleles” 
of age-modulatory gene polymorphisms (i.e. SIRT5) in a brain area specific manner, 
resulting in this case in earlier age at which decreased expression reaches a critical 
theoretical threshold for symptom or disease onset. Conversely, protective factors 
(genetic and/or environmental) would delaying onset. A similar mechanism would 
occur for age upregulated disease-related genes. 
 
We investigated whether SIRT5prom2’s correlation with older molecular ages was 
global or potentially driven by a subset of genes. We determined the significance of 
SIRT5prom2 genotype association with transcript changes for all other genes in well 
age-matched subgroups, as an exploratory approach for potential indirect SIRT5prom2-
mediated effects (Supplementary Figure S10). SIRT5prom2 associated (p<0.01) with 
altered levels for 972 transcripts, including 231 age-regulated transcripts (Figure 3b). 
These latter transcript changes almost unanimously (98%) associated with older 
molecular ages in SIRT5-C/C carriers. Indeed, based on these “core” snp-by-age 
intersection transcripts, subjects carrying the C/C allele were on average 24.1 
molecular years older than C/T carriers (p=0.0004, Figure 4b). We conjecture that 
these core transcripts represent proximal effectors in SIRT5’s putative modulation of 
age-related expression changes. 
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These predominantly (74%) neuronally-enriched transcripts included potential 
brain-aging regulators, transcription factors (GTF3A , TCF7L2), Histone 3 
(H3F3A/3B), Chromatin Modifying Protein 2A (CHMP2A), and CDK5 (Supplementary 
Table 11). Strikingly, considering SIRT5’s mitochondrial localization (54, 297), was 
that many core transcripts coded for mitochondrial-localized proteins, including 
numerous components of the electron transport chain (Figure 4c). The top two 
identified canonical pathways were mitochondrial dysfunction and oxidative 
phosphorylation, and the top functional categories - genetic and neurological 
diseases- were predominated by two diseases linked to mitochondrial dysfunction: 
Parkinson’s (9 associated genes) and Huntington’s (22 associated genes) (Figure 4c, 
Supplementary Figures 9-11). Most directly, SIRT5prom2 genotype accounted for all 
age-related declines in expression of the familial Parkinson’s genes, PINK1 and 
DJ1/PARK7 (Figure 4d; qPCR-validated, Supplementary Figure 12). People with loss 
of expression/function mutations in these genes develop early onset Parkinson’s 
(298). Together, these findings suggest that SIRT5prom2 may represent a risk factor 
for mitochondria-related diseases, potentially including Parkinson’s and Huntington’s 
diseases. 
Discussion     
 In this report, we demonstrate that molecular aging of the human brain is 
highly conserved across cohorts and brain areas, and provide evidence suggesting 
an underlying transcriptional program that promotes neurological diseases and is 
under genetic control. 
Expanding from our prior report (60), we demonstrate high brain-area and cross-
cohort conservation of molecular brain aging, selectively affecting ~5-10% of all 
detected genes. Consistent with studies in model systems (299-302), the presence of 
many affected regulators of gene expression (transcription factors, histones, and 
methylases) suggest an underlying genetic program regulating cascades of 
downstream gene expression changes and offering potential entry points to 
molecular dissection of this putative genetic program. Moreover, the characterization 
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of an age-derived molecular biosignature that is highly predictive of chronological age 
pointed towards cell-cycle and neurotransmitter-modulating drugs as potential aging-
regulators, offering insight into how age-related changes may be regulated by new 
candidate anti-aging therapies.   
A notable feature of this molecular signature of aging is a large over-
representation of neurological-related genes almost unanimously affected during age 
in disease-promoting directions, revealing that pathways to several neurological 
diseases may actually be intrinsic aspects of normal aging. Furthermore, the top six 
represented diseases (Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis, 
Huntington’s, bipolar disorder and schizophrenia) were not only all neurological, but 
age-gated. This data suggest a converse interpretation, where age-related diseases 
may stem from expression changes in the most age-vulnerable genes, hence 
promoting age-vulnerable genes as novel candidate disease genes. However, the 
large representation of age-affected schizophrenia and bipolar-related genes is 
intriguing, as while these diseases are age-gated, their onsets occur at younger ages 
and they are often considered development-related diseases. Here, as 
developmental genes were a top represented age-regulated category, our results 
support the concept that aging and development may share overlapping pathways, or 
alternatively, that aging may extend from development. This makes conceptual 
sense, as synaptic pruning for instance is beneficial during development, but related 
mechanisms may lead to deleterious synaptic losses during aging. Moreover, similar 
to our observations during adult and late-life aging, changes in the rates of these 
developmental processes and associated genes can lead to altered brain connectivity 
or subtle changes in synaptic connections, as observed in bipolar and schizophrenia. 
This is consistent with the recent study by Colantuoni et al showing robust changes in 
transcript levels for schizophrenia-related genes during development and early 
adulthood (303).  
An important exception to these age-by-neurological disease observations is the 
absence of depression-related genes and of related functional groups identified within 
the age-related transcriptome changes. However, this is in line with our prior (60) and 
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current (Figure S1) findings describing no correlative effects of depression on the 
trajectory of molecular aging. Interestingly, depression is not considered to be age-
gated, as rates of diseases are consistently high throughout life (304). This is also 
consistent with our observation that chronic stress does not affect molecular aging in 
rodent models (C.Glorioso, C.Belzung and E.Sibille, unpublished data). Nevertheless, 
the presence of subjects with diagnostics of depression is a potential limitation of this 
study that will need to be addressed in larger studies of control subjects only. 
We conjecture that rates of molecular aging of disease-related genes may 
determine at what age (and therefore if) highly prevalent diseases such as 
Alzheimer’s occur, and at what age less prevalent diseases (Huntington’s, 
Parkinson’s) may occur in the context of additional genetic/environmental hits. 
Supporting this gene expression level “gating” model of age-of-onset, promoter 
polymorphisms affecting disease-gene expression, such as Parkin for instance, 
associate with younger disease onset (305). Additionally, the brain-area specificity of 
neurological disorders can potentially be accounted for by this model, as differences 
in rates of disease-gene expression changes varied across areas by as much as 2.5 
fold. Accordingly, a proposed model suggests that people on an older or accelerated 
molecular aging trajectory may present earlier onset of age-related functional 
declines and related diseases (Figure 4e). Conversely, slower molecular age 
trajectory may have protective effects against the same functional outcomes and 
neurological disorders.  
In support of a genetic modulation/control of this molecular aging-by-disease risk 
model, we show that the cross-sectional trajectory of a large component of molecular 
aging was differentially affected in subjects carrying a common polymorphism in the 
SIRT5 putative longevity gene (Sirt5prom2), which we also show correlated with 
reduced SIRT5 expression. Specifically, the greater age-downregulation of 
mitochondrial-related subset of genes in association with Sirt5prom2 suggests first that 
molecular aging may be affected in a modular fashion, and second that longevity 
genes may regulate patterns of transcript changes encompassing different disease 
pathways. Note here that the present investigation was supported by an a priori 
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hypothesis for a putative SIRT5 effect, and that the molecular correlates of the 
SIRT5prom2 variant were supported by FDR estimates. However, FDR takes into 
account a limited amount of information only, namely p-value, rank, number of 
significant transcripts, and total transcripts tested. It does not take into account other 
information present in the dataset such as multiple probesets for the same gene with 
convergent results, relatedness of genes found, and genes with convergent functional 
information. For example, we show that genes identified Sirt5prom2  has an estimated 
FDR of 19%, which can be interpreted as any single significant Sirt5prom2–affected 
gene is estimated to have an 81% chance of being a true positive. However, the fact 
that 227 out of the 231 genes (98%) are in pro-aging directions suggests that the 
actual FDR may be lower.  Additionally, many genes converge on a cellular 
compartment (mitochondria), code for different subunits of the same protein complex 
(Complex 1 for example; Figure 4D), or are identified by significant effects on multiple 
probesets coding for the same gene present (Pink-1 and GTF3A for example), 
together increasing the confidence level in the biological validity of the findings, in 
addition to statistical criteria. Together, our results suggest that SIRT5-risk allele 
(C/C) carriers may be at increased risk for mitochondrial-dysfunction related 
disorders, including Parkinson’s and Huntington’s diseases.  
This proof-of-concept study suggests that genetic modulation of molecular aging 
may associate with differential regulation of specific age-promoted disease pathways 
in the human brain. The confirmation of this model would have profound 
consequences for identifying genetic risk factors and for potential new drug 
development (i.e. SIRT5 targeting in Parkinson’s). To this end, large-scale replication 
of these findings is needed in other postmortem cohorts and in brain areas directly 
relevant to respective disorders (i.e. substantia nigra and basal ganglia for 
Parkinson’s). Here, the association with reduced SIRT5 transcript levels suggests 
that either SIRT5prom2 or closely-linked DNA variants may mediate the observed 
effects, but the extension of these findings to large-scale genetic studies combined 
with molecular aging assays will need larger test and replication cohorts. Further 
confirmation of the model will also necessarily come from assessment of live subjects 
with those neurological disorders and normal control cohorts to assess whether either 
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disease onset and severity, or age-related functional declines (motor, cognition and 
emotionality for instance) are differentially associated with this particular SIRT5 snp 
or with other variants identified using the same methodological approach.  
Concluding, our findings suggest a uniting gene-expression level mechanism for 
age-of-onset across neurological diseases that is congruent with a “common disease 
- common variant” hypothesis. Confirmation of this model will provide new avenues 
for predicting disease onset and trajectory and potentially for creation of novel 
therapeutics through monitoring rates of molecular brain aging (by proxy in peripheral 
blood for example or by advancing neuroimaging techniques), in concert with 
assessment of novel age-related genetic risk factors (e.g. SIRT5prom2) and associated 
biological (e.g. mitochondrial dysfunction) or phenotypic (e.g. cognitive decline) 
mediators.  
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V. DISCUSSION 
 
 Normal human brain aging is an understudied area that has many 
fundamentally different molecular mechanisms and modulators from the periphery. 
Understanding these mechanisms is crucial to the creation and safety of new 
therapies/interventions for neurological functional decline and disease. The research 
presented here investigates several important pieces of this (highlighted in Figure 
25); we demonstrate 1. a causal role of 5-HT and BDNF in modulating molecular 
brain aging in mice, 2. an associative link between a novel low-expressing Sirt5 
polymorphism and human molecular brain aging rates and mitochondrial disease 
promotion, 3. that human molecular brain aging is so highly robust and conserved 
that it is suggestive of a “genetically controlled transcriptional program”, and 4. the 
first evidence for a potential “universal” gene-expression level gating mechanism for 
neurological disease age-of-onset. Here we discuss these findings in their broader 
context, including their caveats and future directions. 
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Figure 25. Investigated aspects of the overarching schema. Neuronal and glial 
“normal” molecular aging: modulators, mediators, and consequences. 
 
 
 
Figure 25. We investigated the causal or associative link between the highlighted 
candidate genes and age-regulated gene expression changes (molecular brain 
aging) in mice or humans, respectively. Additionally, we investigated mechanisms of 
neurological disease promotion by human molecular brain aging. In bold is one 
example (amongst >1,000) of an age-gated neurological disease (PD) promoting 
gene expression change (decreased Pink1 expression; loss of function Pink1 
mutations cause early onset familial PD) shown to occur during normal aging (see 
paper 3). 
 
 
 
 
  125 
 
V.A. Microarray signatures of molecular brain aging: advantages and caveats. 
  
 All three of the studies presented here employ post-mortem brain microarray 
to investigate genetic modulation of molecular aging. Given the relative novelty and 
lingering controversy over this technique, it seems useful to make some opening 
remarks about it in this context. There are a few distinct advantages to microarray 
here: 1. it is unbiased, 2. it allows for measurement of overall aging rates as well as 
investigations into single genes, 3. It is useful as an assay for screening and 
quantifying modulators of brain aging.  
 While critics may denote unbiased array approaches as “fishing expeditions”, 
they are no less legitimate than and are indeed complementary to genome-wide 
association studies and other genome-wide approaches (CNVs). In fact, results and 
new leads from these studies are desperately needed in the fields of  
neurodegenerative and psychiatric disorders. In these highly complex and 
heterogeneous contexts, purely hypothesis driven research has not been and is 
unlikely to be successful in uncovering necessary genetic and molecular mechanisms 
to inform design of much-needed preventative and individualized therapies.  
 Secondly, microarray has the advantage of assessing molecular brain aging 
as a whole (at least one “snapshot” of it), as opposed to quantifying a single 
molecular or functional phenotype (D2 receptor level or age-related working memory 
for example), as a proxy. It additionally is not limited to this, as individual transcripts 
or molecular pathways can be investigated, which is especially appealing given that 
pathway and network analysis software (Ingenuity for example) has rapidly evolved to 
become highly informative, going far above and beyond what any individual could 
hand-surmise.   
 Lastly, drug discovery likely will be hugely influenced in the future by 
microarray-based pattern matching software, such as c-map (see paper 3, 
http://www.broadinstitute.org/cmap/, (293, 306)), which can match over one thousand 
microarray drug signatures from an FDA approved drug library to the microarray 
signature of any phenomena, to rapidly identify novel candidate drugs, drug classes, 
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and modulatory mechanisms. We demonstrate the utility of this in paper 3, where by 
c-map screening of our human molecular brain aging microarray biosignature, we 
identified known anti-aging and neuroprotective drugs as positive controls as well as 
new leads for molecular aging mechanisms and therapies. This rapid drug discovery 
method will have profound consequences for the creation of novel therapies for 
devastating age-related neurological diseases, for which there are no effective 
treatment strategies currently. This potential is unique to microarray as no other 
technique has such a rapid and specific read-out for this purpose. 
 That being said, there are three potential caveats associated with microarray 
that should be addressed: 1. observed molecular events are a single “snap-shot” (the 
RNA level), 2. rates of false discovery must be controlled, and 3. cellular origin of 
transcript changes are not distinguishable. Firstly, some studies use microarrays to 
assess gene expression changes as a proxy for protein level or functional changes, 
in which case expression-protein-function level correlation should be confirmed by 
western blot and/or functional assays. However, for many purposes (including our 
own), such as biosignature assessment molecular brain age, use in drug-matching, 
or studies concerned with gene transcript levels specifically, protein levels/function 
are not relevant.  
 Secondly, a criticism often evoked with respect to gene arrays is that they 
have high rates of false positives. This may stem from lingering impressions from 
older studies using less reliable pre-human-genome-project array platforms and/or 
from the relatively poor statistical control observed in many studies to date. However, 
under the statistical and analytical protocols applied to the papers presented here, we 
(and our laboratory) routinely obtain high correlation (0.7-0.9) between array results 
and their independent confirmation by qPCR.  
 Lastly, the inability to distinguish cellular origin of transcript changes is a 
drawback in the context of placing expression changes into pathways or establishing 
molecular cause and effect relationships, but this can be addressed by double-
labeling experiments and/or in tissue culture. Additionally, microarray technology is 
evolving to intrinsically address this caveat. For example, we have created methods 
to categorize transcripts as predominantly neuronal, glial, or both ((296), paper 3, 
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appendix 4) and laser capture techniques in combination with more sensitive 
amplification protocols have enabled arrays experiments on individual cell layers or 
even individual cells.  
 In summary, with awareness of it’s potential caveats, microarray is an 
extremely useful unbiased approach to uncovering molecular mechanisms and 
evaluating/screening for modulators, which can then be confirmed and further 
investigated on a variety of fronts from molecular studies in tissue culture to 
functional measures in living human subjects. 
 
V.B.  Genetics of “normal” brain aging: what we know now, what we still don’t 
know. 
 
 
 
 Here we establish the first causal links between brain molecular aging and 
BDNF and 5-HT in mice (paper 2), as well as associative links with a low-expressing 
Sirtuin 5 promoter polymorphism and Klotho KL-VS (less robustly) in humans (paper 
3). Human association studies and mouse genetic manipulation studies offer 
convergent information, both required to firmly establish causality. Causality cannot 
be definitively established in humans because co-segregating genetic/environmental 
factors may be responsible for (or interacting with) outcome measures. Conversely, 
biological relevance cannot be definitively established in KO mice because gene KO 
is not identical to the gene mutations, polymorphisms, and age-regulated declines 
driving human molecular aging, and because of mouse-human interspecies 
differences. Indeed, our group has recently shown that while molecular aging of the 
mouse and human brain correlate modestly, substantial differences exist (292), 
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highlighting a potential limitation of these studies. This limitation is also revealed in 
certain neurodegenerative disease mouse models. For example, while PINK-1 
mutations in humans cause familial PD, PINK-1 KO mice are not Parkinsonian, 
displaying only mitochondrial dysfunction without neurodegeneration or shortened 
lifespan (307, 308). This may reflect differences in brain molecular aging or 
interacting genetic factors in the two species. Despite these potential caveats, much 
can still be established in mouse and human genetic studies. 
 
V.B.i. BDNF modulation of brain aging. 
 
 BDNF, an exercise and caloric-restriction induced secreted neurotrophic factor 
that decreases with age (59), has been extensively linked to brain aging. It has been 
shown to be neuroprotective and required for neurogenesis (59), BDNF infusion can 
restore age-related LTP impairments in rats (61), the human val66met (secretion 
deficient) polymorphism is associated with accelerated rates of normal cognitive 
decline and decreased grey matter volumes (77, 78) and the val66met knock-in 
mouse displays memory deficits and reduced hippocampal volumes with underlying 
dendritic shrinkage (309), establishing causality and biological relevance for BDNF in 
several brain aging measures (see introduction for details). In paper 2, we further this 
link by demonstrating that the conditional BDNF KO mouse molecular brain signature 
is correlated with normal mouse molecular brain aging, but also provide evidence that 
BDNF is not a “global modulator” as the correlation was not high enough to fully 
account for all age-regulated molecular changes. Many human top age-regulated 
transcripts (see paper 3), were also top BDNF-regulated transcripts (see paper 1), 
including RGS4, CCND2, APBAP2, SYN2, SST, NPY, and PENK1, suggesting that a 
subset of normal age-related molecular changes in both mouse and human are 
directly modulated by BDNF level.  
 However, because it was tangential in the context of paper 2 and paper 1 
focused primarily on the overlap of BDNF-related changes with GABAergic pathways, 
and SCHZ and AD-related changes (see paper 1), we have not yet investigated 
which age-regulated molecular changes/pathways were anticipated in BDNF-ablated 
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animals. We could explore this by investigating the subset of BDNF-modulated 
versus BDNF-independent age-related changes using pathway analysis tools, such 
as Ingenuity(http://www.ingenuity.com/). We could then perform similar analyses in 
humans with relation to the val66met polymorphism and compare the mouse and 
human subsets of BDNF-modulated age-regulated changes. Finally, an important 
question, especially in the context of BDNF being a logical therapeutic candidate for 
neurodegenerative disease and age-related declines (indeed it is in various stages of 
drug testing by companies and research groups), is whether BDNF rescue can 
reverse or delay these age-regulated molecular changes. To this end, we could use 
the inducible system to ablate and then rescue BDNF expression, and test the 
reversal of age-regulated expression effects by microarray. Another important point 
for human therapeutic purposes, given that BDNF is secreted in both a constitutive 
and activity-dependent manner, is the establishment whether BDNF rescue can be 
blanket (by infusion or drug induction) or must be up-regulated in a biologically-
relevant way. This could also be established in the inducible mouse model with adult 
BDNF rescue of anticipated molecular aging by intracranial infusion, versus drug 
targeting, versus exercise, versus inducible expression rescue. In this context, it is 
also important to establish that BDNF infusion or drug targeting does not cause other 
unwanted side-effects, such as overgrowth of dendrites, which could cause functional 
problems in the brain. This could additionally be established using microarray, by 
testing for molecular consequences that are not related to reversal.  
 
V.B.ii. 5-HT modulation of brain aging. 
  
 As was discussed in the introduction, 5-HT has been hypothesized to 
modulate brain aging because it shares pathways with BDNF and insulin (44), 5-HT 
selective drugs modulate aging in C. elegans (64-66) and promote neurogenesis in 
mice (45), and several serotonin signaling polymorphisms have been associated with 
either age-related cognitive decline and/or grey matter volume loss (81-84). In paper 
2, we show the first causal evidence for 5-HT modulation of normal brain aging, 
demonstrating a global anticipation of age-related molecular changes as well as 
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longevity and motor correlates in HTR1B KO mice. In paper 3, we translate this to 
humans, obtaining a negative result between HTR1B G861C polymorphism and 
human brain aging that should be interpreted in light of it’s many caveats.  
 HTR1B KO mice show a global anticipation of molecular brain aging, ie. 98% 
of age-regulated genes, which is in contrast to the selective anticipation of age-
regulated changes see in BDNF KO mice. Additionally, HTR1B changes correlate 
only very modestly with BDNF-related molecular changes, suggesting that these two 
modulators do not share substantial overlapping mechanisms, contrary to what we 
would have hypothesized based on their shared signaling pathways (44). Together 
this suggests that 5-HT potentially may be a more robust candidate than BDNF for 
modulating overall molecular aging, however an obvious next step would be to further 
establish this by demonstrating that lifespan/healthspan extension in HTR1B over-
expressing mice. Interestingly, we did see evidence of cross-talk between Sirtuin and 
Serotonin pathways as Sirt5 expression was consistently upregulated in KO mice at 
all ages. This putative link warrants further investigation, perhaps in tissue culture to 
establish whether HTR1B may directly or indirectly modulate Sirt5 expression.  
 Importantly, in addition to c. elegans lifespan being modulated by serotonergic 
drugs (64-66), the HTR1B KO mouse further suggests in mammalian systems that 
these highly prescribed drugs may be brain age-modulatory. More specifically, the 
HTR1B/1D agonist migraine medication, Sumatriptan, may delay brain aging or be 
neuroprotective. Studies of molecular brain aging in mice treated with serotonergic 
drugs, such as sumatriptan or SSRI’s, or epidemiologic studies in humans prescribed 
these drugs in relation to functional brain aging measurements, are worthwhile next 
steps in investigating this link. 
 Another interesting implication of this study is that brain aging may modulate 
longevity generally, as lifespan was correspondingly shortened in HTR1B KO mice, 
despite HTR1B being almost exclusively expressed in the brain and peripheral 
markers being normal. There is precedent for this as neuronal-specific p53 dominant-
negative expression or daf-2 KO can extend lifespan in drosophila and nematodes, 
respectively (58, 310). This broadens the implications of molecular brain aging 
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studies to include possible implications for longevity generally and peripheral age-
related disease. 
 It is also important to note that while this study establishes 5-HT generally as a 
brain aging modulator, it doesn’t fully address how 5-HT may modulate human brain 
aging normally. This is for two reasons: 1. Age down-regulation of HTR1B has not 
been equivocally shown 2. HTR1B KO was not conditional. HTR1B expression does 
not appear to decrease with age in any of the four human brain areas we assessed 
(http://www.sibille.pitt.edu/data.html), although we have not yet evaluated many areas 
of the brain (including those where HTR1B is expressed the highest). Additionally, 
there is some evidence that HTR1B declines in certain areas of rat brain (311) and 
also that receptors may decline functionally with age in mice (312). So while overall 
serotonergic deregulation with age has been hypothesized by us and others (63, 311, 
312), the age-related changes in levels and function of serotonergic receptors and 
signaling is not fully characterized and thus mechanisms behind serotonergic 
molecular age modulation remain unknown. More thorough characterization of age-
related changes in human serotonergic pathways may clarify this, as well as 
molecular aging studies in other 5-HT receptor KOs or pharmacological models.  
Lastly, a caveat intrinsic to all non-conditional KO mouse studies is that effects on 
development of the brain can not be entirely ruled out, and thus further dissection of 
mechanism using conditional ablation in adulthood versus development may add to 
mechanistic knowledge. 
 Lastly, we translated our findings to humans, assessing whether the HTR1B 
G861C polymorphism, the most consistently associated HTR1B polymorphism with a 
variety of disorders/phenotypes and thus likely functional (313-317), was associated 
with rates of human molecular brain aging. These findings were not statistically 
significant in either the ACC or Amygdala cohort (see appendix 4, paper 3 
supplements). However, this negative result should confirmed in other (ideally larger) 
cohorts, because we were underpowered in this pilot study to see the more subtle 
effects we might expect with this polymorphism (<4 molecular years), especially 
given that complete receptor KO only resulted in a 20% anticipation in molecular 
aging in mice. It is also possible that other HTR1B polymorphisms or other 5-HT 
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signaling polymorphisms may be more relevant to translation, given that it is unknown 
how this polymorphism changes HTR1B function. 
    
V.B.iii.  Sirt5 modulation of brain aging. 
  
 The Sirtuin family of 7 homologues to the yeast longevity gene Sir2, infamous 
as targets of resveratrol, the putative lifespan extending compound in red wine, have 
been hypothesized by us and others to be candidate brain aging modulators. This is 
chiefly because they have been shown to have roles in preventing axonal 
degeneration (55), neurogenesis (56), and abrogation of protein mis-folding and 
accumulation (54) (see introduction). However, to date there has been no causal link 
established between these genes and brain aging specifically, and only one 
association study has linked a Sirt1 polymorphism to rates of cognitive decline (108). 
Sirt1 is the most studied of these Nicotinamide-dependent histone/protein 
deactelylases because it has the greatest homology to Sir2, but even it’s biological 
function and molecular targets are not fully known. We have focused on Sirt5 
because it was one of the most upregulated genes in our HTR1B KO mouse model of 
anticipated brain aging (paper 2) and thus may be an effector in this phenotype. Very 
little is known about Sirt5 besides that it, as well as Sirt3 and Sirt4, are mitochondrial 
localized, and it has been shown to deactelyate CPS1, a component of the 
mitochondrial localized urea cycle (297).   
 In paper 3, we show that human subjects who are C/T heterozygous for a Sirt5 
promoter polymorphism have ~50% less Sirt5 expression and are on average ~9 
molecular years older than C/C subjects, both of which were cortex-specific effects. 
Additionally, and consistent with Sirt5’s mitochondrial localization, the most 
statistically significant age-regulated transcripts were in the mitochondrial dysfunction 
molecular pathway, including many components of the electron transport chain and 
31 genes related to the mitochondrial dysfunction-related diseases, HD and PD. In 
fact, Sirt5prom2 genotype accounted for all age-regulated expression loss of the 
mitochondrial-located familial Parkinson’s disease genes, Pink-1 and DJ-1. Patients 
with mutations in these genes develop early onset PD and a Pink-1 promoter 
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polymorphism has been associated with earlier onset of PD, suggesting that the age-
regulated loss of expression of Pink-1 and DJ-1 seen in association with Sirt5prom2 
would promote PD onset. 
 These findings create many compelling hypotheses and future directions for 
investigation, but first should be replicated in an additional cohort for confirmation. 
Interestingly also, these findings are the converse of our observations in the HTR1B 
KO mouse, where upregulation of Sirt5 was associated with anticipated molecular 
brain aging, suggesting that perhaps this effect was compensatory to HRT1B’s 
anticipation of brain aging. Future directions include: whether Sirt5 KO mice have 
accelerated molecular brain aging and/or mitochondrial dysfunction, whether Sirt5 
directly or indirectly modulates expression levels of these  age-regulated genes in 
culture and in the Sirt5 KO mouse, and whether Sirt5prom2 is associated with age-
related cognitive decline or age of onset in PD or HD in living cohorts. Sirtuins are 
also promising targets for therapeutic intervention, as Sirtuin-specific drugs are 
already under production in the drug company, Sirtris 
(http://www.sirtrispharma.com/). If, for example, Sirt5 agonists can directly or 
indirectly upregulate Pink-1 or DJ-1 expression, which themselves are difficult drug 
targets, then these drugs may be promising for treatment of Parkinson’s disease. 
 
V.B.iv. Klotho and molecular brain aging. 
 
 Of the five longevity gene polymorphisms tested for modulation of molecular 
age in paper 3, we hypothesized that Klotho KL-VS would be most likely to show 
statistically significant results, because Klotho (and KL-VS) have the strongest 
evidence for modulating normal brain aging. Specifically, KL KO mice show 
accelerated neurodegeneration (92), and the KL-VS allele is associated both with 
human longevity and age-related memory differences (although this may be 
accounted for by Klotho’s baseline effects on IQ) (94,98). What we found was a large 
(+33 years) statistically significant association with VS heterozygous subjects on a 
small subset of age-regulated genes (n=18), which, in contrast to Sirt5prom2’s effects, 
was amygdala specific (paper 3, supplementary Figure X). This result was further 
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supported by correct directionality, ie. the minor VS allele associated with older 
molecular ages as we would predict from the literature. We did not discuss this result 
in detail in paper 3 because these findings were much less robust than those in 
association with Sirt5prom2, which we focused on.  
 However, this does encourage investigation of KL-VS in additional (perhaps 
larger powered) cohorts. Also, most studies investigating KL-VS have been large 
enough to evaluate VS homozygotes, which we did not have large enough sample 
sizes to do. Other logical future directions would be to evaluate the Klotho KO and 
overexpressing mice for rates of molecular aging, and/or perhaps even create a 
knock-in mouse of the human KL-VS polymorphism to causally evaluate its molecular 
effects. 
 
V.C. Brain molecular aging: a genetically modulated transcriptional program? 
 
 A few groups, including our own, have investigated human brain molecular 
aging using microarray and found remarkably consistent results in number (~5-10%) 
and identity of age-regulated changes (60, 74, 75). Most convincingly, in paper 3 we 
correlate age-regulated changes from separate cohorts, university brain banks, 
different microarray chip platforms, and brain areas, demonstrating a remarkable 
(p<10-6) conservation of age-regulated changes (see Figure 1B, paper 3). 
Furthermore, for the most age-regulated of genes (GFAP and CALB-1, for example) 
subject age and expression level were so tightly correlated that regression lines 
assessed using only 36 subjects had p-values of ~10-13 (see Figure 1A, paper 3).  
 Together, this strongly suggests to us that these selective and extremely 
consistent changes may be the result of a tightly controlled age-regulated 
transcriptional program. Moreover, in papers 2 and 3 we provide evidence that this 
putative program is under genetic control, being anticipated by HTR1B KO and 
delayed in Sirt5 high-expressing subjects. If this is the case, then what is the 
mechanism underlying age-regulation of this continuous and progressive program 
and how is it rate-controlled by genetic modulators? 
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 In paper 3, we begin to investigate these potential mechanisms. We highlight 
the robust age-regulated changes in expression of transcriptional regulators, such as 
histones H1 and H3, methylation-related proteins, MECP2 and CHMP2, and 
transcription factors, DR1, TFEB, and FOXO1, as potential hubs or upstream 
effectors in this putative transcriptional program. In support of this, FOXO1 is well 
established (318) and histones and histone targeting drugs (such as HDAC inhibitors) 
(302, 319, 320) have recently been revealed as longevity modulators in model 
organisms. Particularly, an example of this mechanism linking longevity genes, such 
as the Sirtuin family of HDACs, to transcriptional programs which rate-modulate 
longevity has recently been demonstrated. Specifically, loss of Sirt6 has been shown 
to cause hyperacetylation of Histone H3 lysine 9 (a top age-regulated gene in our 
study (paper 3, Figure 2A)), which increases expression of NFκB (another top age-
regulated gene in our study) through increasing RELA promoter occupancy, which 
leads to altered NFκB regulated gene expression and cellular senescence (302). 
Proving causality in this mechanism of accelerated aging, Sirt6 KO mouse early 
lethality and degeneration can be rescued by RELA haploinsufficiency(302). Together 
this leads us to hypothesize the below feasible general mechanism: 
 
Figure 26. Mechanistic schema for genetic modulation of molecular brain 
aging  
 
 
 
 This model suggests that in tissue culture for example, molecular aging could 
be dissected into segments of age-regulated changes under control of particular 
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modulators. This fits with our findings surrounding subjects with the low-expressing 
Sirt5prom2 allele, wherein we observed a subset of age-regulated changes were more 
dramatically accelerated than the rest (paper 3), suggesting that these changes may 
be most directly effected by lower SIRT5 levels, perhaps through SIRT5’s modulation 
of a transcriptional regulator (such as our observed effects on GTF3A, paper 3) or a 
more complex multi-step mechanism. To investigate this we could, for example, 
knock down SIRT5 using RNAi in neuronal culture and see if we could recapitulate 
the microarray changes observed in low-expressing SIRT5 subjects, establishing 
causality. We could then systematically knock down candidate “second effector” 
transcriptional regulators, such as GTF3A, and investigate whether we could still 
recapitulate the results (using arrays), thereby beginning to place age-regulated 
changes in a hierarchy. We could then investigate whether SIRT5 directly interacts 
with or deacetylates these “second effectors”. This strategy could be generally 
applied to a variety of brain molecular aging effectors. We could also directly test if 
and which cellular morphological and phenotypic outcomes result from a given 
molecular aging segment of changes downstream of a modulator, thus creating 
causal links between modulator, molecular aging segment, and phenotype. Molecular 
aging dissection would not only shed light on aging mechanisms, but also create a 
plethora of drug targets at different levels of specificity for aging and age-related 
disease. 
 Another interesting unknown in this hypothesized mechanistic schema is the 
upstream “clock input”, ie. what counts the days and years of life and translates it into 
declining function or levels of a molecular aging modulator/longevity gene, such as 
BDNF or Sirt6? Firstly, counting may be accomplished from mitochondrial output, or 
accumulating DNA damage and ROS, for example, although this does not account 
for its translation into steadily declining modulators. This could in some way be 
related to the fact that Sirtuins are NAD-dependent and thus directly coupled to 
output from mitochondrial metabolic pathways. Mitochondria also steadily generate 
ROS from oxidative respiration and the rate of this is slowed by caloric restriction, 
another known modulator. Additionally, Lu et. al demonstrated that promoter regions 
of age-regulated genes are more susceptible to DNA damage(74), and while it is 
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difficult to conceptualize a mechanism whereby promoter damage would directly 
result in such precise and continuous changes in gene expression, this may play 
some role in regulating this putative molecular aging program.  
 It may also be worth speculating about whether redundant mechanisms from 
other contexts wherein “telling time” is necessary, i.e. for proper rate of cell division in 
dividing tissues and in development, or for circadian clock regulation, are at play 
here. To this end, we observed that CDK2 and CDK5 are top age-regulated genes, 
and the microarray signature drug matching program, C-MAP, pointed to a role for 
neuroprotective cell-cycle modulating drugs in molecular brain aging (Figure 3C, 
Paper 3). Could the cell cycle, which plays a large known role in peripheral aging in 
relation to senescence, have a similar role in non-dividing brain cells but instead “tell 
time” for age-regulated morphological/phenotypic changes? This remains to be 
investigated in tissue culture and/or model organisms. 
 In line with another “clock” theory, that of “developmental drift” put forth by Dr. 
Stuart Kim and colleagues in relation to c. elegans aging(321), we found that 
development-related genes were a top Ingenuity indentified age-regulated category, 
comprising ~1/3 of age-regulated changes(paper 3). The developmental drift theory, 
in line with our schema, postulates transcriptional programming driving aging, in this 
case extending from developmental programs, which continue deleteriously through 
adulthood due to the absence of evolutionary pressure post the reproductive window. 
This is a particularly logical hypothesis for brain aging, given that aging and 
development share cellular phenotypic changes. For example, continuation of 
developmental synaptic pruning programs may result in the deleterious losses of 
spines and dendritic complexity seen during aging.  
 In summary, the robustness, consistency, and selectivity of brain molecular 
aging suggests that it may be a transcriptional program intermediary between 
longevity/modulatory genes and cellular morphological/phenotypic changes. Thus 
establishing causality, and determining up-stream modulators and downstream 
consequences of this program will be crucial to understanding aging mechanisms 
and creating new therapeutic targets.  
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V.D Gating of neurological disease by normal brain aging: a universal gene-
 expression level mechanism? 
 
 Why is brain aging required for onset of diseases ranging from psychiatric 
disorders such SCHZ and BPD to neurodegenerative diseases such as AD, PD, HD 
and ALS?  Why are mutations such as expanded tri-nucleotide repeats in HD or Pink-
1 loss-of-function mutations in PD essentially silent in early adulthood, but become 
progressively more deleterious with age? Here we hypothesize about these largely 
unanswered questions, but first it is worth framing this discussion in an evolutionary 
context. Specifically, these age-gated mutations/polymorphisms likely stay in the 
population because they only become phenotypically expressed and thus impact 
fitness after the reproductive window.  
 In paper 3, we hypothesize that a “universal” mechanism potentially drives 
age-gating of many of these diseases. Namely, that progressive age-regulated loss 
or gain of neurological-related disease gene expression promotes (as part of the 
putative transcriptional aging program), and is both additive with and required for 
disease gene mutations/polymorphisms to cause disease. Also, because age-
regulated expression changes are continuous and progressive, this would account for 
the age-specific gating and progressive nature of these neurological disorders. 
 The evidence for this is only observational as of yet (see paper 3), but it is 
compelling. Firstly, the putative highly selective “transcriptional program” of brain 
aging preferentially regulates neurological disease-related genes. In fact, ~34% of 
age-regulated genes (>1,000) in the human brain have known association to one or 
more of six age-gated neurological diseases (AD, PD, HD, ALS, BPD, SCHZ, see 
paper 3, Figure 3). Conversely, almost no genes with known associations to these 
diseases have age-independent expression levels (see paper 3, figure 3). This is 
impressive, given that only 5-10% of the genome is age-regulated. Moreover, the 
direction of age-regulated expression changes in these disease-associated genes is 
almost unanimously in directions known to cause or promote disease (see paper 3, 
table 1).   
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 By way of example, it seems very likely that highly significant 15-35% drops in 
expression of six different familial PD genes in addition to Complex I (rotenone 
complex I inhibition causes PD) by age 79 (paper 3, table 1), would modulate or even 
be “the gating mechanism” for age of PD onset in genetically vulnerable individuals. 
To put this another way, one could conceive that a loss of function mutation or a low-
expressing promoter polymorphism in one copy of Pink-1, for example, would not be 
sufficient to cause disease in early adulthood, but in conjunction with significant age-
regulated loss of expression of the other wild-type Pink-1 allele as well as other 
familial PD genes by age 70, it may be sufficient to cause disease. From an 
evolutionary perspective it may thus make sense to look at preferential age-regulation 
of neurological disease genes in the converse, i.e. the age-gated neurological 
diseases that are present in the population are the result of insufficient/partial (in the 
absence of aging) mutations in the most age-vulnerable genes. Thus, all age-
regulated genes may be good candidates for disease-related genes. 
 While this universal transcriptional age-of-onset mechanism is compelling and 
suggests promising starting points for investigation, many further lines of evidence 
are required for its confirmation. Remaining questions include 1. are these 
declines/increases in disease gene expression sufficient to cause disease? 2. are 
they more rapid/severe or in patients that have earlier disease onset? 3. can delay in 
declines of age-regulated disease genes prevent or delay disease in animal models?. 
Evidence for this could begin in human populations looking at disease risk/onset age 
in association with age-regulated changes in expression levels of disease genes 
(either by proxy in peripheral blood or if technology advances, by neuroimaging). 
However, these studies would not establish causation. For this, novel animal models 
may need to be created where disease gene expression could be progressively up or 
down regulated to reverse or induce disease in the background of disease causing 
genetic mutations/polymorphisms. This technology does not currently exist, however, 
and may be difficult to engineer. 
 If this mechanism proves to be correct, however, it is very encouraging for the 
treatment of these devastating age-gated diseases. Firstly, it implies that delaying 
normal brain aging would likely prevent, delay, or treat these diseases, which there is 
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already some evidence for in model organisms. Additionally, it provides an assay to 
determine whether pharmacological or other interventions are successful, i.e. 
monitoring molecular aging or age-regulated expression changes of specific disease 
genes (by proxy in peripheral blood/neuroimaging) provides an easy read-out for 
success of new therapies. It also implies that by monitoring molecular brain aging 
(perhaps using proxy peripheral blood biosignatures) in conjunction with genetic 
testing, at-disease-risk individuals could be indentified relatively easily and 
preventative measures taken before irreversible neurodegeneration ensues. 
 
V.E. Overall conclusion 
 
 The molecular genetics of brain aging field is full of promise for pharmacologic, 
environmental, and genetic manipulation of rates of cognitive decline and age-gated 
neurological disease. The future is bright for anti-brain-aging measures being 
effective in treating devastating neurological conditions such as AD, PD, HD, and 
ALS. Careful investigation of the highly complex and relatively poorly understood 
mechanisms behind the genetics and molecular pathways of brain aging is required 
to ensure the efficacy and safety future interventions. Here, using brain microarray in 
conjunction with genetic studies in mammals, we provide mechanistic leads in 
biologically relevant contexts to begin to understand these mechanisms. Particularly, 
molecular dissection of our hypothesized “transcriptional program of molecular brain 
aging” and it’s potential gating of neurological disease may be very informative. 
Additionally, we provide support for BDNF, serotonergic drugs, and Sirt5 as 
candidate therapeutic targets for aging and age-related disease. Molecular aging 
biosignatures will likely play a key part in testing and monitoring 
genetic/environmental modulators and interventions in the future. To this end, an 
interactive database of age-regulated genes in the human brain is freely available at 
our website (http://www.sibille.pitt.edu/). 
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APPENDIX A. PAPER 1 SUPPLEMENTS 
 
SUPPLEMENTAL MATERIAL (2 FIGURES +2 TABLES). 
 
 
For Table layout and further explanation, see Table 1 legend.  
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Table 5. Supplemental Table 1. Gene expression differences observed in mice with 
an adult ablation of the BDNF gene.  
 
 
  143 
Table 6. Supplemental Table 2. Gene expression differences observed in mice with 
an embryonic ablation of the BDNF gene.  
For Table layout and further explanation, see Table 1 legend. 
l 
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Figure 27. Supplemental Figure 1. Assessment of false discovery ratio (FDR) 
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Top panel represents experimental outcome with 31 definitively and 46 putatively 
changed genes. FDR was assessed in a permutation test, where experimental and 
control microarrays were randomly assigned to two groups within their own condition. 
These groups were assessed for gene expression differences with the same analysis 
as in the experimental – control comparison.  C1-3 denote control samples, E1-4 
denote experimental samples (a=adult, e=experimental). For each analysis number 
on arrow denote the number of genes with changed expression in a permutation. 
Number of  putatively changed genes is denoted in parenthesis. Note that in this test, 
the FDR was <2% (<16% for the putatively changed genes). 
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Figure 28. Supplemental Figure 2. Two-way clustering of the normalized 
expression levels for 46 putatively changed genes across the adult and embryonic 
BDNF-ablated mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clustering is performed and represented similar to that seen in Figure 1. For source 
data and abbreviations see Table 2. Note that the wild-type and BDNF-ablated mice 
separate according to genotype (vertical dendrogram) in both groups of BDNF-
deficient mice. Together with a low FDR, this suggests that the majority of the 
presented data represents true biological discovery. 
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APPENDIX B- PAPER 2 HIGHLIGHTED IMAGE 
 
 
IMAGE
Upregulated sirtuin 5 gene expression in frontal cortex of
serotonin 1b receptor knock out mice
E Sibille1,2, J Su1, S Leman3, AM Le Guisquet3, Y Ibarguen-Vargas3, J Joeyen-Waldorf1, C Glorioso2,
GC Tseng4, M Pezzone5, R Hen6 and C Belzung3
1Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA; 2Center for Neuroscience, University of Pittsburgh,
Pittsburgh, PA, USA; 3EA3248 Psychobiologie des e´motions, Faculte´ des Sciences et Techniques, Universite´ Franc¸ois Rabelais,
Tours, France; 4Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA; 5Department of Medicine, University of
Pittsburgh, Pittsburgh, PA, USA and 6Center for Neurobiology and Behavior, Columbia University, New York, NY, USA
Molecular Psychiatry (2007) 12, 975; doi:10.1038/sj.mp.4002115
Our studies have demonstrated that altering serotonin (5-HT) signaling through the disruption of the 5-HT1B
presynaptic autoreceptor can modulate the onset of selected age-related events in the central nervous system. A
clear upregulation of sirtuin 5 (Sirt5) gene expression was identified in the brain of serotonin 1b receptor knock
out (Htr1bKO) mice. Sirtuin genes are major cellular components of age-related pathways. The role of altered
Sirt5 transcripts in the age-related phenotype in Htr1bKO mice is currently under investigation, including an
early mechanism for altering the onset of age-related phenotypes, since Sirt5 transcript changes preceded the
appearance of age-related behavioral and molecular changes. Representative color-coded photomicrographs of
sirtuin 5 gene (Sirt5) 35S in situ hybridization histochemistry at 3, 6, 18 and 24 months of age. Color barcode
indicates increased signal intensity. For more information on this topic see the paper by Sibille et al. on pages
1042–1056.
Molecular Psychiatry (2007) 12, 975
& 2007 Nature Publishing Group All rights reserved 1359-4184/07 $30.00
www.nature.com/mp
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SUPPLEMENTAL INFORMATION. 
 
Lack of Serotonin1B Receptor Expression Leads to Age-Related Motor 
Dysfunction, Early Onset of  Brain Molecular Aging and Reduced Longevity. 
  
Etienne Sibille1,4, Jing Su1, Samuel Leman6, Anne-Marie Le Guisquet6, Y. Ibarguen-Vargas6, 
Jennifer Joeyen-Waldorf1, Christin A. Glorioso4, George C. Tseng2, Michael Pezzone3, René 
Hen5 and Catherine Belzung6. 
Departments of 1Psychiatry, 2Biostatistics and 3Medicine, 4Center for Neuroscience, 
University of Pittsburgh, 5Center for Neurobiology & Behavior, Columbia University, 6EA3248 
Psychobiologie des émotions, Université François Rabelais de Tours, France,  
 
----------------------------------------------------------------------------------------------------------------------------
---------------- 
1. Array MIAME format.          
 
2. Figure S1. Anxiety-like behaviors in aging WT and Htr1bKO mice in the open field      
    (OF) and the elevated plus maze (EPM) tests. 
 
3. Table S1.  WT and Htr1bKO age-affected genes in CTX   
(Sample provided; separate downloadable Excel file). 
 
4. Table S2.  WT and Htr1bKO age-affected genes in STR  
(Sample provided; separate downloadable Excel file). 
 
5. Table S3. Selected mouse-human orthologous gene with conserved age-effects on  
     gene transcript levels.  
 
6. Table S4.  Functional analysis of age-related gene expression in WT and Htr1bKO 
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mice.   
 
7. Table S5. Consistent WT- Htr1bKO gene expression differences.     
 
8. References.            
----------------------------------------------------------------------------------------------------------------------------
---------------- 
 
1. MINIMUM INFORMATION ABOUT A MICROARRAYS EXPERIMENT (MIAME) 
1.1. Array design description 
2.1.1. Array used: Affymetrix mouse genome MOE430v2.0 (information regarding the 
details of this array can be found at www.affymetrix.com). 
2.1.2. Normalization: All arrays were scaled to 250 to correct for differences in overall 
signal before analysis in Microarray Suite 5.0 (MAS5.0, Affymetrix, Inc., Santa Clara, Ca). 
MAS5.0 extracted data were used to assess quality control parameters. All other 
analyses were performed with data extracted with the Robust Multi-array Average 
algorithm (GC-RMA)(145)  
Authors and contact information:  
Etienne Sibille1,4, Jing Su1, Samuel Leman6, Anne-Marie Le Guisquet6, Y. Ibarguen-Vargas6, 
Jennifer Joeyen-Waldorf1, Christin A. Glorioso4, George C. Tseng2, Michael Pezzone3, René 
Hen5 and Catherine Belzung6. 
Departments of 1Psychiatry, 2Biostatistics and 3Medicine, 4Center for Neuroscience, 
University of Pittsburgh, 5Center for Neurobiology & Behavior, Columbia University, 6EA3248 
Psychobiologie des émotions, Université François Rabelais de Tours, France,  
Correspondence should be addressed to : 
- Dr. Etienne Sibille, University of Pittsburgh, Department of Psychiatry, 3811 O’Hara Street, 
BST W1656, Pittsburgh, PA 15213, E-mail: sibilleel@upmc.edu, or  
- Dr. Catherine Belzung, EA3248 Psychobiologie des émotions, Université François Rabelais 
de Tours, Parc Granmont, Tours  37200, France, E-mail: catherine.belzung@univ-tours.fr. 
1.2. Experimental design: 
1.2.1. Type of experiment: Determination of the relationship between gene expression 
levels and aging throughout the lifespan. In particular, we investigated the nature of life-
long gene expression changes in the cortex (CTX) and striatum (STR), two brain areas 
with well-characterized roles for the 5-HT1B receptor, and assessed putative differences in 
the trajectories of age-related changes in 5-HT1BKO and WT control mice.   
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1.2.2. Experimental factors: Levels of expression.  
1.2.3. Number of hybridizations in the study: ~ 50. 
1.2.4. A common reference RNA was not used. 
1.2.5. Quality control measures. Arrays were only used if: the noise (Raw Q) was less 
than 5, the background signal was less than 100 (250 targeted intensity for array scaling), 
the 3’/5’ signal ratios of Actin and GAPDH were less than 3, the overall number of genes 
detected as present across arrays was consistent across arrays and in excess of 50%, 
the scaling factor was consistent for arrays compared, and the detection of spiked 
controls BioB and BioC hybridization was in the appropriate amounts. Labeled RNA was 
used for the array analysis if the 260/280 ratio was between 1.8 and 2.1. Arrays were 
done in monoplicate. Real-time PCR reactions were performed to validate array results 
using RNA from the same samples. 
1.3 Samples used, extract preparation and labeling: 
1.3.1. Bio-source properties: Animals were raised under standard conditions (21oC, 25% 
humidity, 12hr photoperiod, ad libitum food and water). WT and KO 129/Sv littermates were 
used for all behavior and array experiments, except for the 3-month time-point microarray 
analysis and for serum level measurements. These latter groups were no more than two 
generations away from heterozygous breeding. To avoid putative confounding effects of the 
previously reported increased aggressiveness of 5-HT1BKO mice, mice were housed under 
reduced cage density, resulting in low intra-cage aggression in both groups, as revealed by 
the absence of bite marks or wounds. All experiments were conducted in accordance with 
the European Communities Council Directive of 24 November 1986 (86/609/EEC) and with 
the University of Pittsburgh Animal Care and Use Committee. 
1.3.1. Biomaterial manipulations: Mice were sacrificed by cervical dislocation. Brains 
were split along the sagittal line, frozen in isopentane and stored at –80°C. To collect 
samples, frozen brains were cut on a cryostat to the appropriate anatomical level where 
series of 1 or 2mm diameter micropunches (Sample corer, Fine Science Tools, Foser 
City, CA), were collected from frontal cortex (CTX) and striatum (STR) and immediately 
stored in Trizol reagent (Invitrogen, Carlsbad, CA). CTX samples were collected from 
prelimbic and cingulate cortices corresponding mostly to non-motor areas between 
Figure18 and 23 (Bregma ~+2 to +1mm) in the Paxinos-Franklin Mouse Brain Atlas(258). 
Dorsal striatum samples were collected starting at Figure23 in the same atlas (Bregma 
~+1 to 0mm). 
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1.3.3. Extract preparation: Total RNA was extracted using the Trizol protocol, cleaned 
with Rneasy microcolumns (QIAGEN, Germany), quantified and verified by 
chromatography using the Agilent Bioanalyzer system.  
1.3.4. Microarray samples were prepared according to the manufacturer’s protocol 
(www.affymetrix.com/ support). In brief, 2µg of total RNA were reverse-transcribed and 
converted into double-stranded cDNA. A biotinylated complementary RNA (cRNA) was 
then transcribed in vivo, using an RNA polymerase T7 promoter site which was 
introduced during the reverse-transcription of RNA into cDNA. 20µg of fragmented 
labeled cRNA sample was hybridized onto MOE 430-2.0 Affymetrix oligonucleotide 
microarrays (Affymetrix, Santa Clara, CA). A high-resolution image of the hybridization 
pattern on the probe array was obtained by laser scanning, and fluorescence intensity 
data were automatically stored in a raw file. To reduce the influence of technical 
variability, samples were randomly distributed at all experimental steps to avoid any 
simultaneous processing of related samples. For data extraction, single arrays were 
analyzed with the Affymetrix Microarray GCOS software. Microarray quality control 
parameters were as follows: noise (RawQ) less than 5 (CTX: 1.53+0.03; STR: 
1.65+0.05), background signal less than 100 (250 targeted intensity for array scaling; 
CTX: 46.2+0.9; STR: 45.3+0.8), consistent number of genes detected as present across 
arrays (CTX: 49.7+0.4; STR: 52.6+0.4), consistent scaling factors (CTX: 1.80+0.05; STR: 
1.52+0.06), Actin and GAPDH 3’/5’ signal ratios less than 3 (CTX: ACT, 2.15+0.19, 
GAPDH, 1.18+0.09; STR: ACT, 1.43+0.04, GAPDH, 0.90+0.03) and consistent detection 
of BioB and BioC hybridization spiked controls.  
1.4. Measurement data and specifications: 
 See Methods in manuscript. 
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Figure 29. Figure S1. Anxiety-like behaviors in aging WT and Htr1bKO mice in the 
open field (OF) and the elevated plus maze (EPM) tests. 
 
 
The number of entries into the aversive center of the OF or the open arms of the EPM are 
indicators of anxiety-like behavior or fearfulness.  
In the OF (A.), WT and Htr1bKO mice displayed the same proportion of entries into the 
aversive center at all ages (Age effect: F=1.23, p=0.23; Genotype effect: F=0.08, p=0.77; 
Genotype*Age: F=1.47, p=0.23). 
In the EPM (B.), WT and Htr1bKO mice displayed a very low level of activity in the aversive 
open arms of the apparatus. Although most parameters reached statistical significance (Age 
effect: F=20.8, p<0.01; Genotype effect: F=12.7, p<0.001; Genotype*Age: F=3.4, p<0.05), 7 
out of 8 averaged data points were below 10% of the total activity (hatched bar), indicating a 
very low level of confidence for these measurements of anxiety-like behaviors.  A-B: n=15 
animals per group. 
Together, and in agreement with the initial behavioral characterization(252) results from 
these two independent behavioral tests did not suggest any effect of 5HT1BR disruption on 
the baseline and on the age-related progression of anxiety-like behaviors in Htr1bKO mice. 
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Table 7. Table S1.  WT and Htr1bKO age-affected genes in CTX   
Sample of Table S1 
Full Table is available and includes 1097 genes (Separate downloadable Excel file). 
 
 
 
Table 8. Table S2.  WT and Htr1bKO age-affected genes in STR  
Sample of Table S2 
Full Table is available and includes 419 genes (Separate downloadable Excel file). 
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Table 9. Table S3. Selected mouse (left) -human (right) orthologous gene with 
conserved age-effects on gene transcript levels.  
 
Alr, average log-ratio. See Methods for details. Blue, increased; Red, decreased.  
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Table 10. Table S4.  Functional analysis of age-related gene expression in WT and 
Htr1bKO mice.   
 
 
Top 25 ranked GO families most affected during aging in CTX of WT and Htr1bKO mice. Color 
codes are as in Figure5. “Probes” indicate the number of MOE-430-2.0 probesets 
represented in the respective GO groups. “Genes” indicate the number of genes taken in 
consideration for analysis (i.e., detected signal, reduced probeset redundancy). 
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Table 11. Table S5. Consistent WT- Htr1bKO gene expression differences  
  
8 probesets (out of 45,101 tested) displayed consistent genotype differences in CTX and 
STR. 
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I. Cohorts 
Table 12. A. Table S1. Summary of Cohorts 
 Cohort 1 Cohort 2 
Number of Subjects 37 39 
Age Range 23- 71 14- 79 
Exclusion Criteria Neurodegenerative disease, 
schizophrenia, bipolar 
disorder, prolonged post-
mortem interval /agonal time, 
illicit drugs. 
Neurodegenerative disease, 
schizophrenia, bipolar 
disorder, prolonged post-
mortem interval /agonal 
time, illicit drugs. 
Included Diagnoses Major Depression 
(50% of Subjects) 
Major Depression 
(50% of Subjects) 
Microarray Platform Affymetrix U133 Plus Affymetrix U133A 
Number of Probesets/Genes in Data 
Sets 
  
           Genes  (Expressed Genes) 21,115 (15,522) 13,795 (13,520) 
           Probesets (Expressed 
Probesets) 
54,715 (35,122) 22,177 (21,961) 
Brain Areas ACC (BA25) AMY PFC (BA9) PFC (BA47) 
Aging Significant Probesets (% of total)     
            α     
            0.001 1309 (3.9%) 814 (2.3%) 1972 (9.0%) 1106 (4.6%) 
            0.01 4443 (13.3%) 2820 (8%) 4240  
(19.3%) 
2801 
(12.8%) 
Aging Estimated False Discovery Rate 
(FDR)  
    
           α     
          0.001 2.8% 4.3% 1.2% 2.0% 
          0.01 8.0% 12.4% 5.2% 7.8% 
Major Depression Significant Probesets 
(fold change < aging at same α) 
    
           α     
          0.001 4 (330X) 4 (200X) 2 (986X) 6 (184X) 
          0.01 93 (48X) 69 (40X) 87 (49X) 68 (41X) 
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Major Depression FDR     
           α     
          0.001 >100% >100% >100% >100% 
          0.01 >100% >100% >100% >100% 
 
 
 
 
 
B.   Effects of depression do not associate with altered rates of molecular aging: 
Subjects with a lifetime diagnosis of depression do not age at different molecular 
rates than subjects without a lifetime diagnosis of major depression in these cohorts 
and in the brain areas investigated. This was discussed in Erraji et al(60) and is also 
shown in Figure S1. 
 
Figure 30. Figure S1. Molecular Ages by Depression Status.  
 Molecular ages were calculated using the cross-area age biosignature (See section 
IV in supplements). C and D refer to Control and Depressed group averages for 
(molecular age-chronological age) and p-values were generated from performing two 
group t-tests on these values.  
 
C. Cohort 1 (PFC BA9&47) Description adapted from Erraji-Benchekroun et al. 20051 
Subjects 
 Samples from 39 subjects, ranging from 14 to 79 years of age (44 +/-20 years, 
Mean +/-SD) were obtained from the brain collection of the Human Neurobiology 
Core of the Conte Center for the Neuroscience of Mental Disorders, the New York 
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State Psychiatric Institute. All cases were clinically free of neurologic disease, as 
determined by psychological autopsy(322) and neuropathologic examination, 
including thioflavine S or immunohistochemical stains on fixed tissue for senile 
plaques and neurofibrillary tangles. Varying degrees of atherosclerosis were present 
in subjects aged 45 or older, and several specimens included foci of 
encephalomalacia, as expected during normal aging. Several subjects contained 
senile plaques or neurofibrillary tangles, but never in sufficient numbers to suggest a 
diagnosis of Alzheimer’s disease. No other significant abnormalities were observed. 
All subjects died rapidly, 20 of which committed suicide (psychological autopsies 
indicated that 17 of them had a lifetime diagnosis of major depression) and 19 died of 
causes other than suicide. An independent study assessed the effect of suicide and 
depression on gene expression and within current analytical limits, found no evidence 
for molecular differences that correlated with depression and suicide(323). Using 
body fluids and brain tissue, a toxicologic screen was carried out for the presence of 
psychotropic or illegal drugs. All samples were psychotropic medication–free with 
minimal other drug exposures.  Caucasians represented 71%, African Americans 8%, 
Hispanics 18%, and Asians 2% of the sample. Average postmortem interval and 
brain pH were 17 ± 1 and 6.53 ± 0.21, respectively. As a group, male subjects (n = 
30) did not differ significantly from female subjects (n = 9) on age, race, postmortem 
delay, or brain pH. No interaction among experimental, demographic, and clinical 
parameters and age were found(262, 323). Hence, we combined all samples for this 
aging study. Details of dissections have been described in our previous 
publications1,22. RNA extraction, microarray samples preparation, and quality control 
were performed according to the manufacturer protocol (http://www.affymetrix.com) 
and in our previous publication(262). Samples were hybridized to Affymetrix U133A 
microarrays. 
 
D. Cohort 2 (AMY and ACC). Adapted from Sibille et al. 2009 3 
Subjects 
 39 all male subject (ages 23-71) brain samples were obtained during 
autopsies conducted at the Allegheny County Medical Examiner’s Office. Subjects 
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with advanced disease stages (i.e., cancer, neurodegenerative disorders) and 
prolonged postmortem interval PMI (>28hrs) were excluded. All subjects were white 
Caucasian and were selected for rapid modes of death and short agonal phases, to 
limit the influence of agonal factors on RNA quality and pH. Toxicological screens on 
peripheral fluids identified the presence of at least one antidepressant in 5 subjects, 
including four different tricyclics, one selective serotonin reuptake inhibitor and one 
weak dopamine reuptake inhibitor.  
Dissections 
 Details of Amygdala and ACC dissections are described in our previous 
publication3 and was adapted from Hamidi et al.(324). Samples were hybridized onto 
Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA). Array 
parameters described in Sibille et al. 2009 3. 
  
E. Data Extraction, normalization, and creation of best-fit age-trajectory equations   
 Log2-transformed probeset signal intensities were extracted and normalized 
with the Robust Multi-array Average (GC-RMA) algorithm for each brain area for both 
datasets. Probesets were considered present if they had expression levels greater 
than 25 in at least 2 datasets in order to preserve area/cohort specificities if present.  
Expression values were then converted for comparability by simple division to be a 
fraction of their mean value of all expression values for their probeset in each brain 
area separately. Then, for each probeset, a separate equation was generated for 
linear, log, exponential, and power fits of expression versus subject age and the best-
fit line (highest regression coefficient) was chosen for each probeset, creating a 
unique age-regression equation per probeset. Lastly, expression values were 
converted a second time by simple division to be a percentage of their expression at 
age 20 yrs (calculated by solving their equation for this value), which was set to 100% 
expression. Equations were re-calculated using this value.  This created equations 
and expression values directly comparable across datasets that are a percentage of 
expression at age 20 yrs, which was set to 100% expression, without transforming or 
altering original expression. P-values for age-trajectory equations were calculated by 
converting regression coefficients of equations taking into account the number of 
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subjects in each brain area. Full datasets of all genes in all brain areas with age-
regression equations, pvalues , expression differences, and cellular origins 
(Supplemental Dataset 1) are available as downloadable files from our website 
(www.sibille.pitt.edu). 
 
II. Quantitative PCR (QPCR) validation of age-regulated expression changes. 
QPCR validation (methods described in previous publications) of a set of 42 age-
regulated  (p<0.01) genes in total was performed and published for in cohorts 1 and 2 
for validation of prior  studies (60, 289),21. Results were re-analyzed here for age 
effects (see below) and converted to percent change over 50 years of (Age 70-Age 
20) for comparability of results to current array data results. 
 
Figure 31. Figure S2. Correlation of Quantitative PCR and Microarray Quantification 
of Gene Expression Levels. 
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III.  Comparing age-related changes across brain areas. 
Table 13. A. Table S2. Percentage of each best-fit equation type by brain area. 
 
 Linear (%) Exponential (%) Power (%) Log (%) 
            ACC 36 21 30 13 
            AMY 12 23 60 5 
            BA9 34 27 16 22 
            BA47 29 22 20 29 
 
 Table 14. B. Table S3. Percentage of transcripts age up or down-regulated and 
cellular origin 
 
 Increased with Age (p<0.001) Decreased with Age (p<0.001) 
 n (% of 
total) 
m(%) N(%) G(%) B(%) 
n(% of 
total) 
m (%) N(%) G(%) B(%) 
ACC 582 (44.5) +95.1 3.0 73.7 23.4 726 (55.5) -31.8 57.9 3.6 38.7 
AM
Y 
726 (88.6) +74.8 6.1 47.0 47.0 87 (10.7) -33.1 32.2 5.8 63.2 
BA9 838 (42.5) +47.7 3.4 66.8 17.1 1133 (57.5) -29.5 59.0 8.5 32.5 
BA4
7 
420 (37.9) +59.7 12.4 49.1 38.8 684 (61.8) -31.9 69.9 6.6 23.7 
 
Average magnitude (age 70-age 20) and cellular origin of age-regulated expression 
changes by up and down-regulated (Supporting Figure 1B). (n) number, (m) average 
magnitude, (N) neuronal, (G) Glial, (B) expressed in both neurons and glia. 
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Table 15. C. Table S4.  Percentage of transcripts changing in the same/opposite 
direction with age across brain areas 
 
 ACC AMY BA9 BA47 
 Same 
(%) 
Opposite(%) Same(%) Opposite(%) Same(%) Opposite(%) Same(%) Opposite(%) 
ACC - - 89.1 10.9 90 11 88.6 12.4 
AMY 89.9 11.1 - - 90.5 10.5 84.1 15.9 
BA9 87.4 14.6 79.4 20.6 - - 88.3 14.7 
BA47 88.0 12.0 84.1 15.9 94.1 5.9 - - 
 
Age-related expression changes (Supporting Figure 1B) compared across brain 
areas. “Same”, expression changed in the same direction; “Opposite”, expression 
changed in the opposite direction. 
 
Table 16. D. Table S5. Percentage of transcripts changing in the same/opposite 
direction with age across brain areas by significance 
 
 ACC (%) AMY (%) BA9 (%) BA47 (%) 
 S -S S-NS O-S O-NS S -S S-NS O-S O-NS S -S S-NS O-S O-NS S -S S-NS O-S O-NS 
ACC - - - - 43.0 46.1 0.7 8.7 75.1 14.9 1.0 9.0 57.4 31.2 1.0 10.4 
AMY 60.2 29.7 0.9 9.8 - - - - 67.3 23.2 3.0 6.5 47.0 37.1 2.7 13.8 
BA9 58.0 29.5 2.1 10.4 31.8 47.6 2.6 18.0 - - - - 65.4 22.9 3.0 8.7 
BA47 54.1 33.9 1.2 10.8 34.8 50.5 1.4 13.3 77.9 16.2 0.5 5.4 - - - - 
 
Age-related expression changes compared across areas (Supporting Figure1B). 
Analyzed by percentage of transcripts in same (S) or opposite (O) directions across 
two brain areas and  (-) whether they were significant p<0.05 (S) or non-significant 
(NS).  
 
IV. Cross-area Brain Aging Biosignature. 
A. Methods Ingenuity gene network and functional analysis 
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Analyses were performed using Ingenuity systems version 7.0. 
(http://www.ingenuity.com/).  Methods are briefly described below. 
Network Generation 
Selected gene identifiers and corresponding expression changes were uploaded and 
overlaid onto a global molecular network in the Ingenuity knowledge base. Networks 
of these genes were then algorithmically generated based on their connectivity with 
scores used to rank networks according to their degree of relevance to the Network 
Eligible molecules in your dataset.  The score takes into account the number of 
Network Eligible molecules in the network and its size, as well as the total number of 
Network Eligible molecules analyzed and the total number of molecules in Ingenuity's 
knowledge base that could potentially be included in networks. The network Score is 
based on the hypergeometric distribution and is calculated with the right-tailed 
Fisher's Exact Test. The score is the negative log of this p-value. 
Functional Analysis  
The Functional Analysis identified the biological functions and/or diseases that were 
most significant to the data set. Genes from the dataset that were associated with 
biological functions and/or diseases in the Ingenuity knowledge base were 
considered for the analysis. Fischer’s exact test was used to calculate a p-value 
determining the probability that each biological function and/or disease assigned to 
that data set is due to chance alone.  
 
Functional Analysis of a Network 
The Functional Analysis of a network identified the biological functions and/or 
diseases that were most significant to the genes in the network.  Fischer’s exact test 
was used to calculate a p-value determining the probability that each biological 
function and/or disease assigned to that network is due to chance alone. 
Canonical Pathways 
Canonical Pathways are a type of functional analysis (see above). Canonical 
Pathways are well-characterized metabolic and cell signaling pathways that have 
been curated and hand-drawn by Ph.D. level scientists. The information contained in 
Canonical Pathways comes from specific journal articles, review articles, text books, 
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and KEGG Ligand. They are distinct from networks because they are generated prior 
to data input based on the literature and have directionality. P-values are based the 
overrepresentation of genes in the queried dataset in a particular canonical pathway 
compared to all genes in that pathway present in the Ingenuity database (ratios). 
Ingenuity Analysis of the biosignature 
356 age-biomarkers were used for gene network and associated functional analysis. 
A summary of functional and network analysis is shown below. The top 5 identified 
gene networks (p<e-35) encompassed most known age-related biological functions 
(Signaling, immune response, vascular function, cell death, DNA repair and protein 
modification; Networks 1-5) and confirmed the substantial overlap between age and 
disease-related genes (Genetic, neurological and psychiatric disorders; Networks 3-
4; Table S7).  
 
Table 17. B. Table S6 Summary of Ingenuity analysis of the biosignature 
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Table 18. C. Table S7. Top age-biomarker gene networks and associated functions 
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Genes in bold (Red, increased; Green, decreased) identify age biomarkers included 
in the networks. Other genes and molecular functions represent added indirect nodes 
in networks. Scores are negative log (p-value). The top functions indicate the 
biological functions and/or diseases that were most significant to the genes in the 
network. 
 
D. Methods CMAP 
The connectivity map is a resource freely available from the Broad Institute at MIT 
(http://www.broadinstitute.org/cmap/) first described by Lamb et al in 2006 (293). C-
Map is a large reference database of genome-wide expression profiles from cultured 
human cell lines treated under standard conditions with FDA approved small 
molecules, shRNAs, and organic compounds (collectively referred to as 
perturbagens) and a pattern-matching software to enable data mining. C-MAP (Build 
02) contains data from 1309 perturbagens in a total of 7056 gene expression profiles 
(6100 individual instances defined as one treatment and vehicle pair), across four 
human cell lines (breast cancer MCF7, acute myeloid leukemia HL-60, prostate 
cancer PC3 and melanoma SKMEL5) on the Affymetrix HGU133A arrays. The C-
Map pattern-matching algorithm is based on the non-parametric rank statistic, the 
Kolmogorov-Smirnov statistic. Permuted p-values are an estimate of the likelihood 
that the enrichment of a set of instances in the list of all instances in a given result 
would be observed by chance. This value is determined empirically by computing the 
enrichment of one hundred thousand sets of instances selected at random from the 
set of all instances in the result. The C-MAP website also provides links for each 
compound to ChemBank (a database for structures and synonyms, 
http://chembank.broad.mit.edu), and displays the Anatomical Therapeutic Chemical 
classification assigned by the World Health Organization to drug substances. A full 
listing of C-MAP-biosignature results and associated statistics is available for 
download upon publication (supplementary dataset 3).  
Descriptions of drug mechanisms for Figure 2C were obtained from ChemBank 
(http://chembank.broad.mit.edu) in addition to the references below. 
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C-MAP Candidate Brain Aging Drugs 
Drug Mechanism P-val 
Anti-aging   
GW-8510 CDK2/CDK5 inhibitor; neuroprotective(325) 1E-4 
α-estradiol Estrogen enantiomer; neuroprotective(326) 1E-4 
Urapidil Antihypertensive, α1 adrenergic antagonist, α2 
adrenergic agonist, 5HT1A agonist, 
neroprotective(327) 
2E-4 
Alsterpaullone Inhibitor of CDK2, CDK1/Cyclin B, CDK5/p25, GSK-
3β, Tau phosphorylation; neuroprotective (328) 
5E-4 
Skimmianine Furoquinoline alkaloid (plant extract) used in folk 
medicine; potentially anti-inflammatory, 
antitumorigenic, and an MAO inhibitor (329, 330) 
6E-4 
H-7 PKC inhibitor, decreases calcium current, alters 
astrocyte morphology(331) 
7E-4 
Niacin (Vitamin 
B3)   
       
Anti-inflammatory properties; used to treat 
hypercholesterolemia, arteriosclerosis, and 
cardiovascular disease (332)  
0.005 
Biotin  (Vitamin 
B7) 
Regulates insulin secretion; therapeutic efficacy in 
diabetes (333, 334) 
0.009 
Pro-Aging   
Wortmannin inhibitor of PI3-K cell survival pathway, mTOR, DNA-
PK, MAPK, and PI4-K(335) 
1E-6 
Benzamil Na/Ca exchange blocker, inhibitor of NGF mediated 
neurite outgrowth(336) 
5E-4 
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V. Neurological disease-associated gene analysis.  
 
Figure 32. A. Figure S3. Top 20 Ingenuity® Functional Categories associated with 
age-regulated genes (Figure adapted from Ingenuity®).  
Criteria for selection for age regulated genes were age-regression p<0.001 in at least 
one area or p<0.01 in two brain areas (n=3,935). The top four functions were largely 
driven by the six neurologic diseases focused on in the paper (AD, PD, ALS, HD, 
SCHZ and BPD).  The top diseases in the top “genetic disease” category were all 
age-related and included autoimmune disease (529 genes), coronary artery disease 
(291 genes), bipolar disorder (285 genes), insulin-dependent diabetes mellitus (270 
genes), Huntington’s disease (267 genes), Alzheimer’s disease (187 genes), 
Parkinson’s disease (170 genes), amyotrophic lateral sclerosis (170 genes), 
schizophrenia (161 genes), prostate cancer (113 genes), colon cancer (103 genes), 
and autism (27 genes). Top Neurologic diseases were the six aforementioned and 
also included several types of brain cancer, autism, and epilepsy. The third ranked 
category, Skeletal and muscular disorders, were largely driven by PD and HD, which 
ingenuity considers to be in this category. The 421 genes associated with 
psychological disorders were almost entirely driven by Schizophrenia and Bipolar 
disorder. 
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Figure 33. B. Figure S4. Age-regulated genes associated with the top six 
neurological diseases. 
Top (most associated genes) neurologic diseases represented (Figure adapted from 
Ingenuity®). Disease associations are based on Ingenuity’s database of hand-
curated literature searches performed by PhD level scientists. Depicted direction of 
age-regulated changes are from the ACC dataset and are not necessarily congruent 
with the direction of change in the other three brain areas.  A complete listing of age-
regulated directions for all genes in all brain areas will be available for download upon 
publication (Supplementary dataset 1).  Genes with asterisks have more than one 
probeset per gene represented in the selection. Directions of change for these genes 
are that of the probeset with the most significant p-value. 
 
Bipolar Disorder (285 Genes) 
 
Huntington’s Disease (267 Genes) 
 
Alzheimer’s Disease (185 Genes) 
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Parkinson’s Disease (170 Genes) 
 
Amyotrophic Lateral Sclerosis (164 Genes) 
 
Schizophrenia (161 Genes) 
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Figure 34. C. Figure S5. Top 20 Ingenuity® functional categories analysis of genes 
that were not age-regulated.  
Criteria for non-age-regulated genes were p>0.05 in all four brain areas (n=7790). 
The top category of non- age regulated genes was cellular growth and proliferation, 
which is logical for the non-dividing tissue of the brain. Notably, neurologic disease 
was not in the top 20 categories, ranking 44th.   
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Table 19. Table S8. References for Direction of Neurologic Disease Expression 
Changes in Disease (Supporting Table 1). 
                                                                          Direction of Change in Disease  
Disease-associated gene_symbol AD PD HD ALS SCZ BPD          References for Pro-disease Directions 
Amyloid beta precursor protein binding-1_Fe65  u      FE65 mRNA levels in AD human brain are 
decreased in cortex, however this appears to be cell 
type and brain region dependent; additionally it is 
unclear whether loss of FE65 would be pro or anti-
disease (337-340) 
Amyloid beta precursor protein binding- 2_APPB2/PAT1 ↑      Involved in APP transport/processing; 
overexpression results in Aβ accumulation (341, 
342) 
 
 
Amyloid precursor-like protein 2_APLP2 ↓      Decreased mRNA levels in AD brain (343, 344) 
. 
-31.1(0.0001) 
-30.5(0.008) 
Clusterin/Apolipoprotein-J_CLU ↑  ↑ ↑   Increased mRNA levels in AD brains, HD striatum, 
and ALS spinal cord (345-348) 
 Monoamine Oxidase B_MAOB ↑ ↑ ↑ ↑   Increased mRNA levels in AD Cortex, HD Caudate 
and ALS spinal cord, also increased activity in PD 
brain. MAO-B inhibitors are a common treatment for 
PD (349-352) 
Microtubule-associated protein tau_MAPT ↑ ↑     AD and PD associated with higher mRNA levels, 
polymorphic haplotypes and toxic gain of function 
mutations (353, 354) 
 
α-synuclein_α-syn ↓ u     Decreased mRNA levels in AD PFC; 
increased/decreased in PD brain (355, 356) 
Parkinson Disease-2_Parkin ↓ ↓     Associated with low expressing promoter 
polymorphisms in PD, and decreased mRNA levels 
in AD brain; also Parkin levels prevents Aβ 
accumulation in primary cortical neurons (305, 357-
359) Parkinson Disease-5_UCHL1 ↓ ↓     Decreased mRNA levels in PD and AD brains (357) 
Parkinson Disease-6_Pink1  ↓     Loss of function mutations cause familial PD; knock-
down of Pink-1 in cell lines causes PD-like 
mitochondrial dysfunction (360) 
Parkinson Disease-7_DJ-1  ↓     Loss of function mutations in familial PD, decreased 
mRNA levels in PD Substantia Nigra(361) 
 Parkinson Disease-13_HTRA2  ↓     Loss of function mutations in PD, loss of function 
mutations cause mitochondrial dysfunction and 
neurodegeneration in mice (362, 363) 
Huntingtin_HD    ↓    Loss of WT Huntington is pro-disease as Huntingtin 
KO mice have a neurodegenerative phenotype, loss 
of wt huntingtin causes more severe/rapid 
degeneration and death in HD YAC128 mouse 
model, and the addition of wt huntingtin to mutant 
HD cell lines reduces cellular toxicity. (364-366) 
Valosin-containing protein_VCP   ↑    Mutant VCP is associated with Paget’s disease.  
While the levels of increased or decreased wt VCP 
is unknown in disease, a drosophila overepression 
model suggests that increased VCP would increase 
aggregate formation and be pro-disease (367) 
 
Mitochondrial Complex 1 Subunit_NDUFB5   ↓    Decreased mRNA levels in HD caudate (350) 
n.s. Mitochondrial Complex 1 Subunit_NDUSF2   ↓    Decreased mRNA levels in HD caudate (350) 
Mitochondrial Complex 1 Subunit_NDUSF3   ↓    Decreased mRNA levels in HD caudate (350) 
Mitochondrial Complex 1 Subunit_NDUSF3   ↓    Decreased mRNA levels in HD caudate (350) 
n.s. 
n.s. 
Mitochondrial Complex 4 Subunit_COX7B   ↓    Decreased mRNA levels in HD caudate (350) 
Cyclin-dependent Kinase-5_CDK5 ↓  ↓    HD is Associated with decreased CDK5 protein in 
striatum and AD hippocampus (368, 369) 
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NF-kappa B_NF-kB ↑ ↑ ↑ ↑  ↑ Increased mRNA levels in ALS Spinal Cord, AD 
hippocampus, PD brainstem and midbrain, BPD 
cortex, cultured HD neurons, HD mouse model 
(370-374) 
 Manganese Superoxide dismutase_SOD2 ↓   ↓   Associated polymorphisms with AD; knock-down 
accelerates disease progression in AD and ALS 
mouse models (375, 376) 
Cholecystokinin_CCK ↓ ↓   ↓  Decreased mRNA levels in SCZ, AD and PD PFC 
(377, 378) Neuropeptide-Y_NPY ↓ u 
 
 ↓ ↓ Decreased mRNA levels in SCZ, BPD, and AD 
cortex (377, 379-381) 
Cannabanoid Receptor-1_CB1 ↓ u ↓  ↓  Decreased mRNA and protein levels in SCZ PFC, 
decreased mRNA in HD Globus Pallidus and AD 
caudate, increased/decreased in PD brain (382-385) 
Parvalbumin_PVALB ↓ u   ↓ ↓ Decreased mRNA levels in SCZ PFC, AD 
parahippocampal gyrus, and BPD cortex. In PD 
there is reports of decreased levels in globus 
pallidus and substantia nigra and PV is decreased in 
a Parkinsonian mouse model. However, there is one 
report of increased PV mRNA levels in PD 
Substantia Nigra (264, 386-391) 
Glutamate decarboxylase 1_GAD67  ↓   ↓ ↓ Decreased mRNA levels in PD globus pallidus and 
SCZ PFC (377, 392) 
 
-39.3(0.02) 
-43.2(0.0009) 
-51.9(0.02) 
GABA transaminase_GABA-T u    ↑  Increased mRNA levels in SCZ cortex and 
increased/decreased AD brain (377, 393-395) 
Brain-derived neurotrophic factor_BDNF ↓ ↓ ↓  ↓ ↓ Decreased mRNA levels in SCZ PFC, BPD 
hippocampus and decreased in mRNA & protein in 
multiple brain areas in AD, PD, and HD (136, 396-
398) 
Serotonin 2A Receptor_HTR2A ↓    ↓ ↓ Decreased mRNA levels in SCZ, BPD, and AD 
Cortex (399-402) 
Serotonin 5A Receptor_HTR5A     u u Associated polymorphisms in SCZ and BPD- 
direction of mRNA levels changes have not been 
investigated (403, 404) 
 Somatostatin_SST ↓ ↓ ↓  ↓  Decreased mRNA levels in SCZ, AD and PD Cortex 
and HD striatum (377, 379, 396, 405, 406) 
Regulator of G-protein signaling-4_RGS4 ↓  ↓  ↓ u Decreased mRNA levels in SCZ and AD PFC , 
multiple PD brain areas, and HD Striatum (153, 407-
409) Reelin_RELN u u   ↓ ↓ Decreased mRNA levels in SCZ, BPD, PD and AD 
cortex (410-412) 
 
Neuregulin-1_NRG1 u    u u Reports are mixed as to whether NRG1 mRNA 
levels are increased or decreased in SCZ and are 
isoform specific; NRG1 polymorphisms are 
associated with BPD and psychosis in AD but 
direction of mRNA level changes have not been 
investigated (413-417) 
Dopamine Receptor D1_DRD1 u  ↓  u u Decreased mRNA levels in SCZ hippocampus; 
linkage to DRD1 haplotypes in BPD with direction of 
levels changes not investigated (418, 419) 
GABA receptor, alpha-5 subunit_GABRA5   ↓  u u Decreased mRNA levels in HD caudate; associated 
polymorphisms with BPD and age of onset in SCZ- 
direction of associated levels changes have not 
been investigated (350, 420, 421) 
Period homolog-3_PER3     u u Associated polymorphisms with BPD and SCZ-
direction of mRNA level changes have not been 
investigated (422, 423) 
Aryl hydrocarbon receptor nuclear translocator-
like_BMAL1   
    u u Associated polymorphisms in SCZ and BPD-
direction of mRNA level changes have not been 
investigated (422, 424) 
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VI. Candidate Longevity Gene SNPs 
A. Rationale for candidate longevity gene snps chosen. 
We chose five candidate snps in three genes for this study that are 1. likely to affect 
brain aging specifically, as rates of aging are known to be tissue specific, and 2. 
known to affect expression or function of their gene product. We have previously 
shown that the Serotonin Receptor 1B (htr1b) knock-out (KO) mouse is a model of 
anticipated molecular brain aging and reduced longevity so we sought to translate 
these findings using the HTR1BG(861)C human polymorphism which is associated with 
decreased gene expression in human cortex(63, 317). We chose Sirt5, a homologue 
of the Sirtuin family of longevity genes with increasing evidence for a role in 
neurodegenerative disease(54), because it displayed altered expression in htr1bKO 
mouse cortex, potentially mediating the anticipated brain age phenotype(63). No 
functional polymorphisms in the Sirt5 gene have been described to date. Thus, we 
chose the Sirt5 prom1, 2, and 3 polymorphisms for their potential to affect gene 
expression due to their location in a mouse-human conserved promoter region (see 
below for details). Lastly, we chose KlothoKL-VS because it alters two amino acids in 
this longevity gene and is associated both with human lifespan and rates of age-
related memory decline(93, 98).  
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Figure 35. B. Figure S6. Chromosomal context of Sirt5 prom polymorphisms and 
there proximity to conserved and predicted promoter regions 
 
 
 
 
 
               
 
 
 
 
 
Chromosomal context of human Sirt5 including up to 5kb upstream of the start of 
transcription and areas of homology between mouse and human DNA (green boxes) 
and putative promoter regions (stars) are shown in this diagram adapted from 
Hapmap (www.hapmap.org).  The Sirt5 prom 1, 2, and 3 snps (leftmost to rightmost) 
are in the yellow highlighted box. Homologous regions were determined by NCBI-
blast analysis of full-length mouse and human gene sequences. For promoter 
prediction, the programs TSSG (recognition of human polII promoter region and start 
of transcription) at CGG Nucleotide Sequence Analysis 
(http://genomic.sanger.ac.uk/gf/gf.html) and Promoter 2.0 
(http://www.cbs.dtu.dk/services/Promoter/) were used.  Snp circles reflect the 
frequency of genotypes in four different ethnic populations for each snp.  We only 
considered snps with at least a 25% frequency of the minor (red pie slice) allele in 
people of European (CEU) descent in order to retain power in our array cohort, which 
is predominantly of European background. We chose these three snps because of 
their proximity to both a putative promoter and an evolutionarily conserved region, 
hypothesizing that they may effect expression.            
 
 
   homologous region 
  putative promoter (TSSG) 
  putative promoter (promoter 2) 
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C. Snp genotyping.     
HTR1B and SIRT5 genotypes were determined by direct sequencing of PCR 
amplified genomic DNA samples extracted from subject brain samples. The KlothoKL-
VS minor allele creates a unique MaeIII restriction site and thus Klotho was genotyped 
by PCR amplification followed by restriction digest and diagnostic gel(95). 
 
Table 20. Table S9. Candidate Longevity SNP Subject Genotypes and Comparison 
with Reported Frequencies.  
 
Gene 
refsnp (common 
name) Allele 
Allele 
frequencies 
Hapmap(CEU)*or 
Ensembl** 
Published frequencies  
HTR-1B rs6296 (G861C) 
G/G, G/C, 
C/C 
0.44, 0.47, 
0.0 
0.40 , 0.52, 0.08* 
rs2804914 
(prom1) 
G/G, G/A, 
A/A 
0.44, 0.55, 
0.0 
0.46, 0.46, 0.09* 
rs938222 (prom2) 
C/C, C/T, 
T/T 
0.50, 0.37, 
0.13 
0.43, 0.46, 0.10*  SIRT5 
rs11753306 
(prom3) 
T/T, T/C, 
C/C 
0.42, 0.58, 
0.0 
0.47, 0.45, 0.08* 
Klotho 
rs9536314 (KL-
VS) 
T/T, T/G, 
G/G 
0.76, 0.24, 
0.0 
0.79, 0.21, 0.0 ** 
 
*Hapmap (CEU) frequencies (http://www.hapmap.org) are from a single study of 30 
father-mother-son trios from a sample of Utah residents of European descent. 
**Ensembl database (http://ensembl.org) is another database that compiles snp 
frequencies which we used when Hapmap frequencies were not available for a snp. 
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D. Rationale for focusing on Sirt5 prom2 and not prom1 or 3.  
The three Sirtuin 5 snps were in close proximity to each other and prom 1 and 3 were 
in almost complete linkage disequilibrium. Prom2 was in partial linkage disequilibrium 
with prom1 and 3. All three Sirtuin 5 snps had overlapping affected transcripts due to 
linkage disequilibrium between the snps. We focused exclusively on Prom2 because 
it had the largest number of significant transcripts associated with it and the most 
significant effects on molecular age. A further study with larger subject numbers 
would be needed to determine if prom1 or 3 interact or modify prom2 effects on 
molecular age.   
 
Figure 36. E. Figure S7. Leave one out molecular ages of subjects calculated using 
ACC (n=4443) or AMY (n=2820) specific age-regulated genes (p<0.01) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  M
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Table 21. F. Table S10. Significance of genotypic effects on molecular age in ACC 
and AMY 
 
 
 
 
Figure 35. G. Figure S8. Quantitative PCR of Sirt5 expression by Sirtprom2 genotype 
in AMY.  Methods for QPCR are described above in Section II. Expression 
differences were non- significant. 
 
 
 
 
 
 
 
 
 
 
 
 
Intersection transcripts :           
n in pro-aging direction/ 
total  
Molecular Years 
Different (p-val) 
Intersection 
FDR 
Difference in total 
molecular age using all age 
transcripts (p-val) 
ACC     
   Sirt 5 prom2 227/231 CC  +24 (0.0001) 19% CC +9.1 yrs (0.004) 
   Klotho KL-VS 7/9 VS  +11.1 (0.12) 100% VS  +0.46 (0.9) 
   HTR1B 18/23 GG  +9.8 (0.12) 100% GG  +7.9 (0.09) 
AMY     
   Sirt 5 prom2 30/48 CT  +2.0 (0.55) 100% CT +2.2 (0.69) 
   Klotho KL-VS 38/39 
VS  +23.6 
(0.001) 
100% VS +4.7 (0.18) 
   HTR1B 14/24 GG  +5.3 (0.25) 100% GG -0.6 (0.86) 
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Figure 36. H. Figure S9. Ingenuity® Canonical Pathways significantly affected by 
Sirt5prom2 intersection transcripts in ACC (n=231).  
 
 
 
 
 
 
 
 
 
 
 
 
A full list of Sirt5prom2 intersection transcripts and expression changes can be found in 
Supplementary dataset 4. The top 2 pathways were oxidative phosphorylation (n=15 
genes) and mitochondrial dysfunction (n=13 genes). 
 
Figure 37. I. Figure S10. Ingenuity® Functional Categories significantly affected by 
Sirt5prom2 genotype.   
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The top two neurologic disorders were related to mitochondrial dysfunction, 
Huntington’s (n=22 genes) and Parkinson’s disease (n=9 genes). 
 
Figure 38. J. Figure S11. Huntington’s and Parkinson’s associated genes affected 
by Sirt5prom2 genotype in ACC. Starred genes have more than one probeset 
represented. 
 
Huntington’s Disease (22 genes) 
 
Parkinson’s Disease (9 genes)  
 
 
Table 22. K. Table S11. Table for Schematic Figure 3D- Mitochondrial Age-regulated 
Transcripts Effected By Sirt5 Genotype in ACC. 
 
CC-CT (%) are the differences in average expression in age-matched groups (see 
Section VI-E). CC-CT (years) were calculated by averaging molecular-chronological 
year deviations for a gene in age-matched groups (see Section VI-E). Age expression 
differences and p-values were determined from age regression lines (see Section I-
E). N (neuronally-enriched expression), G (Glial-enriched expression), B (expressed 
to similar levels in both neurons and glia) (see Section III-C for methods of 
determining cellular origin of transcript changes. A complete list of Sirt5prom2 affected 
genes in the below format will be available for download upon publication 
(Supplementary dataset 4). 
Probeset ID Gene Name 
Gene 
Symbol 
CC-CT 
(%) 
CC-CT 
(years) 
Snp      
P-val 
Age,    
70-
20(%) 
Age     
P-val N G B 
210149_s_
at 
ATP synthase, H+ 
transporting, mitochondrial 
F0 complex, subunit d 
ATP5H -17.2 31.6 6.2E-04 -27.2 8.1E-
03 
1 0 0 
208678_at ATPase, H+ transporting, 
lysosomal 31kDa, V1 
subunit E1 
ATP6V1E1 -13.3 25.6 9.4E-03 -25.9 5.6E-
03 
0 0 1 
203880_at COX17 cytochrome c 
oxidase assembly homolog 
COX17 -14.9 28.7 6.7E-03 -25.9 7.5E-
03 
0 0 1 
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(S. cerevisiae) 
202698_x_
at 
cytochrome c oxidase 
subunit IV isoform 1 
COX4I1 -11.9 23.4 2.3E-03 -25.4 2.0E-
03 
0 0 1 
213735_s_
at 
cytochrome c oxidase 
subunit Vb 
COX5B -11.8 32.5 3.3E-03 -18.1 8.4E-
03 
0 0 1 
201441_at cytochrome c oxidase 
subunit Vib polypeptide 1 
(ubiquitous) 
COX6B1 -13.7 31.0 1.5E-03 -22.1 5.1E-
03 
0 0 1 
202110_at cytochrome c oxidase 
subunit VIIb 
COX7B -11.3 25.0 9.1E-04 -22.7 3.8E-
04 
1 0 0 
201066_at cytochrome c-1 CYC1 -11.3 31.3 1.4E-03 -18.1 2.2E-
03 
0 0 1 
205012_s_
at 
hydroxyacylglutathione 
hydrolase 
HAGH -16.6 30.6 1.1E-03 -27.2 3.1E-
03 
1 0 0 
213132_s_
at 
malonyl CoA:ACP 
acyltransferase 
(mitochondrial) 
MCAT -23.5 32.4 4.2E-03 -36.2 7.1E-
03 
1 0 0 
213333_at malate dehydrogenase 2, 
NAD (mitochondrial) 
MDH2 -14.2 24.0 4.5E-03 -29.5 1.5E-
03 
1 0 0 
204386_s_
at 
mitochondrial ribosomal 
protein 63 
MRP63 -10.6 32.3 3.5E-03 -16.4 6.3E-
03 
0 0 1 
224330_s_
at 
mitochondrial ribosomal 
protein L27 
MRPL27 -10.8 29.8 7.6E-03 -18.1 7.1E-
03 
0 0 1 
224331_s_
at 
mitochondrial ribosomal 
protein L36 
MRPL36 -15.9 27.0 2.7E-05 -29.5 6.1E-
04 
0 0 1 
203152_at mitochondrial ribosomal 
protein L40 
MRPL40 -11.4 35.1 1.4E-03 -16.2 6.4E-
03 
0 0 1 
223480_s_
at 
mitochondrial ribosomal 
protein L47 
MRPL47 -13.6 23.9 4.3E-04 -28.4 1.6E-
04 
0 0 1 
201717_at mitochondrial ribosomal 
protein L49 
MRPL49 -7.2 23.4 7.6E-03 -15.4 3.9E-
03 
0 0 1 
211595_s_
at 
mitochondrial ribosomal 
protein S11 
MRPS11 -15.2 25.7 9.5E-03 -29.5 6.8E-
03 
0 0 1 
224948_at mitochondrial ribosomal 
protein S24 
MRPS24 -16.6 28.2 5.7E-03 -29.5 8.6E-
03 
1 0 0 
220688_s_
at 
mRNA turnover 4 homolog  MRTO4 -12.2 20.7 3.1E-03 -29.5 8.1E-
04 
1 0 0 
218160_at NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 8, 19kDa 
NDUFA8 -13.3 25.6 7.4E-03 -25.9 1.7E-
03 
1 0 0 
218200_s_
at 
NADH dehydrogenase 
(ubiquinone) 1 beta 
subcomplex, 2, 8kDa 
NDUFB2 -12.5 21.1 8.8E-03 -29.5 1.2E-
03 
0 0 1 
202839_s_
at 
NADH dehydrogenase 
(ubiquinone) 1 beta 
subcomplex, 7, 18kDa 
NDUFB7 -13.5 27.0 3.6E-03 -25.0 3.3E-
03 
0 0 1 
201226_at NADH dehydrogenase 
(ubiquinone) 1 beta 
subcomplex, 8, 19kDa /// 
SEC31 homolog B  
NDUFB8 /// 
SEC31B 
-9.2 28.0 1.2E-03 -16.4 1.4E-
03 
1 0 0 
201966_at NADH dehydrogenase 
(ubiquinone) Fe-S protein 
2, 49kDa (NADH-
coenzyme Q reductase) 
NDUFS2 -15.0 22.8 6.4E-03 -33.0 3.1E-
03 
0 0 1 
218809_at pantothenate kinase 2 
(Hallervorden-Spatz 
syndrome) 
PANK2 -16.6 25.1 7.5E-03 -33.0 1.6E-
03 
1 0 0 
200006_at Parkinson disease 
(autosomal recessive, early 
DJ-1 -12.9 24.9 3.0E-03 -25.9 5.5E-
04 
0 0 1 
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onset) 7 
209019_s_
at 
PTEN induced putative 
kinase 1 
PINK-1 -18.6 31.4 1.6E-03 -29.5 7.2E-
03 
1 0 0 
209018_s_
at 
PTEN induced putative 
kinase 1 
PINK-1 -17.5 24.2 6.9E-03 -36.2 2.9E-
03 
1 0 0 
224913_s_
at 
translocase of inner 
mitochondrial membrane 
50 homolog  
TIMM50 -21.0 27.8 7.2E-03 -37.7 5.2E-
03 
1 0 0 
218357_s_
at 
translocase of inner 
mitochondrial membrane 8 
homolog B  
TIMM8B -9.6 23.6 2.6E-03 -20.4 3.2E-
03 
0 0 1 
218190_s_
at 
ubiquinol-cytochrome c 
reductase complex (7.2 kD) 
UCRC -9.4 21.2 8.4E-03 -22.1 1.2E-
04 
1 0 0 
208909_at ubiquinol-cytochrome c 
reductase, Rieske iron-
sulfur polypeptide 1 
UQCRFS1 -14.0 24.5 9.1E-03 -28.6 1.4E-
03 
1 0 0 
 
 
Figure 39. L. Figure S12.  QPCR validation Pink1 and DJ-1 expression differences 
by Sirt5prom2 genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative PCR was performed as described above (Section II).  Differences in 
expression were calculated for age-matched cohorts used to determine snp-affected 
transcripts (Section V-E).  * denotes genotypic expression difference p<0.05 and ** 
denotes genotypic expression difference p<0.01 
  188 
REFERENCES 
 
 1.  Salthouse TA. Adult Cognition. Springer‐Verlag: New York, 1982.  2.  Salthouse  TA.  Mechanisms  of  age­cognition  relations  in  adulthood.  Lawrence Earlbaum Associates: Hillsdale, NJ, 1996.  3.  Schaie  KW.  Intellectual  development  in  adulthood.  Cambridge  University  Press: Cambridge, 1996.  4.  Christensen H. What cognitive changes can be expected with normal ageing? Aust 
N Z J Psychiatry 2001 Dec; 35(6): 768‐775.  5.  Ruffman  T,  Henry  JD,  Livingstone  V,  Phillips  LH.  A  meta‐analytic  review  of emotion  recognition  and  aging:  implications  for  neuropsychological  models  of aging. Neurosci Biobehav Rev 2008; 32(4): 863‐881.  6.  Park  DC,  Reuter‐Lorenz  P.  The  adaptive  brain:  aging  and  neurocognitive scaffolding. Annu Rev Psychol 2009; 60: 173‐196.  7.  Wechsler  D.  Manual  for  the  Weschler  Adult  Intelligence  Scale­  Revised.  The Psychological Corporation: New York, 1981.  8.  Kaufman AS. Assessing  adolescent  and  adult  intelligence.  Allyn & Bacon: Boston, 1990.  9.  Park DC, Lautenschlager G, Hedden T, Davidson NS, Smith AD, Smith PK. Models of visuospatial and verbal memory across the adult life span. Psychol Aging 2002 Jun; 17(2): 299‐320.  10.  Fozard  JL,  Vercryssen M,  Reynolds  SL,  Hancock  PA,  Quilter  RE.  Age  differences and  changes  in  reaction  time:  the  Baltimore  Longitudinal  Study  of  Aging.  J 
Gerontol 1994 Jul; 49(4): P179‐189.  11.  Era  P,  Jokela  J,  Heikkinen  E.  Reaction  and movement  times  in men  of  different ages: a population study. Percept Mot Skills 1986 Aug; 63(1): 111‐130.  12.  Kauranen K, Vanharanta H. Influences of aging, gender, and handedness on motor performance of upper and lower extremities. Percept Mot Skills 1996 Apr; 82(2): 515‐525.  
  189 
13.  Volkow  ND,  Logan  J,  Fowler  JS,  Wang  GJ,  Gur  RC,  Wong  C  et  al.  Association between age‐related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry 2000 Jan; 157(1): 75‐80.  14.  Volkow ND,  Gur  RC, Wang  GJ,  Fowler  JS,  Moberg  PJ,  Ding  YS  et  al.  Association between  decline  in  brain  dopamine  activity  with  age  and  cognitive  and motor impairment in healthy individuals. Am J Psychiatry 1998 Mar; 155(3): 344‐349.  15.  Mather M, Carstensen LL. Aging and motivated cognition: the positivity effect  in attention and memory. Trends Cogn Sci 2005 Oct; 9(10): 496‐502.  16.  Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder:  results  from  the  National  Epidemiologic  Survey  on  Alcoholism  and Related Conditions. Arch Gen Psychiatry 2005 Oct; 62(10): 1097‐1106.  17.  Hawton K, van Heeringen K. Suicide. Lancet 2009 Apr 18; 373(9672): 1372‐1381.  18.  De Leo D, Padoani W, Scocco P, Lie D, Bille‐Brahe U, Arensman E et al. Attempted and completed suicide in older subjects: results from the WHO/EURO Multicentre Study of Suicidal Behaviour. Int J Geriatr Psychiatry 2001 Mar; 16(3): 300‐310.  19.  Fiske A, Wetherell  JL, Gatz M. Depression  in older adults. Annu Rev Clin Psychol 2009; 5: 363‐389.  20.  Wilson RS, Beckett LA, Barnes LL, Schneider JA, Bach J, Evans DA et al. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002 Jun; 17(2): 179‐193.  21.  Deary  IJ, Gow AJ, Taylor MD, Corley  J, Brett C, Wilson V  et al. The Lothian Birth Cohort 1936:  a  study  to examine  influences on  cognitive ageing  from age 11  to age 70 and beyond. BMC Geriatr 2007; 7: 28.  22.  Mattay VS, Goldberg TE, Sambataro F, Weinberger DR. Neurobiology of cognitive aging: insights from imaging genetics. Biol Psychol 2008 Sep; 79(1): 9‐22.  23.  Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward C, Wright AF et al. Cognitive change and the APOE epsilon 4 allele. Nature 2002 Aug 29; 418(6901): 932.  24.  Anstey  K,  Christensen  H.  Education,  activity,  health,  blood  pressure  and apolipoprotein  E  as  predictors  of  cognitive  change  in  old  age:  a  review. 
Gerontology 2000 May‐Jun; 46(3): 163‐177.  25.  Deary  IJ,  Wright  AF,  Harris  SE,  Whalley  LJ,  Starr  JM.  Searching  for  genetic influences on normal cognitive ageing. Trends Cogn Sci 2004 Apr; 8(4): 178‐184.  
  190 
26.  Fillit  HM,  Butler  RN,  O'Connell  AW,  Albert  MS,  Birren  JE,  Cotman  CW  et  al. Achieving and maintaining cognitive vitality with aging. Mayo Clin Proc 2002 Jul; 
77(7): 681‐696.  27.  Joseph J, Cole G, Head E, Ingram D. Nutrition, brain aging, and neurodegeneration. 
J Neurosci 2009 Oct 14; 29(41): 12795‐12801.  28.  Muscari A, Giannoni C, Pierpaoli L, Berzigotti A, Maietta P, Foschi E et al. Chronic endurance  exercise  training  prevents  aging‐related  cognitive  decline  in  healthy older adults: a randomized controlled trial. Int J Geriatr Psychiatry 2009 Dec 23.  29.  Panza  F,  Solfrizzi  V,  Colacicco  AM,  D'Introno  A,  Capurso  C,  Torres  F  et  al. Mediterranean diet and cognitive decline. Public Health Nutr 2004 Oct; 7(7): 959‐963.  30.  Tisserand DJ, van Boxtel MP, Pruessner JC, Hofman P, Evans AC, Jolles J. A voxel‐based  morphometric  study  to  determine  individual  differences  in  gray  matter density  associated with  age  and  cognitive  change  over  time. Cereb  Cortex  2004 Sep; 14(9): 966‐973.  31.  Tisserand DJ, Pruessner JC, Sanz Arigita EJ, van Boxtel MP, Evans AC, Jolles J et al. Regional frontal cortical volumes decrease differentially in aging: an MRI study to compare  volumetric  approaches  and  voxel‐based  morphometry.  Neuroimage 2002 Oct; 17(2): 657‐669.  32.  Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Markesbery WR. Age and gender effects  on human brain  anatomy:  a  voxel‐based morphometric  study  in healthy elderly. Neurobiol Aging 2007 Jul; 28(7): 1075‐1087.  33.  Good  CD,  Johnsrude  IS,  Ashburner  J,  Henson  RN,  Friston  KJ,  Frackowiak  RS.  A voxel‐based morphometric  study  of  ageing  in  465  normal  adult  human  brains. 
Neuroimage 2001 Jul; 14(1 Pt 1): 21‐36.  34.  Resnick  SM,  Pham  DL,  Kraut  MA,  Zonderman  AB,  Davatzikos  C.  Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci 2003 Apr 15; 23(8): 3295‐3301.  35.  Gianaros PJ, Greer PJ, Ryan CM, Jennings JR. Higher blood pressure predicts lower regional  grey  matter  volume:  Consequences  on  short‐term  information processing. Neuroimage 2006 Jun; 31(2): 754‐765.  36.  Seshadri  S, Wolf PA, Beiser A, Elias MF, Au R, Kase CS  et  al.  Stroke  risk profile, brain volume, and cognitive function: the Framingham Offspring Study. Neurology 2004 Nov 9; 63(9): 1591‐1599.  37.  Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol 2008; 3: 41‐66. 
  191 
 38.  Morrison  JH, Hof PR. Life and death of neurons  in  the aging brain. Science 1997 Oct 17; 278(5337): 412‐419.  39.  Dickstein DL, Kabaso D, Rocher AB, Luebke JI, Wearne SL, Hof PR. Changes in the structural complexity of the aged brain. Aging Cell 2007 Jun; 6(3): 275‐284.  40.  Duan  H,  Wearne  SL,  Rocher  AB,  Macedo  A,  Morrison  JH,  Hof  PR.  Age‐related dendritic  and  spine  changes  in  corticocortically  projecting  neurons  in macaque monkeys. Cereb Cortex 2003 Sep; 13(9): 950‐961.  41.  Finch  CE.  Neurons,  glia,  and  plasticity  in  normal  brain  aging.  Neurobiol  Aging 2003 May‐Jun; 24 Suppl 1: S123‐127; discussion S131.  42.  Conde JR, Streit WJ. Microglia  in the aging brain.  J Neuropathol Exp Neurol 2006 Mar; 65(3): 199‐203.  43.  Unger JW. Glial reaction in aging and Alzheimer's disease. Microsc Res Tech 1998 Oct 1; 43(1): 24‐28.  44.  Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing  and  age‐related  disease:  insulin/IGF‐1,  BDNF  and  serotonin. Ageing  Res 
Rev 2004 Nov; 3(4): 445‐464.  45.  Mattson MP, Maudsley S, Martin B. BDNF and 5‐HT: a dynamic duo in age‐related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004 Oct; 
27(10): 589‐594.  46.  Mattson  MP.  Glutamate  and  neurotrophic  factors  in  neuronal  plasticity  and disease. Ann N Y Acad Sci 2008 Nov; 1144: 97‐112.  47.  Backman L, Nyberg L, Lindenberger U, Li SC, Farde L. The correlative triad among aging,  dopamine,  and  cognition:  current  status  and  future  prospects.  Neurosci 
Biobehav Rev 2006; 30(6): 791‐807.  48.  Narasimhan  SD,  Yen  K,  Tissenbaum  HA.  Converging  pathways  in  lifespan regulation. Curr Biol 2009 Aug 11; 19(15): R657‐666.  49.  Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009 Jul 10; 325(5937): 201‐204.  50.  Witte  AV,  Fobker  M,  Gellner  R,  Knecht  S,  Floel  A.  Caloric  restriction  improves memory in elderly humans. Proc Natl Acad Sci U S A 2009 Jan 27; 106(4): 1255‐1260.  
  192 
51.  Papaconstantinou J. Insulin/IGF‐1 and ROS signaling pathway cross‐talk in aging and longevity determination. Mol Cell Endocrinol 2009 Feb 5; 299(1): 89‐100.  52.  Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P et al. Suppression of aging in mice by the hormone Klotho. Science 2005 Sep 16; 309(5742): 1829‐1833.  53.  Bartke A. Long‐lived Klotho mice: new insights into the roles of IGF‐1 and insulin in aging. Trends Endocrinol Metab 2006 Mar; 17(2): 33‐35.  54.  Gan L, Mucke L. Paths of convergence: sirtuins  in aging and neurodegeneration. 
Neuron 2008 Apr 10; 58(1): 10‐14.  55.  Araki  T,  Sasaki  Y,  Milbrandt  J.  Increased  nuclear  NAD  biosynthesis  and  SIRT1 activation prevent axonal degeneration. Science 2004 Aug 13; 305(5686): 1010‐1013.  56.  Libert S, Cohen D, Guarente L. Neurogenesis directed by Sirt1. Nat Cell Biol 2008 Apr; 10(4): 373‐374.  57.  Droge  W,  Schipper  HM.  Oxidative  stress  and  aberrant  signaling  in  aging  and cognitive decline. Aging Cell 2007 Jun; 6(3): 361‐370.  58.  Bauer JH, Poon PC, Glatt‐Deeley H, Abrams JM, Helfand SL. Neuronal expression of p53  dominant‐negative  proteins  in  adult  Drosophila  melanogaster  extends  life span. Curr Biol 2005 Nov 22; 15(22): 2063‐2068.  59.  Tapia‐Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights  into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 2008 Nov; 59(1): 201‐220.  60.  Erraji‐Benchekroun  L,  Underwood  MD,  Arango  V,  Galfalvy  H,  Pavlidis  P, Smyrniotopoulos P et al. Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. Biol Psychiatry 2005 Mar 1; 57(5): 549‐558.  61.  Rex CS, Lauterborn JC, Lin CY, Kramar EA, Rogers GA, Gall CM et al. Restoration of long‐term  potentiation  in  middle‐aged  hippocampus  after  induction  of  brain‐derived neurotrophic factor. J Neurophysiol 2006 Aug; 96(2): 677‐685.  62.  Glorioso  C,  Sabatini  M,  Unger  T,  Hashimoto  T,  Monteggia  LM,  Lewis  DA  et  al. Specificity and timing of neocortical transcriptome changes in response to BDNF gene  ablation  during  embryogenesis  or  adulthood.  Mol  Psychiatry  2006  Jul; 
11(7): 633‐648.  63.  Sibille E, Su J, Leman S, Le Guisquet AM, Ibarguen‐Vargas Y, Joeyen‐Waldorf J et al. Lack of serotonin1B receptor expression leads to age‐related motor dysfunction, 
  193 
early onset of brain molecular aging and reduced longevity. Mol Psychiatry 2007 Nov; 12(11): 1042‐1056, 1975.  64.  Petrascheck M,  Ye  X,  Buck  LB.  An  antidepressant  that  extends  lifespan  in  adult Caenorhabditis elegans. Nature 2007 Nov 22; 450(7169): 553‐556.  65.  Petrascheck  M,  Ye  X,  Buck  LB.  A  high‐throughput  screen  for  chemicals  that increase the lifespan of Caenorhabditis elegans. Ann N Y Acad Sci 2009 Jul; 1170: 698‐701.  66.  Murakami  H,  Bessinger  K,  Hellmann  J,  Murakami  S.  Manipulation  of  serotonin signal  suppresses  early  phase  of  behavioral  aging  in  Caenorhabditis  elegans. 
Neurobiol Aging 2008 Jul; 29(7): 1093‐1100.  67.  Sze JY, Victor M, Loer C, Shi Y, Ruvkun G. Food and metabolic signalling defects in a  Caenorhabditis  elegans  serotonin‐synthesis  mutant.  Nature  2000  Feb  3; 
403(6769): 560‐564.  68.  Cotzias GC, Miller ST, Tang LC, Papavasiliou PS. Levodopa, fertility, and longevity. 
Science 1977 Apr 29; 196(4289): 549‐551.  69.  Cotzias GC, Miller ST, Nicholson AR, Jr., Maston WH, Tang LC. Prolongation of the life‐span  in mice  adapted  to  large  amounts  of  L‐dopa. Proc Natl  Acad  Sci  U  S  A 1974 Jun; 71(6): 2466‐2469.  70.  Diaz‐Torga  G,  Feierstein  C,  Libertun  C,  Gelman  D,  Kelly  MA,  Low  MJ  et  al. Disruption of the D2 dopamine receptor alters GH and IGF‐I secretion and causes dwarfism in male mice. Endocrinology 2002 Apr; 143(4): 1270‐1279.  71.  Backman  L,  Ginovart  N,  Dixon  RA,  Wahlin  TB,  Wahlin  A,  Halldin  C  et  al.  Age‐related  cognitive deficits mediated by  changes  in  the  striatal  dopamine  system. 
Am J Psychiatry 2000 Apr; 157(4): 635‐637.  72.  Luo Y, Roth GS. The  roles  of  dopamine oxidative  stress  and dopamine  receptor signaling in aging and age‐related neurodegeneration. Antioxid Redox Signal 2000 Fall; 2(3): 449‐460.  73.  Rollo  CD.  Dopamine  and  aging:  intersecting  facets.  Neurochem  Res  2009  Apr; 
34(4): 601‐629.  74.  Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J et al. Gene regulation and DNA damage in the ageing human brain. Nature 2004 Jun 24; 429(6994): 883‐891.  75.  Berchtold  NC,  Cribbs  DH,  Coleman  PD,  Rogers  J,  Head  E,  Kim  R  et  al.  Gene expression changes  in  the course of normal brain aging are sexually dimorphic. 
Proc Natl Acad Sci U S A 2008 Oct 7; 105(40): 15605‐15610. 
  194 
 76.  Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al. The BDNF val66met polymorphism affects activity‐dependent secretion of BDNF and human memory and hippocampal function. Cell 2003 Jan 24; 112(2): 257‐269.  77.  Nemoto  K,  Ohnishi  T,  Mori  T,  Moriguchi  Y,  Hashimoto  R,  Asada  T  et  al.  The Val66Met  polymorphism  of  the  brain‐derived  neurotrophic  factor  gene  affects age‐related brain morphology. Neurosci Lett 2006 Apr 10‐17; 397(1‐2): 25‐29.  78.  Harris  SE,  Fox H, Wright  AF,  Hayward  C,  Starr  JM, Whalley  LJ  et  al.  The  brain‐derived  neurotrophic  factor  Val66Met  polymorphism  is  associated  with  age‐related change in reasoning skills. Mol Psychiatry 2006 May; 11(5): 505‐513.  79.  Sublette ME, Baca‐Garcia E, Parsey RV, Oquendo MA, Rodrigues SM, Galfalvy H et 
al.  Effect  of  BDNF  val66met  polymorphism  on  age‐related  amygdala  volume changes in healthy subjects. Prog Neuropsychopharmacol Biol Psychiatry 2008 Oct 1; 32(7): 1652‐1655.  80.  Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al. Influence of life  stress  on  depression:  moderation  by  a  polymorphism  in  the  5‐HTT  gene. 
Science 2003 Jul 18; 301(5631): 386‐389.  81.  O'Hara  R,  Schroder  CM,  Mahadevan  R,  Schatzberg  AF,  Lindley  S,  Fox  S  et  al. Serotonin  transporter  polymorphism, memory  and  hippocampal  volume  in  the elderly: association and interaction with cortisol. Mol Psychiatry 2007 Jun; 12(6): 544‐555.  82.  Gondo  Y,  Hirose  N,  Arai  Y,  Yamamura  K,  Shimizu  K,  Takayama  M  et  al. Contribution of an affect‐associated gene  to human  longevity: prevalence of  the long‐allele  genotype  of  the  serotonin  transporter‐linked  gene  in  Japanese centenarians. Mech Ageing Dev 2005 Nov; 126(11): 1178‐1184.  83.  Payton  A,  Gibbons  L,  Davidson  Y,  Ollier  W,  Rabbitt  P,  Worthington  J  et  al. Influence of serotonin transporter gene polymorphisms on cognitive decline and cognitive abilities in a nondemented elderly population. Mol Psychiatry 2005 Dec; 
10(12): 1133‐1139.  84.  Reynolds  CA,  Jansson M,  Gatz M,  Pedersen NL.  Longitudinal  change  in memory performance  associated with HTR2A  polymorphism. Neurobiol  Aging  2006  Jan; 
27(1): 150‐154.  85.  Houlihan  LM,  Harris  SE,  Luciano  M,  Gow  AJ,  Starr  JM,  Visscher  PM  et  al. Replication  study  of  candidate  genes  for  cognitive  abilities:  the  Lothian  Birth Cohort 1936. Genes Brain Behav 2009 Mar; 8(2): 238‐247.  
  195 
86.  Starr  JM,  Fox  H,  Harris  SE,  Deary  IJ, Whalley  LJ.  COMT  genotype  and  cognitive ability: a longitudinal aging study. Neurosci Lett 2007 Jun 21; 421(1): 57‐61.  87.  de  Frias  CM,  Annerbrink  K,  Westberg  L,  Eriksson  E,  Adolfsson  R,  Nilsson  LG. COMT  gene  polymorphism  is  associated with  declarative memory  in  adulthood and old age. Behav Genet 2004 Sep; 34(5): 533‐539.  88.  Rowe  JB,  Hughes  L, Williams‐Gray  CH,  Bishop  S,  Fallon  S,  Barker  RA  et  al.  The val(158)met  COMT  polymorphism's  effect  on  atrophy  in  healthy  aging  and Parkinson's disease. Neurobiol Aging 2008 Aug 26.  89.  De  Luca  M,  Rose  G,  Bonafe  M,  Garasto  S,  Greco  V,  Weir  BS  et  al.  Sex‐specific longevity  associations  defined  by  Tyrosine  Hydroxylase‐Insulin‐Insulin  Growth Factor 2 haplotypes on the 11p15.5 chromosomal region. Exp Gerontol 2001 Nov; 
36(10): 1663‐1671.  90.  Kuro‐o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al. Mutation of  the mouse klotho  gene  leads  to  a  syndrome  resembling  ageing. Nature  1997 Nov 6; 390(6655): 45‐51.  91.  Uchida  A,  Komiya  Y,  Tashiro  T,  Yorifuji  H,  Kishimoto  T,  Nabeshima  Y  et  al. Neurofilaments  of Klotho,  the mutant mouse prematurely displaying  symptoms resembling human aging. J Neurosci Res 2001 May 15; 64(4): 364‐370.  92.  Thomson PA, Harris  SE,  Starr  JM, Whalley LJ, Porteous DJ, Deary  IJ. Association between  genotype  at  an  exonic  SNP  in  DISC1  and  normal  cognitive  aging. 
Neurosci Lett 2005 Nov 25; 389(1): 41‐45.  93.  Arking  DE,  Krebsova  A,  Macek  M,  Sr.,  Macek  M,  Jr.,  Arking  A,  Mian  IS  et  al. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci 
U S A 2002 Jan 22; 99(2): 856‐861.  94.  Arking  DE,  Atzmon  G,  Arking  A,  Barzilai  N,  Dietz  HC.  Association  between  a functional variant of the KLOTHO gene and high‐density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res 2005 Mar 4; 96(4): 412‐418.  95.  Arking DE, Becker DM, Yanek LR, Fallin D, Judge DP, Moy TF et al. KLOTHO allele status and the risk of early‐onset occult coronary artery disease. Am J Hum Genet 2003 May; 72(5): 1154‐1161.  96.  Imamura  A,  Okumura  K,  Ogawa  Y, Murakami  R,  Torigoe M,  Numaguchi  Y  et  al. Klotho  gene  polymorphism  may  be  a  genetic  risk  factor  for  atherosclerotic coronary artery disease but not for vasospastic angina in Japanese. Clin Chim Acta 2006 Mar 6.  
  196 
97.  Ogata  N,  Matsumura  Y,  Shiraki  M,  Kawano  K,  Koshizuka  Y,  Hosoi  T  et  al. Association of klotho gene polymorphism with bone density and spondylosis of the lumbar spine in postmenopausal women. Bone 2002 Jul; 31(1): 37‐42.  98.  Deary  IJ,  Harris  SE,  Fox  HC,  Hayward  C,  Wright  AF,  Starr  JM  et  al.  KLOTHO genotype and cognitive ability  in childhood and old age  in the same individuals. 
Neurosci Lett 2005 Apr 11; 378(1): 22‐27.  99.  Bonafe  M,  Barbieri  M,  Marchegiani  F,  Olivieri  F,  Ragno  E,  Giampieri  C  et  al. Polymorphic  variants  of  insulin‐like  growth  factor  I  (IGF‐I)  receptor  and phosphoinositide 3‐kinase genes affect IGF‐I plasma levels and human longevity: cues  for  an  evolutionarily  conserved  mechanism  of  life  span  control.  J  Clin 
Endocrinol Metab 2003 Jul; 88(7): 3299‐3304.  100.  Kenyon C. The plasticity of aging: insights from long‐lived mutants. Cell 2005 Feb 25; 120(4): 449‐460.  101.  Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller‐Eberstein H, Nikolaus S 
et  al.  Association  of  FOXO3A  variation  with  human  longevity  confirmed  in German centenarians. Proc Natl Acad Sci U S A 2009 Feb 24; 106(8): 2700‐2705.  102.  Pawlikowska  L,  Hu  D,  Huntsman  S,  Sung  A,  Chu  C,  Chen  J  et  al.  Association  of common  genetic  variation  in  the  insulin/IGF1  signaling  pathway  with  human longevity. Aging Cell 2009 Aug; 8(4): 460‐472.  103.  Bonafe  M,  Olivieri  F.  Genetic  polymorphism  in  long‐lived  people:  cues  for  the presence  of  an  insulin/IGF‐pathway‐dependent  network  affecting  human longevity. Mol Cell Endocrinol 2009 Feb 5; 299(1): 118‐123.  104.  Bishop  NA,  Guarente  L.  Genetic  links  between  diet  and  lifespan:  shared mechanisms from yeast to humans. Nat Rev Genet 2007 Nov; 8(11): 835‐844.  105.  Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009 Jul 30; 460(7255): 587‐591.  106.  Rose G, Dato S, Altomare K, Bellizzi D, Garasto S, Greco V et al. Variability of the SIRT3  gene,  human  silent  information  regulator  Sir2  homologue,  and survivorship in the elderly. Exp Gerontol 2003 Oct; 38(10): 1065‐1070.  107.  Bellizzi D, Rose G, Cavalcante P, Covello G, Dato S, De Rango F et al. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics 2005 Feb; 85(2): 258‐263.  108.  Kuningas M, Putters M, Westendorp RG, Slagboom PE, van Heemst D. SIRT1 gene, age‐related diseases, and mortality: the Leiden 85‐plus study. J Gerontol A Biol Sci 
Med Sci 2007 Sep; 62(9): 960‐965. 
  197 
 109.  Smith JD. Apolipoproteins and aging: emerging mechanisms. Ageing Res Rev 2002 Jun; 1(3): 345‐365.  110.  Kachiwala SJ, Harris SE, Wright AF, Hayward C, Starr JM, Whalley LJ et al. Genetic influences on oxidative stress and their association with normal cognitive ageing. 
Neurosci Lett 2005 Sep 30; 386(2): 116‐120.  111.  Berr C, Richard F, Dufouil C, Amant C, Alperovitch A, Amouyel P. Polymorphism of the prion protein is associated with cognitive impairment in the elderly: the EVA study. Neurology 1998 Sep; 51(3): 734‐737.  112.  Rujescu D, Hartmann AM, Gonnermann C, Moller HJ, Giegling I. M129V variation in  the  prion  protein may  influence  cognitive  performance. Mol  Psychiatry  2003 Nov; 8(11): 937‐941.  113.  Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003 Apr 3; 348(14): 1356‐1364.  114.  Tsuang  MT,  Tohen  M.  Textbook  in  Psychiatric  Epidemiology.  2  edn.  Wiley: Weinheim, Germany, 2002.  115.  Feher  A,  Juhasz  A,  Rimanoczy  A,  Kalman  J,  Janka  Z.  Association  between  BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease. Alzheimer Dis Assoc Disord 2009 Jul‐Sep; 23(3): 224‐228.  116.  Bialecka M, Kurzawski M, Klodowska‐Duda G, Opala G, Tan EK, Drozdzik M. The association  of  functional  catechol‐O‐methyltransferase  haplotypes  with  risk  of Parkinson's  disease,  levodopa  treatment  response,  and  complications. 
Pharmacogenet Genomics 2008 Sep; 18(9): 815‐821.  117.  Numata  S,  Ueno  S,  Iga  J,  Yamauchi  K,  Hongwei  S,  Ohta  K  et  al.  Brain‐derived neurotrophic  factor  (BDNF)  Val66Met  polymorphism  in  schizophrenia  is associated with age at onset and symptoms. Neurosci Lett 2006 Jun 19; 401(1‐2): 1‐5.  118.  Qin W, Chachich M, Lane M, Roth G, Bryant M, de Cabo R et al. Calorie restriction attenuates  Alzheimer's  disease  type  brain  amyloidosis  in  Squirrel  monkeys (Saimiri sciureus). J Alzheimers Dis 2006 Dec; 10(4): 417‐422.  119.  Maswood  N,  Young  J,  Tilmont  E,  Zhang  Z,  Gash  DM,  Gerhardt  GA  et  al.  Caloric restriction  increases  neurotrophic  factor  levels  and  attenuates  neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad 
Sci U S A 2004 Dec 28; 101(52): 18171‐18176.  
  198 
120.  Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM et al. Neuroprotective  effects  of  brain‐derived  neurotrophic  factor  in  rodent  and primate models of Alzheimer's disease. Nat Med 2009 Mar; 15(3): 331‐337.  121.  Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT et al. SIRT1 deacetylase  protects  against  neurodegeneration  in  models  for  Alzheimer's disease  and  amyotrophic  lateral  sclerosis.  EMBO  J  2007  Jul  11;  26(13):  3169‐3179.  122.  Masuda  H,  Chikuda  H,  Suga  T,  Kawaguchi  H,  Kuro‐o  M.  Regulation  of  multiple ageing‐like  phenotypes  by  inducible  klotho  gene  expression  in  klotho  mutant mice. Mech Ageing Dev 2005 Dec; 126(12): 1274‐1283.  123.  Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age‐onset proteotoxicity. Science 2006 Sep 15; 313(5793): 1604‐1610.  124.  Cohen E, Paulsson JF, Blinder P, Burstyn‐Cohen T, Du D, Estepa G et al. Reduced IGF‐1  signaling  delays  age‐associated  proteotoxicity  in mice. Cell  2009  Dec  11; 
139(6): 1157‐1169.  125.  Angelucci  F,  Brene  S,  Mathe  AA.  BDNF  in  schizophrenia,  depression  and corresponding animal models. Mol Psychiatry 2005 Jan 18.  126.  Mody  I.  The  GAD‐given  Right  of  Dentate  Gyrus  Granule  Cells  to  Become GABAergic. Epilepsy Curr 2002 Sep; 2(5): 143‐145.  127.  Marty S, Berninger B, Carroll P, Thoenen H. GABAergic stimulation regulates the phenotype of hippocampal interneurons through the regulation of brain‐derived neurotrophic factor. Neuron 1996 Mar; 16(3): 565‐570.  128.  de  Lima  AD,  Opitz  T,  Voigt  T.  Irreversible  loss  of  a  subpopulation  of  cortical interneurons  in  the  absence  of  glutamatergic  network  activity.  Eur  J  Neurosci 2004 Jun; 19(11): 2931‐2943.  129.  Chattopadhyaya B, Di Cristo G, Higashiyama H, Knott GW, Kuhlman SJ, Welker E et 
al.  Experience  and  activity‐dependent  maturation  of  perisomatic  GABAergic innervation in primary visual cortex during a postnatal critical period. J Neurosci 2004 Oct 27; 24(43): 9598‐9611.  130.  Huang ZJ, Kirkwood A, Pizzorusso T, Porciatti V, Morales B, Bear MF et al. BDNF regulates  the  maturation  of  inhibition  and  the  critical  period  of  plasticity  in mouse visual cortex. Cell 1999 Sep 17; 98(6): 739‐755.  131.  Bramham  CR,  Messaoudi  E.  BDNF  function  in  adult  synaptic  plasticity:  The synaptic consolidation hypothesis. Prog Neurobiol 2005 Aug 10.  
  199 
132.  Baldelli  P,  Novara  M,  Carabelli  V,  Hernandez‐Guijo  JM,  Carbone  E.  BDNF  up‐regulates  evoked  GABAergic  transmission  in  developing  hippocampus  by potentiating presynaptic N‐ and P/Q‐type Ca2+ channels signalling. Eur J Neurosci 2002 Dec; 16(12): 2297‐2310.  133.  Markram  H,  Toledo‐Rodriguez  M,  Wang  Y,  Gupta  A,  Silberberg  G,  Wu  C. Interneurons  of  the  neocortical  inhibitory  system. Nat  Rev  Neurosci  2004  Oct; 
5(10): 793‐807.  134.  McBain CJ, Fisahn A. Interneurons unbound. Nat Rev Neurosci 2001 Jan; 2(1): 11‐23.  135.  Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T et al. Essential role of brain‐derived neurotrophic factor in adult hippocampal function. Proc Natl 
Acad Sci U S A 2004 Jul 20; 101(29): 10827‐10832.  136.  Hashimoto  T,  Bergen  SE,  Nguyen  QL,  Xu  B,  Monteggia  LM,  Pierri  JN  et  al. Relationship of brain‐derived neurotrophic factor and its receptor TrkB to altered inhibitory  prefrontal  circuitry  in  schizophrenia.  J  Neurosci  2005  Jan  12; 25(2): 372‐383.  137.  Niblock  MM,  Brunso‐Bechtold  JK,  Riddle  DR.  Laminar  variation  in  neuronal viability and trophic dependence in neocortical slices. J Neurosci Res 2001 Sep 1; 
65(5): 455‐462.  138.  Itami  C,  Mizuno  K,  Kohno  T,  Nakamura  S.  Brain‐derived  neurotrophic  factor requirement  for  activity‐dependent  maturation  of  glutamatergic  synapse  in developing mouse somatosensory cortex. Brain Res 2000 Feb 28; 857(1‐2): 141‐150.  139.  Lotto  RB,  Asavaritikrai  P,  Vali  L,  Price  DJ.  Target‐derived  neurotrophic  factors regulate the death of developing forebrain neurons after a change in their trophic requirements. J Neurosci 2001 Jun 1; 21(11): 3904‐3910.  140.  Chen J, Kelz MB, Zeng G, Sakai N, Steffen C, Shockett PE et al. Transgenic animals with  inducible,  targeted  gene  expression  in  brain.  Mol  Pharmacol  1998  Sep; 
54(3): 495‐503.  141.  Radomska  HS,  Gonzalez  DA,  Okuno  Y,  Iwasaki  H,  Nagy  A,  Akashi  K  et  al. Transgenic  targeting with  regulatory  elements  of  the  human  CD34  gene. Blood 2002 Dec 15; 100(13): 4410‐4419.  142.  Perl AK, Wert SE, Nagy A, Lobe CG, Whitsett JA. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc Natl Acad Sci U S A 2002 Aug 6; 99(16): 10482‐10487.  
  200 
143.  Rios M,  Fan G,  Fekete C, Kelly  J,  Bates B, Kuehn R  et  al.  Conditional  deletion of brain‐derived  neurotrophic  factor  in  the  postnatal  brain  leads  to  obesity  and hyperactivity. Mol Endocrinol 2001 Oct; 15(10): 1748‐1757.  144.  Irizarry  RA,  Hobbs  B,  Collin  F,  Beazer‐Barclay  YD,  Antonellis  KJ,  Scherf  U  et  al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003 Apr; 4(2): 249‐264.  145.  Irizarry  RA,  Bolstad  BM,  Collin  F,  Cope  LM,  Hobbs  B,  Speed  TP.  Summaries  of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003 Feb 15; 31(4): e15.  146.  Mirnics K, Pevsner  J.  Progress  in  the use of microarray  technology  to  study  the neurobiology of disease. Nat Neurosci 2004 May; 7(5): 434‐439.  147.  Unger  T,  Korade  Z,  Lazarov O,  Terrano D,  Sisodia  SS, Mirnics K.  True  and  false discovery  in  DNA  microarray  experiments:  transcriptome  changes  in  the hippocampus of Presenilin‐1 mutant mice. Methods 2005; (in press.).  148.  Mirnics K, Korade Z, Arion D, Lazarov O, Unger T, Macioce M et al. Presenilin‐1‐dependent transcriptome changes. J Neurosci 2005 Feb 9; 25(6): 1571‐1578.  149.  Lazarov  O,  Robinson  J,  Tang  I,  Korade  Mirnics  Z,  Hairston  V,  Lee  M‐Y  et  al. Environmental  enrichment  reduces  A‐beta  levels  and  amyloid  deposition  in transgenic mice. Cell 2005: in press.  150.  Lepre  J,  Rice  JJ,  Tu  Y,  Stolovitzky  G.  Genes@Work:  an  efficient  algorithm  for pattern  discovery  and  multivariate  feature  selection  in  gene  expression  data. 
Bioinformatics 2004 May 1; 20(7): 1033‐1044.  151.  Mimmack  ML,  Brooking  J,  Bahn  S.  Quantitative  polymerase  chain  reaction: validation of microarray  results  from postmortem brain  studies. Biol Psychiatry 2004 Feb 15; 55(4): 337‐345.  152.  Mirnics  K,  Middleton  FA,  Marquez  A,  Lewis  DA,  Levitt  P.  Molecular characterization  of  schizophrenia  viewed  by  microarray  analysis  of  gene expression in prefrontal cortex. Neuron 2000 Oct; 28(1): 53‐67.  153.  Mirnics  K,  Middleton  FA,  Stanwood  GD,  Lewis  DA,  Levitt  P.  Disease‐specific changes in regulator of G‐protein signaling 4 (RGS4) expression in schizophrenia. 
Mol Psychiatry 2001 May; 6(3): 293‐301.  154.  Hendry SH, Jones EG, Emson PC. Morphology, distribution, and synaptic relations of somatostatin‐ and neuropeptide Y‐immunoreactive neurons in rat and monkey neocortex. J Neurosci 1984 Oct; 4(10): 2497‐2517.  
  201 
155.  Chan‐Palay V. Somatostatin immunoreactive neurons in the human hippocampus and  cortex  shown  by  immunogold/silver  intensification  on  vibratome  sections: coexistence  with  neuropeptide  Y  neurons,  and  effects  in  Alzheimer‐type dementia. J Comp Neurol 1987 Jun 8; 260(2): 201‐223.  156.  Eriksdotter‐Nilsson M, Meister  B,  Hokfelt  T,  Elde  R,  Fahrenkrug  J,  Frey  P  et  al. Glutamic  acid  decarboxylase‐  and  peptide‐immunoreactive  neurons  in  cortex cerebri following development in isolation: evidence of homotypic and disturbed patterns in intraocular grafts. Synapse 1987; 1(6): 539‐551.  157.  Gascon E, Vutskits L, Zhang H, Barral‐Moran MJ, Kiss PJ, Mas C  et al.  Sequential activation of p75 and TrkB is involved in dendritic development of subventricular zone‐derived neuronal progenitors  in vitro. Eur  J Neurosci  2005  Jan; 21(1): 69‐80.  158.  Marty  S,  Berzaghi  Mda  P,  Berninger  B.  Neurotrophins  and  activity‐dependent plasticity of cortical interneurons. Trends Neurosci 1997 May; 20(5): 198‐202.  159.  Marty  S.  Differences  in  the  regulation  of  neuropeptide  Y,  somatostatin  and parvalbumin levels in hippocampal interneurons by neuronal activity and BDNF. 
Prog Brain Res 2000; 128: 193‐202.  160.  Morris BJ. Neuronal localisation of neuropeptide Y gene expression in rat brain. J 
Comp Neurol 1989 Dec 15; 290(3): 358‐368.  161.  McDonald  AJ.  Coexistence  of  somatostatin  with  neuropeptide  Y,  but  not  with cholecystokinin or vasoactive intestinal peptide,  in neurons of the rat amygdala. 
Brain Res 1989 Oct 23; 500(1‐2): 37‐45.  162.  Papadopoulos  GC,  Parnavelas  JG,  Cavanagh  ME.  Extensive  co‐existence  of neuropeptides in the rat visual cortex. Brain Res 1987 Sep 8; 420(1): 95‐99.  163.  Chronwall  BM,  Chase  TN,  O'Donohue  TL.  Coexistence  of  neuropeptide  Y  and somatostatin  in  rat and human cortical and rat hypothalamic neurons. Neurosci 
Lett 1984 Dec 21; 52(3): 213‐217.  164.  Cotman  CW,  Engesser‐Cesar  C.  Exercise  enhances  and  protects  brain  function. 
Exerc Sport Sci Rev 2002 Apr; 30(2): 75‐79.  165.  Tong L,  Shen H, Perreau VM, Balazs R, Cotman CW. Effects of exercise on gene‐expression profile  in  the  rat hippocampus. Neurobiol Dis  2001 Dec; 8(6): 1046‐1056.  166.  Walton M, Connor B, Lawlor P, Young D, Sirimanne E, Gluckman P et al. Neuronal death  and  survival  in  two models  of  hypoxic‐ischemic  brain  damage. Brain  Res 
Brain Res Rev 1999 Apr; 29(2‐3): 137‐168. 
  202 
 167.  Mattson MP, Scheff SW. Endogenous neuroprotection factors and traumatic brain injury: mechanisms of action and  implications  for  therapy.  J Neurotrauma 1994 Feb; 11(1): 3‐33.  168.  Nakazawa  T,  Tamai  M,  Mori  N.  Brain‐derived  neurotrophic  factor  prevents axotomized  retinal  ganglion  cell  death  through  MAPK  and  PI3K  signaling pathways. Invest Ophthalmol Vis Sci 2002 Oct; 43(10): 3319‐3326.  169.  Yamada K, Mizuno M, Nabeshima T. Role for brain‐derived neurotrophic factor in learning and memory. Life Sci 2002 Jan 4; 70(7): 735‐744.  170.  Shieh  PB,  Ghosh  A.  Molecular  mechanisms  underlying  activity‐dependent regulation of BDNF expression. J Neurobiol 1999 Oct; 41(1): 127‐134.  171.  Black  IB.  Trophic  regulation  of  synaptic  plasticity.  J Neurobiol  1999 Oct; 41(1): 108‐118.  172.  Zhang  J,  Zhang  D,  McQuade  JS,  Behbehani  M,  Tsien  JZ,  Xu  M.  c‐fos  regulates neuronal excitability and survival. Nat Genet 2002 Apr; 30(4): 416‐420.  173.  Ryser S, Massiha A, Piuz I, Schlegel W. Stimulated initiation of mitogen‐activated protein  kinase  phosphatase‐1  (MKP‐1)  gene  transcription  involves  the synergistic  action  of  multiple  cis‐acting  elements  in  the  proximal  promoter. 
Biochem J 2004 Mar 1; 378(Pt 2): 473‐484.  174.  Murphy LO, MacKeigan JP, Blenis J. A network of immediate early gene products propagates  subtle  differences  in  mitogen‐activated  protein  kinase  signal amplitude and duration. Mol Cell Biol 2004 Jan; 24(1): 144‐153.  175.  Barnea A, Roberts J, Croll SD. Continuous exposure to brain‐derived neurotrophic factor  is  required  for  persistent  activation  of  TrkB  receptor,  the  ERK  signaling pathway,  and  the  induction  of  neuropeptide  Y  production  in  cortical  cultures. 
Brain Res 2004 Sep 10; 1020(1‐2): 106‐117.  176.  Rakhit S, Clark CJ, O'Shaughnessy C T, Morris BJ. NMDA and BDNF induce distinct profiles  of  Extracellular  regulated  kinase  (ERK),  Mitogen  and  stress  activated kinase  (MSK)  and  Ribosomal  S6  kinase  (RSK)  phosphorylation  in  cortical neurones. Mol Pharmacol 2004 Dec 29.  177.  Spalding  KL,  Rush  RA,  Harvey  AR.  Target‐derived  and  locally  derived neurotrophins support  retinal ganglion cell  survival  in  the neonatal  rat  retina.  J 
Neurobiol 2004 Sep 5; 60(3): 319‐327.  
  203 
178.  Wetmore  C,  Olson  L,  Bean  AJ.  Regulation  of  brain‐derived  neurotrophic  factor (BDNF) expression and  release  from hippocampal neurons  is mediated by non‐NMDA type glutamate receptors. J Neurosci 1994 Mar; 14(3 Pt 2): 1688‐1700.  179.  Bryja V,  Pachernik  J,  Faldikova L, Krejci  P,  Pogue R, Nevriva  I  et  al.  The  role  of p27(Kip1)  in  maintaining  the  levels  of  D‐type  cyclins  in  vivo.  Biochim  Biophys 
Acta 2004 May 3; 1691(2‐3): 105‐116.  180.  Morris TA, DeLorenzo RJ, Tombes RM. CaMK‐II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells. Exp Cell Res 1998 May 1; 240(2): 218‐227.  181.  Ross  ME,  Risken  M.  MN20,  a  D2  cyclin  found  in  brain,  is  implicated  in  neural differentiation. J Neurosci 1994 Nov; 14(11 Pt 1): 6384‐6391.  182.  Tamaru T, Okada M, Nakagawa H. Differential expression of D type cyclins during neuronal maturation. Neurosci Lett 1994 Feb 28; 168(1‐2): 229‐232.  183.  Kabos P, Kabosova A, Neuman T. Blocking HES1 expression  initiates GABAergic differentiation and induces the expression of p21(CIP1/WAF1) in human neural stem cells. J Biol Chem 2002 Mar 15; 277(11): 8763‐8766.  184.  Xie F, Raetzman LT, Siegel RE. Neuregulin induces GABAA receptor beta2 subunit expression  in  cultured  rat  cerebellar  granule  neurons  by  activating  multiple signaling pathways. J Neurochem 2004 Sep; 90(6): 1521‐1529.  185.  Klugmann M, Wymond Symes C, Leichtlein CB, Klaussner BK, Dunning J, Fong D et 
al.  AAV‐mediated  hippocampal  expression  of  short  and  long  Homer  1  proteins differentially affect cognition and seizure activity  in adult rats. Mol Cell Neurosci 2005 Feb; 28(2): 347‐360.  186.  Feldker DE, Datson NA, Veenema AH, Proutski V, Lathouwers D, De Kloet ER et al. GeneChip  analysis  of  hippocampal  gene  expression  profiles  of  short‐  and  long‐attack‐latency mice: technical and biological implications. J Neurosci Res 2003 Dec 1; 74(5): 701‐716.  187.  D'Adamo P, Wolfer DP, Kopp C, Tobler I, Toniolo D, Lipp HP. Mice deficient for the synaptic  vesicle  protein  Rab3a  show  impaired  spatial  reversal  learning  and increased explorative activity but none of the behavioral changes shown by mice deficient  for  the  Rab3a  regulator  Gdi1.  Eur  J  Neurosci  2004  Apr; 19(7):  1895‐1905.  188.  Gonchar  Y,  Burkhalter  A.  Three  distinct  families  of  GABAergic  neurons  in  rat visual cortex. Cereb Cortex 1997 Jun; 7(4): 347‐358.  
  204 
189.  Kawaguchi  Y,  Kondo  S.  Parvalbumin,  somatostatin  and  cholecystokinin  as chemical  markers  for  specific  GABAergic  interneuron  types  in  the  rat  frontal cortex. J Neurocytol 2002 Mar‐Jun; 31(3‐5): 277‐287.  190.  Demeulemeester  H,  Vandesande  F,  Orban  GA,  Brandon  C,  Vanderhaeghen  JJ. Heterogeneity of GABAergic cells in cat visual cortex. J Neurosci 1988 Mar; 8(3): 988‐1000.  191.  Alho  H,  Ferrarese  C,  Vicini  S,  Vaccarino  F.  Subsets  of  GABAergic  neurons  in dissociated cell cultures of neonatal rat cerebral cortex show co‐localization with specific modulator peptides. Brain Res 1988 Apr 1; 467(2): 193‐204.  192.  Kubota  Y,  Kawaguchi  Y.  Two  distinct  subgroups  of  cholecystokinin‐immunoreactive  cortical  interneurons. Brain  Res  1997 Mar  28; 752(1‐2):  175‐183.  193.  Nawa H, Bessho Y, Carnahan J, Nakanishi S, Mizuno K. Regulation of neuropeptide expression  in  cultured  cerebral  cortical  neurons  by  brain‐derived  neurotrophic factor. J Neurochem 1993 Feb; 60(2): 772‐775.  194.  Mizuno  K,  Carnahan  J,  Nawa  H.  Brain‐derived  neurotrophic  factor  promotes differentiation  of  striatal  GABAergic  neurons. Dev  Biol  1994  Sep; 165(1):  243‐256.  195.  Reibel  S,  Vivien‐Roels  B,  Le  BT,  Larmet  Y,  Carnahan  J,  Marescaux  C  et  al. Overexpression of neuropeptide Y induced by brain‐derived neurotrophic factor in the rat hippocampus is long lasting. Eur J Neurosci 2000 Feb; 12(2): 595‐605.  196.  Egan  MF,  Weinberger  DR,  Lu  B.  Schizophrenia,  III:  brain‐derived  neurotropic factor and genetic risk. Am J Psychiatry 2003 Jul; 160(7): 1242.  197.  Szekeres G, Juhasz A, Rimanoczy A, Keri S, Janka Z. The C270T polymorphism of the  brain‐derived  neurotrophic  factor  gene  is  associated  with  schizophrenia. 
Schizophr Res 2003 Dec 1; 65(1): 15‐18.  198.  Krebs MO,  Guillin  O,  Bourdell  MC,  Schwartz  JC,  Olie  JP,  Poirier  MF  et  al.  Brain derived neurotrophic  factor  (BDNF) gene variants association with age at onset and therapeutic response  in schizophrenia. Mol Psychiatry 2000 Sep; 5(5): 558‐562.  199.  de Krom M, Bakker SC, Hendriks J, van Elburg A, Hoogendoorn M, Verduijn W et 
al.  Polymorphisms  in  the  brain‐derived  neurotrophic  factor  gene  are  not associated  with  either  anorexia  nervosa  or  schizophrenia  in  Dutch  patients. 
Psychiatr Genet 2005 Jun; 15(2): 81.  
  205 
200.  Anttila  S,  Illi  A,  Kampman  O,  Mattila  KM,  Lehtimaki  T,  Leinonen  E.  Lack  of association  between  two  polymorphisms  of  brain‐derived  neurotrophic  factor and response to typical neuroleptics. J Neural Transm 2005 Jun; 112(7): 885‐890.  201.  Galderisi  S, Maj M,  Kirkpatrick  B,  Piccardi  P, Mucci  A,  Invernizzi  G  et  al.  COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case‐control study. Schizophr Res 2005 Feb 1; 73(1): 27‐30.  202.  Neves‐Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P et al. BDNF gene is  a  risk  factor  for  schizophrenia  in  a  Scottish  population. Mol  Psychiatry  2005 Feb; 10(2): 208‐212.  203.  Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K et al. Abnormal expression of brain‐derived neurotrophic factor and its receptor in the corticolimbic  system  of  schizophrenic  patients. Mol  Psychiatry  2000 May; 5(3): 293‐300.  204.  Iritani S, Niizato K, Nawa H,  Ikeda K, Emson PC.  Immunohistochemical  study of brain‐derived  neurotrophic  factor  and  its  receptor,  TrkB,  in  the  hippocampal formation  of  schizophrenic  brains.  Prog  Neuropsychopharmacol  Biol  Psychiatry 2003 Aug; 27(5): 801‐807.  205.  Weickert  CS,  Hyde  TM,  Lipska  BK,  Herman  MM,  Weinberger  DR,  Kleinman  JE. Reduced brain‐derived neurotrophic  factor  in prefrontal  cortex of patients with schizophrenia. Mol Psychiatry 2003 Jun; 8(6): 592‐610.  206.  Weickert  CS,  Ligons  DL,  Romanczyk  T,  Ungaro  G,  Hyde  TM,  Herman MM  et  al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2005 Jul; 10(7): 637‐650.  207.  Toyooka  K,  Asama  K,  Watanabe  Y,  Muratake  T,  Takahashi  M,  Someya  T  et  al. Decreased  levels  of  brain‐derived  neurotrophic  factor  in  serum  of  chronic schizophrenic patients. Psychiatry Res 2002 Jul 31; 110(3): 249‐257.  208.  Lipska BK, Khaing ZZ, Weickert  CS, Weinberger DR. BDNF mRNA expression  in rat hippocampus and prefrontal  cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 2001 Jul; 14(1): 135‐144.  209.  Ashe  PC,  Chlan‐Fourney  J,  Juorio  AV,  Li  XM.  Brain‐derived  neurotrophic  factor (BDNF)  mRNA  in  rats  with  neonatal  ibotenic  acid  lesions  of  the  ventral hippocampus. Brain Res 2002 Nov 22; 956(1): 126‐135.  210.  Fiore M,  Korf  J,  Antonelli  A,  Talamini  L,  Aloe  L.  Long‐lasting  effects  of  prenatal MAM  treatment  on  water  maze  performance  in  rats:  associations  with  altered brain development and neurotrophin levels. Neurotoxicol Teratol 2002 Mar‐Apr; 
24(2): 179‐191. 
  206 
 211.  Fumagalli F, Molteni R, Roceri M, Bedogni F, Santero R, Fossati C  et al. Effect of antipsychotic  drugs  on  brain‐derived  neurotrophic  factor  expression  under reduced N‐methyl‐D‐aspartate receptor activity. J Neurosci Res 2003 Jun 1; 72(5): 622‐628.  212.  Fumagalli F, Bedogni F, Perez J, Racagni G, Riva MA. Corticostriatal brain‐derived neurotrophic  factor  dysregulation  in  adult  rats  following  prenatal  stress.  Eur  J 
Neurosci 2004 Sep; 20(5): 1348‐1354.  213.  Erdely  HA,  Lahti  RA,  Roberts  RC,  Vogel  MW,  Tamminga  CA.  Reduced  levels  of RGS4  mRNA  and  protein  in  schziophrenia.  Society  for  Neuroscience  Online 
Abstract  Viewer/Itinerary  Planner  2003;  2003(Washington,  DC):  Program  No. 317.318.  214.  Hashimoto T, Arion D, Unger T, Mirnics K, Lewis DA. Analysis of the GABA‐related transcriptome  in  the  prefrontal  cortex  of  subjects  with  schizophrenia.  2005 
Abstract Viewer/Itinerary Planner Washington, DC: Society for Neuroscience, 2005; 
2005, Online: Program No. 675.674.  215.  Chowdari  KV,  Mirnics  K,  Semwal  P,  Wood  J,  Lawrence  E,  Bhatia  T  et  al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum 
Mol Genet 2002 Jun 1; 11(12): 1373‐1380.  216.  Mirnics K, Middleton FA, Lewis DA, Levitt P. Analysis of complex brain disorders with  gene  expression  microarrays:  schizophrenia  as  a  disease  of  the  synapse. 
Trends Neurosci 2001 Aug; 24(8): 479‐486.  217.  Bennett  GW,  Ballard  TM,  Watson  CD,  Fone  KC.  Effect  of  neuropeptides  on cognitive function. Exp Gerontol 1997 Jul‐Oct; 32(4‐5): 451‐469.  218.  Matsuoka  N,  Maeda  N,  Yamaguchi  I,  Satoh  M.  Possible  involvement  of  brain somatostatin in the memory formation of rats and the cognitive enhancing action of FR121196 in passive avoidance task. Brain Res 1994 Apr 11; 642(1‐2): 11‐19.  219.  Schettini  G.  Brain  somatostatin:  receptor‐coupled  transducing mechanisms  and role in cognitive functions. Pharmacol Res 1991 Apr; 23(3): 203‐215.  220.  Craft  S,  Asthana  S,  Newcomer  JW,  Wilkinson  CW,  Matos  IT,  Baker  LD  et  al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 1999 Dec; 56(12): 1135‐1140.  221.  Morrison  JH,  Rogers  J,  Scherr  S,  Benoit  R,  Bloom  FE.  Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients. Nature 1985 Mar 7‐13; 314(6006): 90‐92.  
  207 
222.  Davies P, Katzman R, Terry RD. Reduced  somatostatin‐like  immunoreactivity  in cerebral  cortex  from cases of Alzheimer disease and Alzheimer  senile dementa. 
Nature 1980 Nov 20; 288(5788): 279‐280.  223.  Arai H, Moroji T, Kosaka K. Somatostatin and vasoactive intestinal polypeptide in postmortem  brains  from  patients  with  Alzheimer‐type  dementia. Neurosci  Lett 1984 Nov 23; 52(1‐2): 73‐78.  224.  Davies  P,  Terry  RD.  Cortical  somatostatin‐like  immunoreactivity  in  cases  of Alzheimer's disease and senile dementia of  the Alzheimer type. Neurobiol Aging 1981 Spring; 2(1): 9‐14.  225.  Savonenko  A,  Xu  GM,  Melnikova  T,  Morton  JL,  Gonzales  V,  Wong  MP  et  al. Episodic‐like  memory  deficits  in  the  APPswe/PS1dE9  mouse  model  of Alzheimer's  disease:  relationships  to  beta‐amyloid  deposition  and neurotransmitter abnormalities. Neurobiol Dis 2005 Apr; 18(3): 602‐617.  226.  Tong  L,  Balazs  R,  Thornton  PL,  Cotman  CW.  Beta‐amyloid  peptide  at  sublethal concentrations  downregulates  brain‐derived  neurotrophic  factor  functions  in cultured cortical neurons. J Neurosci 2004 Jul 28; 24(30): 6799‐6809.  227.  ADEAR.  FK962  ‐  Evaluation  in  Mild  to  Moderate  AD. 
http://wwwalzheimersorg/clintrials/fullrecasp?PrimaryKey=197 2005.  228.  Lazarov  O,  Robinson  J,  Tang  YP,  Hairston  IS,  Korade‐Mirnics  Z,  Lee  VM  et  al. Environmental  enrichment  reduces  Abeta  levels  and  amyloid  deposition  in transgenic mice. Cell 2005 Mar 11; 120(5): 701‐713.  229.  Sowell  ER,  Peterson  BS,  Thompson  PM, Welcome  SE,  Henkenius  AL,  Toga  AW. Mapping  cortical  change  across  the  human  life  span.  NatNeurosci  2003;  6(3): 309‐315.  230.  Terry RD, DeTeresa R, Hansen LA. Neocortical cell counts in normal human adult aging. AnnNeurol 1987; 21(6): 530‐539.  231.  Bertoni‐Freddari  C,  Fattoretti  P,  Paoloni R,  Caselli U,  Galeazzi  L, Meier‐Ruge W. Synaptic structural dynamics and aging. Gerontology 1996; 42(3): 170‐180.  232.  Pakkenberg B, Gundersen HJ. Neocortical neuron number in humans: effect of sex and age. JComp Neurol 1997; 384(2): 312‐320.  233.  Thibault  O,  Hadley  R,  Landfield  PW.  Elevated  postsynaptic  [Ca2+]i  and  L‐type calcium channel activity  in aged hippocampal neurons: relationship to  impaired synaptic plasticity. JNeurosci 2001; 21(24): 9744‐9756.  
  208 
234.  Davare  MA,  Hell  JW.  Increased  phosphorylation  of  the  neuronal  L‐type  Ca2+ channel Cav1.2 during aging. ProcNatlAcadSciUSA 2003; 100(26): 16018‐16023.  235.  Verkhratsky A, Toescu EC.  Calcium and neuronal  ageing. Trends Neurosci  1998; 
21(1): 2‐7.  236.  Lerer B, Gillon D, Lichtenberg P, Gorfine M, Gelfin Y, Shapira B. Interrelationship of age, depression, and central serotonergic function: evidence from fenfluramine challenge studies. IntPsychogeriatr 1996; 8(1): 83‐102.  237.  Mattson  MP,  Magnus  T.  Ageing  and  neuronal  vulnerability.  Nat  Rev  Neurosci 2006; 7(4): 278‐294.  238.  Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY et al. Serotonin in  aging,  late‐life  depression,  and  Alzheimer's  disease:  the  emerging  role  of functional imaging. Neuropsychopharmacology 1998; 18(6): 407‐430.  239.  Reynolds  CF,  III,  Kupfer  DJ.  Depression  and  aging:  a  look  to  the  future. 
PsychiatrServ 1999; 50(9): 1167‐1172.  240.  Carlsson A. Neurotransmitter  changes  in  the  aging brain. DanMedBull  1985; 32 
Suppl 1: 40‐43.  241.  Davidoff MS, Lolova IS. Age‐related changes in serotonin‐immunoreactivity in the telencephalon and diencephalon of rats. J Hirnforsch 1991; 32(6): 745‐753.  242.  Nishimura  A,  Ueda  S,  Takeuchi  Y,  Matsushita  H,  Sawada  T,  Kawata  M. Vulnerability  to  aging  in  the  rat  serotonergic  system.  Acta  Neuropathol(Berl) 1998; 96(6): 581‐595.  243.  Arango  V,  Ernsberger  P,  Marzuk  PM,  Chen  JS,  Tierney  H,  Stanley  M  et  al. Autoradiographic  demonstration  of  increased  serotonin  5‐HT2  and  beta‐adrenergic  receptor  binding  sites  in  the  brain  of  suicide  victims. 
ArchGenPsychiatry 1990; 47(11): 1038‐1047.  244.  Marcusson J, Oreland L, Winblad B. Effect of age on human brain serotonin (S‐1) binding sites. JNeurochem 1984; 43(6): 1699‐1705.  245.  Marcusson  JO,  Morgan  DG,  Winblad  B,  Finch  CE.  Serotonin‐2  binding  sites  in human  frontal  cortex  and  hippocampus.  Selective  loss  of  S‐2A  sites  with  age. 
Brain Res 1984; 311(1): 51‐56.  246.  Bach‐Mizrachi H, Underwood MD, Kassir SA, Bakalian MJ, Sibille E, Tamir H et al. Neuronal  tryptophan  hydroxylase  mRNA  expression  in  the  human  dorsal  and median  raphe  nuclei:  major  depression  and  suicide. Neuropsychopharmacology 2006 Apr; 31(4): 814‐824. 
  209 
 247.  Meltzer CC, Smith G, Price JC, Reynolds CF, III, Mathis CA, Greer P et al. Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res 1998; 813(1): 167‐171.  248.  Goldberg  S,  Smith  GS,  Barnes  A,  Ma  Y,  Kramer  E,  Robeson  K  et  al.  Serotonin modulation  of  cerebral  glucose  metabolism  in  normal  aging.  Neurobiol  Aging 2004; 25(2): 167‐174.  249.  van Luijtelaar MG, Tonnaer JA, Steinbusch HW. Aging of the serotonergic system in the rat forebrain: an immunocytochemical and neurochemical study. Neurobiol 
Aging 1992; 13(2): 201‐215.  250.  David DJ, Bourin M, Hascoet M, Colombel MC, Baker GB, Jolliet P. Comparison of antidepressant activity in 4‐ and 40‐week‐old male mice in the forced swimming test:  involvement  of  5‐HT1A  and  5‐HT1B  receptors  in  old  mice. 
Psychopharmacology (Berl) 2001; 153(4): 443‐449.  251.  Trillat AC, Malagie I, Scearce K, Pons D, Anmella MC, Jacquot C et al. Regulation of serotonin release  in the  frontal cortex and ventral hippocampus of homozygous mice  lacking 5‐HT1B receptors:  in vivo microdialysis studies.  JNeurochem 1997; 
69(5): 2019‐2025.  252.  Ramboz S, Saudou F, Amara DA, Belzung C, Dierich A, LeMeur M et al. Behavioral characterization  of  mice  lacking  the  5‐HT1B  receptor. NIDA  Res  Monogr  1996; 
161: 39‐57.  253.  Caspi A, Moffitt TE. Gene‐environment  interactions  in psychiatry:  joining  forces with neuroscience. Nat Rev Neurosci 2006; 7(7): 583‐590.  254.  Saudou  F,  Amara  DA,  Dierich  A,  LeMeur  M,  Ramboz  S,  Segu  L  et  al.  Enhanced aggressive behavior  in mice  lacking 5‐HT1B receptor. Science 1994; 265(5180): 1875‐1878.  255.  Shippenberg TS, Hen R, He M. Region‐specific enhancement of basal extracellular and  cocaine‐evoked  dopamine  levels  following  constitutive  deletion  of  the Serotonin(1B) receptor. JNeurochem 2000; 75(1): 258‐265.  256.  Ase AR, Reader TA, Hen R, Riad M, Descarries L. Altered serotonin and dopamine metabolism  in  the  CNS  of  serotonin  5‐HT(1A)  or  5‐HT(1B)  receptor  knockout mice. J Neurochem 2000; 75(6): 2415‐2426.  257.  Joyal  CC,  Beaudin  S,  Lalonde  R.  Longitudinal  age‐related  changes  in  motor activities  and  spatial  orientation  in  CD‐1  mice.  Arch  Physiol  Biochem  2000; 
108(3): 248‐256.  
  210 
258.  Paxinos  G,  Franklin  KBJ.  The  mouse  brain  in  stereotoxic  coordinates,  vol.  2nd Edition. Academic Press: San Diego, CA, 2001.  259.  Pavlidis  P,  Qin  J,  Arango  V,  Mann  JJ,  Sibille  E.  Using  the  gene  ontology  for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res 2004 Jun; 29(6): 1213‐1222.  260.  Pavlidis P, Lewis DP, Noble WS. Exploring gene expression data with class scores. 
PacSympBiocomput 2002: 474‐485.  261.  Ashburner  M,  Ball  CA,  Blake  JA,  Botstein  D,  Butler  H,  Cherry  JM  et  al.  Gene ontology:  tool  for  the  unification  of  biology.  The  Gene  Ontology  Consortium. 
NatGenet 2000; 25(1): 25‐29.  262.  Galfalvy HC, Erraji‐Benchekroun L, Smyrniotopoulos P, Pavlidis P, Ellis SP, Mann JJ  et  al.  Sex  genes  for  genomic  analysis  in  human  brain:  internal  controls  for comparison of probe level data extraction. BMC Bioinformatics 2003 Sep 8; 4: 37.  263.  Sibille E, Hen R. Serotonin(1A) receptors in mood disorders: a combined genetic and genomic approach. BehavPharmacol 2001; 12(6‐7): 429‐438.  264.  Hashimoto  T,  Volk  DW,  Eggan  SM,  Mirnics  K,  Pierri  JN,  Sun  Z  et  al.  Gene expression  deficits  in  a  subclass  of  GABA  neurons  in  the  prefrontal  cortex  of subjects with schizophrenia. J Neurosci 2003 Jul 16; 23(15): 6315‐6326.  265.  Sibille E, Hen R. Serotonin(1A) receptors in mood disorders: a combined genetic and genomic approach. Behav Pharmacol 2001 Nov; 12(6‐7): 429‐438.  266.  Buhot MC, Wolff M, Benhassine N, Costet P, Hen R, Segu L. Spatial learning in the 5‐HT1B  receptor  knockout  mouse:  selective  facilitation/impairment  depending on the cognitive demand. LearnMem 2003; 10(6): 466‐477.  267.  Keegan A, Morecroft  I, Smillie D, Hicks MN, MacLean MR. Contribution of  the 5‐HT(1B)  receptor  to  hypoxia‐induced  pulmonary  hypertension:  converging evidence using 5‐HT(1B)‐receptor knockout mice and the 5‐HT(1B/1D)‐receptor antagonist GR127935. CircRes 2001; 89(12): 1231‐1239.  268.  Ciaranello  RD,  Tan  GL,  Dean  R.  G‐protein‐linked  serotonin  receptors  in  mouse kidney exhibit identical properties to 5‐HT1b receptors in brain. J Pharmacol Exp 
Ther 1990; 252(3): 1347‐1354.  269.  Gershon  MD.  Review  article:  serotonin  receptors  and  transporters  ‐‐  roles  in normal and abnormal gastrointestinal motility. AlimentPharmacolTher 2004; 20 
Suppl 7: 3‐14.  
  211 
270.  Mossner  R,  Lesch  KP.  Role  of  serotonin  in  the  immune  system  and  in neuroimmune interactions. Brain BehavImmun 1998; 12(4): 249‐271.  271.  Tatar  M,  Bartke  A,  Antebi  A.  The  endocrine  regulation  of  aging  by  insulin‐like signals. Science 2003; 299(5611): 1346‐1351.  272.  Suji G, Sivakami S. Glucose, glycation and aging. Biogerontology 2004; 5(6): 365‐373.  273.  Holzenberger M,  Dupont  J,  Ducos  B,  Leneuve  P,  Geloen  A,  Even  PC  et  al.  IGF‐1 receptor  regulates  lifespan  and  resistance  to  oxidative  stress  in  mice.  Nature 2003; 421(6919): 182‐187.  274.  Lee CK, Klopp RG, Weindruch R, Prolla TA. Gene expression profile of aging and its retardation by caloric restriction. Science 1999; 285(5432): 1390‐1393.  275.  DeVellis JS. Neuroglia in the Aging Brain. Humana Press: Totowa, NJ, 2002.  276.  Webster  MJ,  Weickert  CS,  Herman  MM,  Kleinman  JE.  BDNF  mRNA  expression during  postnatal  development,  maturation  and  aging  of  the  human  prefrontal cortex. Brain ResDevBrain Res 2002; 139(2): 139‐150.  277.  Hekimi  S,  Guarente  L.  Genetics  and  the  specificity  of  the  aging  process. Science 2003; 299(5611): 1351‐1354.  278.  Fabrizio P, Gattazzo C, Battistella L, Wei M, Cheng C, McGrew K et al. Sir2 blocks extreme life‐span extension. Cell 2005; 123(4): 655‐667.  279.  Parker  JA,  Arango M,  Abderrahmane  S,  Lambert  E,  Tourette  C,  Catoire  H  et  al. Resveratrol  rescues  mutant  polyglutamine  cytotoxicity  in  nematode  and mammalian neurons. Nat Genet 2005; 37(4): 349‐350.  280.  Kujoth  GC,  Hiona  A,  Pugh  TD,  Someya  S,  Panzer  K,  Wohlgemuth  SE  et  al. Mitochondrial  DNA  mutations,  oxidative  stress,  and  apoptosis  in  mammalian aging. Science 2005; 309(5733): 481‐484.  281.  Mounkes  LC,  Kozlov  S,  Hernandez  L,  Sullivan  T,  Stewart  CL.  A  progeroid syndrome in mice is caused by defects in A‐type lamins. Nature 2003; 423(6937): 298‐301.  282.  Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE et 
al.  Premature  ageing  in  mice  expressing  defective  mitochondrial  DNA polymerase. Nature 2004; 429(6990): 417‐423.  
  212 
283.  Malberg  JE,  Eisch  AJ,  Nestler  EJ,  Duman  RS.  Chronic  antidepressant  treatment increases neurogenesis in adult rat hippocampus. JNeurosci 2000; 20(24): 9104‐9110.  284.  Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E et al. A  new  progeroid  syndrome  reveals  that  genotoxic  stress  suppresses  the somatotroph axis. Nature 2006; 444(7122): 1038‐1043.  285.  Alvarez FJ, Pearson JC, Harrington D, Dewey D, Torbeck L, Fyffe RE. Distribution of  5‐hydroxytryptamine‐immunoreactive  boutons  on  alpha‐motoneurons  in  the lumbar spinal cord of adult cats. J Comp Neurol 1998; 393(1): 69‐83.  286.  Wallis DI. 5‐HT receptors involved in initiation or modulation of motor patterns: opportunities for drug development. Trends Pharmacol Sci 1994; 15(8): 288‐292.  287.  Wolkow CA, Kimura KD, Lee MS, Ruvkun G. Regulation of C. elegans life‐span by insulinlike signaling in the nervous system. Science 2000; 290(5489): 147‐150.  288.  Hwangbo DS, Gershman B, Tu MP, Palmer M, Tatar M. Drosophila dFOXO controls lifespan  and  regulates  insulin  signalling  in  brain  and  fat  body.  Nature  2004; 
429(6991): 562‐566.  289.  Sibille  E, Wang Y,  Joeyen‐Waldorf  J,  Gaiteri  C,  Surget A, Oh  S  et  al.  A Molecular Signature of Depression in the Amygdala. Am J Psychiatry 2009 Jul 15.  290.  Brickman  AM,  Zimmerman  ME,  Paul  RH,  Grieve  SM,  Tate  DF,  Cohen  RA  et  al. Regional  white  matter  and  neuropsychological  functioning  across  the  adult lifespan. Biol Psychiatry 2006 Sep 1; 60(5): 444‐453.  291.  Benjamini  Y,  Hochberg,  Y.  Controlling  the  false  discovery  rate:  A  practical  and powerful  approach  to multiple  testing.  J Royal  Stat  Soc  Series B Methodol  1995; 
57: 289‐300.  292.  Oh S, Tseng GC, Sibille E. Reciprocal phylogenetic conservation of molecular aging in mouse and human brain. Neurobiol Aging 2009 Sep 1.  293.  Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map:  using  gene‐expression  signatures  to  connect  small  molecules,  genes,  and disease. Science 2006 Sep 29; 313(5795): 1929‐1935.  294.  Sibille  E, Wang Y,  Joeyen‐Waldorf  J,  Gaiteri  C,  Surget A, Oh  S  et  al.  A molecular signature of depression in the amygdala. Am J Psychiatry 2009 Sep; 166(9): 1011‐1024.  
  213 
295.  Nakanishi  K,  Ida  M,  Suzuki  H,  Kitano  C,  Yamamoto  A,  Mori  N  et  al.  Molecular characterization  of  a  transport  vesicle  protein  Neurensin‐2,  a  homologue  of Neurensin‐1, expressed in neural cells. Brain Res 2006 Apr 7; 1081(1): 1‐8.  296.  Sibille E, Arango V, Joeyen‐Waldorf J, Wang Y, Leman S, Surget A et al. Large‐scale estimates  of  cellular  origins  of  mRNAs:  enhancing  the  yield  of  transcriptome analyses. J Neurosci Methods 2008 Jan 30; 167(2): 198‐206.  297.  Nakagawa  T,  Lomb  DJ,  Haigis  MC,  Guarente  L.  SIRT5  Deacetylates  carbamoyl phosphate  synthetase 1  and  regulates  the urea  cycle. Cell  2009 May 1; 137(3): 560‐570.  298.  Schapira  AH.  Mitochondria  in  the  aetiology  and  pathogenesis  of  Parkinson's disease. Lancet Neurol 2008 Jan; 7(1): 97‐109.  299.  Kim  S,  Benguria  A,  Lai  CY,  Jazwinski  SM.  Modulation  of  life‐span  by  histone deacetylase  genes  in  Saccharomyces  cerevisiae. Mol Biol  Cell  1999 Oct; 10(10): 3125‐3136.  300.  Lin  K,  Hsin  H,  Libina  N,  Kenyon  C.  Regulation  of  the  Caenorhabditis  elegans longevity  protein  DAF‐16  by  insulin/IGF‐1  and  germline  signaling.  Nat  Genet 2001 Jun; 28(2): 139‐145.  301.  Chen S, Whetstine JR, Ghosh S, Hanover JA, Gali RR, Grosu P et al. The conserved NAD(H)‐dependent  corepressor  CTBP‐1  regulates  Caenorhabditis  elegans  life span. Proc Natl Acad Sci U S A 2009 Feb 3; 106(5): 1496‐1501.  302.  Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin M et al. SIRT6 links histone H3 lysine 9 deacetylation to NF‐kappaB‐dependent gene expression and organismal life span. Cell 2009 Jan 9; 136(1): 62‐74.  303.  Colantuoni  C,  Hyde  TM,  Mitkus  S,  Joseph  A,  Sartorius  L,  Aguirre  C  et  al.  Age‐related  changes  in  the  expression  of  schizophrenia  susceptibility  genes  in  the human prefrontal cortex. Brain Struct Funct 2008 Sep; 213(1‐2): 255‐271.  304.  Kessler  RC,  Berglund  P,  Demler  O,  Jin  R,  Koretz  D,  Merikangas  KR  et  al.  The epidemiology  of  major  depressive  disorder:  results  from  the  National Comorbidity Survey Replication (NCS‐R). JAMA 2003; 289(23): 3095‐3105.  305.  Sutherland  G,  Mellick  G,  Sue  C,  Chan  DK,  Rowe  D,  Silburn  P  et  al.  A  functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. Neurosci Lett 2007 Mar 6; 414(2): 170‐173.  306.  Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007 Jan; 7(1): 54‐60.  
  214 
307.  Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, Martella G et al. Impaired dopamine release and synaptic plasticity in the striatum of PINK1‐deficient mice. 
Proc Natl Acad Sci U S A 2007 Jul 3; 104(27): 11441‐11446.  308.  Gautier  CA,  Kitada  T,  Shen  J.  Loss  of  PINK1  causes  mitochondrial  functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci U S A 2008 Aug 12; 105(32): 11364‐11369.  309.  Chen  ZY,  Jing  D,  Bath  KG,  Ieraci  A,  Khan  T,  Siao  CJ  et  al.  Genetic  variant  BDNF (Val66Met)  polymorphism  alters  anxiety‐related  behavior.  Science  2006  Oct  6; 
314(5796): 140‐143.  310.  Apfeld  J,  Kenyon  C.  Cell  nonautonomy  of  C.  elegans  daf‐2  function  in  the regulation of diapause and life span. Cell 1998 Oct 16; 95(2): 199‐210.  311.  Mitchell ES, McDevitt RA, Neumaier JF. Adaptations in 5‐HT receptor expression and  function:  implications  for  treatment  of  cognitive  impairment  in  aging.  J 
Neurosci Res 2009 Sep; 87(12): 2803‐2811.  312.  David DJ, Bourin M, Hascoet M, Colombel MC, Baker GB, Jolliet P. Comparison of antidepressant activity in 4‐ and 40‐week‐old male mice in the forced swimming test:  involvement  of  5‐HT1A  and  5‐HT1B  receptors  in  old  mice. 
Psychopharmacology (Berl) 2001 Feb; 153(4): 443‐449.  313.  Huang YY, Oquendo MA, Friedman JM, Greenhill LL, Brodsky B, Malone KM et al. Substance abuse disorder and major depression are associated with the human 5‐HT1B  receptor  gene  (HTR1B) G861C polymorphism. Neuropsychopharmacology 2003 Jan; 28(1): 163‐169.  314.  Lappalainen J, Long JC, Eggert M, Ozaki N, Robin RW, Brown GL et al. Linkage of antisocial  alcoholism  to  the  serotonin  5‐HT1B  receptor  gene  in  2  populations. 
Arch Gen Psychiatry 1998 Nov; 55(11): 989‐994.  315.  Levitan  RD,  Kaplan  AS,  Masellis  M,  Basile  VS,  Walker  ML,  Lipson  N  et  al. Polymorphism of  the serotonin 5‐HT1B receptor gene (HTR1B) associated with minimum  lifetime  body  mass  index  in  women  with  bulimia  nervosa.  Biol 
Psychiatry 2001 Oct 15; 50(8): 640‐643.  316.  Smoller  JW,  Biederman  J,  Arbeitman  L,  Doyle  AE,  Fagerness  J,  Perlis  RH  et  al. Association  between  the  5HT1B  receptor  gene  (HTR1B)  and  the  inattentive subtype of ADHD. Biol Psychiatry 2006 Mar 1; 59(5): 460‐467.  317.  Huang YY, Grailhe R, Arango V, Hen R, Mann JJ. Relationship of psychopathology to the human serotonin1B genotype and receptor binding kinetics in postmortem brain tissue. Neuropsychopharmacology 1999 Aug; 21(2): 238‐246.  
  215 
318.  Daitoku H, Fukamizu A. FOXO transcription factors in the regulatory networks of longevity. J Biochem 2007 Jun; 141(6): 769‐774.  319.  Dang W, Steffen KK, Perry R, Dorsey JA, Johnson FB, Shilatifard A et al. Histone H4 lysine 16 acetylation regulates cellular lifespan. Nature 2009 Jun 11; 459(7248): 802‐807.  320.  Zhao Y, Sun H, Lu J, Li X, Chen X, Tao D et al. Lifespan extension and elevated hsp gene expression in Drosophila caused by histone deacetylase inhibitors. J Exp Biol 2005 Feb; 208(Pt 4): 697‐705.  321.  Budovskaya YV, Wu K, Southworth LK,  Jiang M, Tedesco P,  Johnson TE et al. An elt‐3/elt‐5/elt‐6 GATA transcription circuit guides aging  in C. elegans. Cell 2008 Jul 25; 134(2): 291‐303.  322.  Kelly  TM,  Mann  JJ.  Validity  of  DSM‐III‐R  diagnosis  by  psychological  autopsy:  a comparison  with  clinician  ante‐mortem  diagnosis.  Acta  Psychiatr  Scand  1996 Nov; 94(5): 337‐343.  323.  Sibille  E, Arango V, Galfalvy HC,  Pavlidis  P,  Erraji‐Benchekroun L,  Ellis  SP  et  al. Gene expression profiling of depression and suicide in human prefrontal cortex. 
Neuropsychopharmacology 2004 Feb; 29(2): 351‐361.  324.  Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004 Mar 15; 55(6): 563‐569.  325.  Johnson K, Liu L, Majdzadeh N, Chavez C, Chin PC, Morrison B et al. Inhibition of neuronal  apoptosis  by  the  cyclin‐dependent  kinase  inhibitor  GW8510: identification  of  3'  substituted  indolones  as  a  scaffold  for  the  development  of neuroprotective drugs. J Neurochem 2005 May; 93(3): 538‐548.  326.  Simpkins JW, Green PS, Gridley KE, Singh M, de Fiebre NC, Rajakumar G. Role of estrogen  replacement  therapy  in  memory  enhancement  and  the  prevention  of neuronal  loss  associated  with  Alzheimer's  disease.  Am  J  Med  1997  Sep  22; 
103(3A): 19S‐25S.  327.  Prehn JH, Welsch M, Backhauss C, Nuglisch J, Ausmeier F, Karkoutly C et al. Effects of  serotonergic drugs  in  experimental brain  ischemia:  evidence  for  a protective role of serotonin in cerebral ischemia. Brain Res 1993 Dec 10; 630(1‐2): 10‐20.  328.  Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M et al. Efficacy of  small‐molecule  glycogen  synthase  kinase‐3  inhibitors  in  the  postnatal  rat model of tau hyperphosphorylation. Br J Pharmacol 2007 Nov; 152(6): 959‐979.  
  216 
329.  Jeong SH, Han XH, Hong SS, Hwang JS, Hwang JH, Lee D et al. Monoamine oxidase inhibitory  coumarins  from  the  aerial  parts  of Dictamnus  albus. Arch Pharm Res 2006 Dec; 29(12): 1119‐1124.  330.  Varamini  P,  Javidnia  K,  Soltani M, Mehdipour  AR,  Ghaderi  A.  Cytotoxic  Activity and  Cell  Cycle  Analysis  of  Quinoline  Alkaloids  Isolated  from  Haplophyllum canaliculatum Boiss. Planta Med 2009 Jun 23.  331.  Bedoy  CA,  Mobley  PL.  Astrocyte  morphology  altered  by  1‐(5‐isoquinolinylsulfonyl)  2‐methyl  piperazine  (H‐7)  and  other  protein  kinase inhibitors. Brain Res 1989 Jun 26; 490(2): 243‐254.  332.  Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 2007 Dec 3; 100(11 A): S53‐61.  333.  Romero‐Navarro  G,  Cabrera‐Valladares  G,  German  MS,  Matschinsky  FM, Velazquez A, Wang J et al. Biotin regulation of pancreatic glucokinase and insulin in primary cultured rat islets and in biotin‐deficient rats. Endocrinology 1999 Oct; 
140(10): 4595‐4600.  334.  Singer  GM,  Geohas  J.  The  effect  of  chromium  picolinate  and  biotin supplementation  on  glycemic  control  in  poorly  controlled  patients with  type  2 diabetes  mellitus:  a  placebo‐controlled,  double‐blinded,  randomized  trial. 
Diabetes Technol Ther 2006 Dec; 8(6): 636‐643.  335.  Vanhaesebroeck  B,  Leevers  SJ,  Ahmadi  K,  Timms  J,  Katso  R,  Driscoll  PC  et  al. Synthesis  and  function  of  3‐phosphorylated  inositol  lipids.  Annu  Rev  Biochem 2001; 70: 535‐602.  336.  Drummond HA, Furtado MM, Myers S, Grifoni S, Parker KA, Hoover A et al. ENaC proteins are  required  for NGF‐induced neurite growth. Am  J Physiol Cell Physiol 2006 Feb; 290(2): C404‐410.  337.  Xie  Z,  Dong  Y,  Maeda  U,  Xia  W,  Tanzi  RE.  RNA  interference  silencing  of  the adaptor molecules ShcC and Fe65 differentially affect amyloid precursor protein processing and Abeta generation. J Biol Chem 2007 Feb 16; 282(7): 4318‐4325.  338.  McLoughlin DM, Miller CC. The FE65 proteins and Alzheimer's disease. J Neurosci 
Res 2008 Mar; 86(4): 744‐754.  339.  Sabo  SL,  Lanier  LM,  Ikin  AF,  Khorkova  O,  Sahasrabudhe  S,  Greengard  P  et  al. Regulation  of  beta‐amyloid  secretion  by  FE65,  an  amyloid  protein  precursor‐binding protein. J Biol Chem 1999 Mar 19; 274(12): 7952‐7957.  
  217 
340.  Hu Q, Jin LW, Starbuck MY, Martin GM. Broadly altered expression of the mRNA isoforms of FE65, a  facilitator of beta amyloidogenesis,  in Alzheimer cerebellum and other brain regions. J Neurosci Res 2000 Apr 1; 60(1): 73‐86.  341.  Kuan  YH,  Gruebl  T,  Soba  P,  Eggert  S,  Nesic  I,  Back  S  et  al.  PAT1a  modulates intracellular  transport  and  processing  of  amyloid  precursor  protein  (APP), APLP1, and APLP2. J Biol Chem 2006 Dec 29; 281(52): 40114‐40123.  342.  Zheng P, Eastman J, Vande Pol S, Pimplikar SW. PAT1, a microtubule‐interacting protein,  recognizes  the  basolateral  sorting  signal  of  amyloid  precursor  protein. 
Proc Natl Acad Sci U S A 1998 Dec 8; 95(25): 14745‐14750.  343.  Alves da Costa C, Sunyach C, Pardossi‐Piquard R, Sevalle J, Vincent B, Boyer N et 
al.  Presenilin‐dependent  gamma‐secretase‐mediated  control  of  p53‐associated cell death in Alzheimer's disease. J Neurosci 2006 Jun 7; 26(23): 6377‐6385.  344.  Johnston  JA,  Norgren  S,  Ravid  R,  Wasco  W,  Winblad  B,  Lannfelt  L  et  al. Quantification of APP and APLP2 mRNA in APOE genotyped Alzheimer's disease brains. Brain Res Mol Brain Res 1996 Dec 31; 43(1‐2): 85‐95.  345.  Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res 1995 Oct; 33(1): 174‐178.  346.  May  PC,  Lampert‐Etchells  M,  Johnson  SA,  Poirier  J,  Masters  JN,  Finch  CE. Dynamics  of  gene  expression  for  a  hippocampal  glycoprotein  elevated  in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990 Dec; 5(6): 831‐839.  347.  Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp 
Neurol 1999 Oct; 159(2): 362‐376.  348.  Grewal  RP,  Morgan  TE,  Finch  CE.  C1qB  and  clusterin  mRNA  increase  in association  with  neurodegeneration  in  sporadic  amyotrophic  lateral  sclerosis. 
Neurosci Lett 1999 Aug 13; 271(1): 65‐67.  349.  Emilsson  L,  Saetre  P,  Balciuniene  J,  Castensson A,  Cairns N,  Jazin  EE.  Increased monoamine  oxidase  messenger  RNA  expression  levels  in  frontal  cortex  of Alzheimer's disease patients. Neurosci Lett 2002 Jun 21; 326(1): 56‐60.  350.  Hodges A,  Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G  et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum 
Mol Genet 2006 Mar 15; 15(6): 965‐977.  
  218 
351.  Mandel  S,  Grunblatt  E,  Riederer  P,  Gerlach  M,  Levites  Y,  Youdim  MB. Neuroprotective  strategies  in  Parkinson's  disease  :  an  update  on  progress. CNS 
Drugs 2003; 17(10): 729‐762.  352.  Ekblom  J,  Jossan  SS,  Bergstrom  M,  Oreland  L,  Walum  E,  Aquilonius  SM. Monoamine oxidase‐B in astrocytes. Glia 1993 Jun; 8(2): 122‐132.  353.  Pittman  AM,  Fung  HC,  de  Silva  R.  Untangling  the  tau  gene  association  with neurodegenerative disorders. Hum Mol Genet 2006 Oct 15; 15 Spec No 2: R188‐195.  354.  Wolfe MS. Tau mutations in neurodegenerative diseases. J Biol Chem 2009 Mar 6; 
284(10): 6021‐6025.  355.  Dachsel  JC, Lincoln SJ, Gonzalez J, Ross OA, Dickson DW, Farrer MJ. The ups and downs of alpha‐synuclein mRNA expression. Mov Disord 2007 Jan 15; 22(2): 293‐295.  356.  Beyer K, Humbert J, Ferrer A, Lao JI, Carrato C, Lopez D et al. Low alpha‐synuclein 126  mRNA  levels  in  dementia  with  Lewy  bodies  and  Alzheimer  disease. 
Neuroreport 2006 Aug 21; 17(12): 1327‐1330.  357.  West  AB,  Maraganore  D,  Crook  J,  Lesnick  T,  Lockhart  PJ,  Wilkes  KM  et  al. Functional  association of  the parkin  gene promoter with  idiopathic Parkinson's disease. Hum Mol Genet 2002 Oct 15; 11(22): 2787‐2792.  358.  Li  H,  Wetten  S,  Li  L,  St  Jean  PL,  Upmanyu  R,  Surh  L  et  al.  Candidate  single‐nucleotide  polymorphisms  from  a  genomewide  association  study  of  Alzheimer disease. Arch Neurol 2008 Jan; 65(1): 45‐53.  359.  Rosen KM, Moussa CE,  Lee HK, Kumar P,  Kitada T, Qin G  et  al.  Parkin  reverses intracellular  beta‐amyloid  accumulation  and  its  negative  effects  on  proteasome function. J Neurosci Res 2009 Jul 16.  360.  Exner N, Treske B, Paquet D, Holmstrom K, Schiesling C, Gispert S et al. Loss‐of‐function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 2007 Nov 7; 27(45): 12413‐12418.  361.  Nural  H,  He  P,  Beach  T,  Sue  L,  Xia W,  Shen  Y.  Dissembled  DJ‐1  high molecular weight  complex  in  cortex mitochondria  from  Parkinson's  disease  patients. Mol 
Neurodegener 2009; 4: 23.  362.  Jones  JM,  Datta  P,  Srinivasula  SM,  Ji  W,  Gupta  S,  Zhang  Z  et  al.  Loss  of  Omi mitochondrial  protease  activity  causes  the  neuromuscular  disorder  of  mnd2 mutant mice. Nature 2003 Oct 16; 425(6959): 721‐727.  
  219 
363.  Strauss  KM, Martins  LM,  Plun‐Favreau  H, Marx  FP,  Kautzmann  S,  Berg  D  et  al. Loss  of  function  mutations  in  the  gene  encoding  Omi/HtrA2  in  Parkinson's disease. Hum Mol Genet 2005 Aug 1; 14(15): 2099‐2111.  364.  Ho  LW,  Brown  R,  Maxwell  M,  Wyttenbach  A,  Rubinsztein  DC.  Wild  type Huntingtin reduces the cellular toxicity of mutant Huntingtin  in mammalian cell models of Huntington's disease. J Med Genet 2001 Jul; 38(7): 450‐452.  365.  Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in  progressive  neurodegeneration  and  sterility  in  mice.  Nat  Genet  2000  Nov; 
26(3): 300‐306.  366.  Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR et al. Loss  of  wild‐type  huntingtin  influences  motor  dysfunction  and  survival  in  the YAC128  mouse  model  of  Huntington  disease.  Hum  Mol  Genet  2005  May  15; 
14(10): 1379‐1392.  367.  Higashiyama H, Hirose F, Yamaguchi M, Inoue YH, Fujikake N, Matsukage A et al. Identification of ter94, Drosophila VCP, as a modulator of polyglutamine‐induced neurodegeneration. Cell Death Differ 2002 Mar; 9(3): 264‐273.  368.  Anne  SL,  Saudou  F,  Humbert  S.  Phosphorylation  of  huntingtin  by  cyclin‐dependent  kinase  5  is  induced  by  DNA  damage  and  regulates  wild‐type  and mutant huntingtin toxicity in neurons. J Neurosci 2007 Jul 4; 27(27): 7318‐7328.  369.  Miller JA, Oldham MC, Geschwind DH. A systems level analysis of transcriptional changes  in Alzheimer's disease and normal aging.  J Neurosci 2008 Feb 6; 28(6): 1410‐1420.  370.  Jiang  YM,  Yamamoto M,  Kobayashi  Y,  Yoshihara  T,  Liang  Y,  Terao  S  et  al.  Gene expression  profile  of  spinal  motor  neurons  in  sporadic  amyotrophic  lateral sclerosis. Ann Neurol 2005 Feb; 57(2): 236‐251.  371.  Terai K, Matsuo A, McGeer PL. Enhancement of immunoreactivity for NF‐kappa B in  the hippocampal  formation and cerebral  cortex of Alzheimer's disease. Brain 
Res 1996 Sep 30; 735(1): 159‐168.  372.  Ghosh  A,  Roy  A,  Liu  X,  Kordower  JH,  Mufson  EJ,  Hartley  DM  et  al.  Selective inhibition  of  NF‐kappaB  activation  prevents  dopaminergic  neuronal  loss  in  a mouse  model  of  Parkinson's  disease.  Proc  Natl  Acad  Sci  U  S  A  2007  Nov  20; 
104(47): 18754‐18759.  373.  Hunot  S,  Brugg  B,  Ricard  D,  Michel  PP,  Muriel  MP,  Ruberg  M  et  al.  Nuclear translocation of NF‐kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A 1997 Jul 8; 94(14): 7531‐7536.  
  220 
374.  Spiliotaki M, Salpeas V, Malitas P, Alevizos V, Moutsatsou P. Altered glucocorticoid receptor  signaling  cascade  in  lymphocytes  of  bipolar  disorder  patients. 
Psychoneuroendocrinology 2006 Jul; 31(6): 748‐760.  375.  Esposito  L,  Raber  J,  Kekonius  L,  Yan  F,  Yu  GQ,  Bien‐Ly  N  et  al.  Reduction  in mitochondrial  superoxide  dismutase  modulates  Alzheimer's  disease‐like pathology  and  accelerates  the  onset  of  behavioral  changes  in  human  amyloid precursor protein transgenic mice. J Neurosci 2006 May 10; 26(19): 5167‐5179.  376.  Muller FL,  Liu Y,  Jernigan A, Borchelt D, Richardson A, Van Remmen H. MnSOD deficiency  has  a  differential  effect  on  disease  progression  in  two  different  ALS mutant mouse models. Muscle Nerve 2008 Sep; 38(3): 1173‐1183.  377.  Hashimoto T, Arion D, Unger T, Maldonado‐Aviles JG, Morris HM, Volk DW et al. Alterations in GABA‐related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2008 Feb; 13(2): 147‐161.  378.  Mazurek MF, Beal MF. Cholecystokinin and  somatostatin  in Alzheimer's disease postmortem cerebral cortex. Neurology 1991 May; 41(5): 716‐719.  379.  Beal MF, Martin JB. Neuropeptides in neurological disease. Ann Neurol 1986 Nov; 
20(5): 547‐565.  380.  Kuromitsu  J,  Yokoi  A,  Kawai  T,  Nagasu  T,  Aizawa  T,  Haga  S  et  al.  Reduced neuropeptide Y mRNA  levels  in  the  frontal  cortex of people with  schizophrenia and bipolar disorder. Brain Res Gene Expr Patterns 2001 Aug; 1(1): 17‐21.  381.  Caberlotto  L,  Hurd  YL.  Reduced  neuropeptide  Y  mRNA  expression  in  the prefrontal  cortex  of  subjects  with  bipolar  disorder.  Neuroreport  1999  Jun  3; 
10(8): 1747‐1750.  382.  Eggan  SM,  Hashimoto  T,  Lewis  DA.  Reduced  cortical  cannabinoid  1  receptor messenger  RNA  and  protein  expression  in  schizophrenia.  Arch  Gen  Psychiatry 2008 Jul; 65(7): 772‐784.  383.  Glass  M,  Dragunow  M,  Faull  RL.  The  pattern  of  neurodegeneration  in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and  GABA(A)  receptor  alterations  in  the  human  basal  ganglia  in  Huntington's disease. Neuroscience 2000; 97(3): 505‐519.  384.  Maccarrone  M,  Battista  N,  Centonze  D.  The  endocannabinoid  pathway  in Huntington's disease: a comparison with other neurodegenerative diseases. Prog 
Neurobiol 2007 Apr; 81(5‐6): 349‐379.  385.  Lastres‐Becker  I, Cebeira M, de Ceballos ML, Zeng BY,  Jenner P, Ramos  JA  et al. Increased  cannabinoid  CB1  receptor  binding  and  activation  of  GTP‐binding 
  221 
proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets. Eur J Neurosci 2001 Dec; 14(11): 1827‐1832.  386.  Inaguma  Y,  Shinohara  H,  Inagaki  T,  Kato  K.  Immunoreactive  parvalbumin concentrations  in parahippocampal gyrus decrease  in patients with Alzheimer's disease. J Neurol Sci 1992 Jul; 110(1‐2): 57‐61.  387.  Pantazopoulos H,  Lange N,  Baldessarini  RJ,  Berretta  S.  Parvalbumin  neurons  in the  entorhinal  cortex  of  subjects  diagnosed  with  bipolar  disorder  or schizophrenia. Biol Psychiatry 2007 Mar 1; 61(5): 640‐652.  388.  Hardman CD, Halliday GM. The internal globus pallidus is affected in progressive supranuclear  palsy  and  Parkinson's  disease. Exp Neurol  1999  Jul; 158(1): 135‐142.  389.  Hardman  CD, McRitchie  DA,  Halliday  GM,  Cartwright  HR, Morris  JG.  Substantia nigra  pars  reticulata  neurons  in  Parkinson's  disease.  Neurodegeneration  1996 Mar; 5(1): 49‐55.  390.  Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, Imai Y et al. Cerebral  alterations  in  a  MPTP‐mouse  model  of  Parkinson's  disease‐‐an immunocytochemical study. J Neural Transm 2003 Oct; 110(10): 1129‐1144.  391.  Soos J, Engelhardt JI, Siklos L, Havas L, Majtenyi K. The expression of PARP, NF‐kappa  B  and  parvalbumin  is  increased  in  Parkinson  disease. Neuroreport  2004 Aug 6; 15(11): 1715‐1718.  392.  Nisbet AP, Eve DJ, Kingsbury AE, Daniel SE, Marsden CD, Lees AJ et al. Glutamate decarboxylase‐67 messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1996 Nov; 75(2): 389‐406.  393.  Gluck  MR,  Thomas  RG,  Davis  KL,  Haroutunian  V.  Implications  for  altered glutamate  and  GABA  metabolism  in  the  dorsolateral  prefrontal  cortex  of  aged schizophrenic patients. Am J Psychiatry 2002 Jul; 159(7): 1165‐1173.  394.  Aoyagi  T,  Wada  T,  Nagai  M,  Kojima  F,  Harada  S,  Takeuchi  T  et  al.  Increased gamma‐aminobutyrate  aminotransferase  activity  in  brain  of  patients  with Alzheimer's disease. Chem Pharm Bull (Tokyo) 1990 Jun; 38(6): 1748‐1749.  395.  Sherif  F,  Gottfries  CG,  Alafuzoff  I,  Oreland  L.  Brain  gamma‐aminobutyrate aminotransferase  (GABA‐T)  and  monoamine  oxidase  (MAO)  in  patients  with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1992; 4(3): 227‐240.  396.  Zuccato  C,  Cattaneo  E.  Brain‐derived  neurotrophic  factor  in  neurodegenerative diseases. Nat Rev Neurol 2009 Jun; 5(6): 311‐322.  
  222 
397.  de Oliveira GS, Cereser KM, Fernandes BS, Kauer‐Sant'anna M, Fries GR, Stertz L 
et  al.  Decreased  brain‐derived  neurotrophic  factor  in  medicated  and  drug‐free bipolar patients. J Psychiatr Res 2009 May 26.  398.  Dunham JS, Deakin JF, Miyajima F, Payton A, Toro CT. Expression of hippocampal brain‐derived neurotrophic factor and its receptors in Stanley consortium brains. 
J Psychiatr Res 2009 Apr 17.  399.  Norton  N,  Owen  MJ.  HTR2A:  association  and  expression  studies  in neuropsychiatric genetics. Ann Med 2005; 37(2): 121‐129.  400.  Lopez‐Figueroa AL, Norton CS,  Lopez‐Figueroa MO, Armellini‐Dodel D, Burke  S, Akil H et al. Serotonin 5‐HT1A, 5‐HT1B, and 5‐HT2A receptor mRNA expression in  subjects  with  major  depression,  bipolar  disorder,  and  schizophrenia.  Biol 
Psychiatry 2004 Feb 1; 55(3): 225‐233.  401.  Bowen  DM,  Procter  AW,  Mann  DM,  Snowden  JS,  Esiri  MM,  Neary  D  et  al. Imbalance of a serotonergic system in  frontotemporal dementia:  implication  for pharmacotherapy. Psychopharmacology (Berl) 2008 Mar; 196(4): 603‐610.  402.  Lorke DE,  Lu  G,  Cho  E,  Yew DT.  Serotonin  5‐HT2A  and  5‐HT6  receptors  in  the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci 2006; 7: 36.  403.  Birkett  JT,  Arranz MJ,  Munro  J,  Osbourn  S,  Kerwin  RW,  Collier  DA.  Association analysis of the 5‐HT5A gene in depression, psychosis and antipsychotic response. 
Neuroreport 2000 Jun 26; 11(9): 2017‐2020.  404.  Dubertret C, Hanoun N, Ades  J, Hamon M, Gorwood P. Family‐based association studies between 5‐HT5A receptor gene and  schizophrenia.  J Psychiatr Res  2004 Jul‐Aug; 38(4): 371‐376.  405.  Epelbaum J, Ruberg M, Moyse E, Javoy‐Agid F, Dubois B, Agid Y. Somatostatin and dementia in Parkinson's disease. Brain Res 1983 Nov 14; 278(1‐2): 376‐379.  406.  Norris PJ, Waldvogel HJ, Faull RL, Love DR, Emson PC. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease. Neuroscience 1996 Jun; 72(4): 1037‐1047.  407.  Emilsson  L,  Saetre  P,  Jazin  E.  Low  mRNA  levels  of  RGS4  splice  variants  in Alzheimer's disease: association between a rare haplotype and decreased mRNA expression. Synapse 2006 Mar 1; 59(3): 173‐176.  408.  Zhang Y,  James M, Middleton  FA, Davis RL.  Transcriptional  analysis  of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing,  energy  metabolism,  and  signaling  pathways,  and  suggests  novel 
  223 
disease  mechanisms.  Am  J  Med  Genet  B  Neuropsychiatr  Genet  2005  Aug  5; 
137B(1): 5‐16.  409.  Kuhn  A,  Goldstein  DR,  Hodges  A,  Strand  AD,  Sengstag  T,  Kooperberg  C  et  al. Mutant  huntingtin's  effects  on  striatal  gene  expression  in  mice  recapitulate changes  observed  in  human  Huntington's  disease  brain  and  do  not  differ  with mutant  huntingtin  length  or wild‐type  huntingtin  dosage. Hum Mol  Genet  2007 Aug 1; 16(15): 1845‐1861.  410.  Guidotti  A,  Auta  J,  Davis  JM,  Di‐Giorgi‐Gerevini  V,  Dwivedi  Y,  Grayson DR  et  al. Decrease  in  reelin  and  glutamic  acid  decarboxylase67  (GAD67)  expression  in schizophrenia  and  bipolar  disorder:  a  postmortem  brain  study.  Arch  Gen 
Psychiatry 2000 Nov; 57(11): 1061‐1069.  411.  Chin J, Massaro CM, Palop JJ, Thwin MT, Yu GQ, Bien‐Ly N et al. Reelin depletion in the  entorhinal  cortex  of  human amyloid precursor protein  transgenic mice  and humans with Alzheimer's disease. J Neurosci 2007 Mar 14; 27(11): 2727‐2733.  412.  Botella‐Lopez A, Burgaya F, Gavin R, Garcia‐Ayllon MS, Gomez‐Tortosa E,  Pena‐Casanova  J  et  al.  Reelin  expression  and  glycosylation  patterns  are  altered  in Alzheimer's disease. Proc Natl Acad Sci U S A 2006 Apr 4; 103(14): 5573‐5578.  413.  Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006 Jul 15; 60(2): 132‐140.  414.  Bertram I, Bernstein HG, Lendeckel U, Bukowska A, Dobrowolny H, Keilhoff G et 
al.  Immunohistochemical  evidence  for  impaired  neuregulin‐1  signaling  in  the prefrontal cortex  in schizophrenia and  in unipolar depression. Ann N Y Acad Sci 2007 Jan; 1096: 147‐156.  415.  Chong  VZ,  Thompson M,  Beltaifa  S, Webster MJ,  Law  AJ, Weickert  CS.  Elevated neuregulin‐1  and  ErbB4  protein  in  the  prefrontal  cortex  of  schizophrenic patients. Schizophr Res 2008 Mar; 100(1‐3): 270‐280.  416.  Georgieva  L,  Dimitrova  A,  Ivanov  D,  Nikolov  I,  Williams  NM,  Grozeva  D  et  al. Support  for  neuregulin  1  as  a  susceptibility  gene  for  bipolar  disorder  and schizophrenia. Biol Psychiatry 2008 Sep 1; 64(5): 419‐427.  417.  Go  RC,  Perry  RT, Wiener  H,  Bassett  SS,  Blacker  D,  Devlin  B  et  al.  Neuregulin‐1 polymorphism  in  late  onset  Alzheimer's  disease  families  with  psychoses.  Am  J 
Med Genet B Neuropsychiatr Genet 2005 Nov 5; 139B(1): 28‐32.  418.  Pantazopoulos  H,  Stone  D,  Walsh  J,  Benes  FM.  Differences  in  the  cellular distribution  of  D1  receptor  mRNA  in  the  hippocampus  of  bipolars  and schizophrenics. Synapse 2004 Dec 1; 54(3): 147‐155.  
  224 
419.  Ni  X,  Trakalo  JM,  Mundo  E,  Macciardi  FM,  Parikh  S,  Lee  L  et  al.  Linkage disequilibrium  between  dopamine  D1  receptor  gene  (DRD1)  and  bipolar disorder. Biol Psychiatry 2002 Dec 15; 52(12): 1144‐1150.  420.  Craddock N, Jones L, Jones IR, Kirov G, Green EK, Grozeva D et al. Strong genetic evidence  for  a  selective  influence  of GABA(A)  receptors  on  a  component  of  the bipolar disorder phenotype. Mol Psychiatry 2008 Jul 1.  421.  Papadimitriou  G,  Dikeos  D,  Daskalopoulou  E,  Karadima  G,  Avramopoulos  D, Contis C et al. Association between GABA‐A receptor alpha 5 subunit gene locus and schizophrenia of a later age of onset. Neuropsychobiology 2001; 43(3): 141‐144.  422.  Mansour HA, Wood J, Logue T, Chowdari KV, Dayal M, Kupfer DJ et al. Association study  of  eight  circadian  genes  with  bipolar  I  disorder,  schizoaffective  disorder and schizophrenia. Genes Brain Behav 2006 Mar; 5(2): 150‐157.  423.  Benedetti F, Dallaspezia S, Colombo C, Pirovano A, Marino E, Smeraldi E. A length polymorphism in the circadian clock gene Per3 influences age at onset of bipolar disorder. Neurosci Lett 2008 Nov 14; 445(2): 184‐187.  424.  Le‐Niculescu  H,  Patel  SD,  Bhat  M,  Kuczenski  R,  Faraone  SV,  Tsuang  MT  et  al. Convergent  functional  genomics  of  genome‐wide  association  data  for  bipolar disorder:  comprehensive  identification  of  candidate  genes,  pathways  and mechanisms. Am J Med Genet B Neuropsychiatr Genet 2009 Mar 5; 150B(2): 155‐181.   
 
